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Maternal docosahexaenoic acid (DHA) intake during pregnancy and/or lactation has been 
positively associated with infant growth and neurocognitive development. However, randomized 
controlled clinical trials (RCT) report mixed results. Several RCT that failed to demonstrate an 
effect of DHA supplementation have found correlations between DHA status and cognitive 
benefits, possibly due to a failure to account for total maternal DHA intake. The majority of 
studies to date investigating neurocognitive development have not examined the effect of 
supplementing women with DHA during both pregnancy and lactation and fail to determine the 
effects of maternal genetic variation on infant neurocognitive development. Single nucleotide 
polymorphisms (SNPs) within the fatty acid desaturase (FADS)1 FADS2 gene cluster encoding 
for Δ5- and Δ6-desaturase enzymes were previously reported to be associated with altered 
omega-3 (n-3) and omega-6 (n-6) fatty acid proportions of erythrocyte, plasma phospholipids 
and breastmilk, possibly effecting DHA transfer to the infant. 
This study was conducted to determine the relationship between DHA intake in women 
obtaining varying amounts of DHA daily during pregnancy and lactation and infant 
neurocognitive development in the first year of life and the association of maternal SNPs in the 
FADS1 FADS2 gene cluster. One hundred and fifteen pregnant women were randomized to 
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receive purified tuna oil supplement containing 300 mg of DHA and 67 mg EPA per day or an 
identical placebo (Sunola oil) for the last trimester of pregnancy through the first 3 months of 
lactation in a double-blinded placebo controlled clinical trial. Two SNPs in the FADS1 FADS2 
gene cluster, rs174575 and rs174561, were genotyped from maternal DNA and erythrocyte, 
plasma phospholipid and breastmilk fatty acids and daily DHA intake from food frequency 
questionnaires (FFQ) were analyzed. Neurocognitive development of the infants was measured 
using the Mental Development Index (MDI) of the Bayley Scales of Infant Development III 
(BSID-III) at 4 and 12 months of age. Gestational length in days was calculated based upon last 
menstrual period and birth date. Infant birth weights and lengths were obtained from pediatric 
medical records at delivery and at 2 months of age.  
Total daily DHA intake was estimated to range from 18 mg to 1.374 g per day calculated 
from all sources of DHA, including food and supplementation. Data was analyzed based on 
treatment group, placebo versus DHA, and by total daily DHA intake broken into three groups: 
low = 0-299 mg per day DHA, medium = 300-599 mg per day DHA, high = ≥600 mg per day 
DHA. DHA portion of 2 month breastmilk fatty acids directly correlated with daily DHA intake 
(r=0.37, p=0.0002). Erythrocyte and breastmilk DHA proportions significantly increased in 
women homozygous for the major allele (SNP rs174575, p=0.0002 and p=0.030, respectively; 
SNP rs174561, p=0.003 and p=0.040, respectively) in the high daily DHA intake compared to 
the low intake group. However, daily DHA intake had no effect significantly increasing DHA 
proportions in women homozygous for the minor alleles of both SNPs studied. Infants born to 
mothers in the high DHA intake group showed significantly higher scores on the 12 month 
cognitive scale of the MDI of the BSID-III (p=0.018), compared to the low intake group. No 
significant differences were seen between treatment groups or DHA intake groups on any of the 
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4 month infant cognitive testing. Genotype had no direct effect on BSID-III scores, however, 
ANCOVA for 12 month cognitive MDI subtest showed a statistically significant interaction 
between SNP rs174575 genotype and daily DHA intake group (p=0.023). Additionally, infants 
born to mothers in the DHA treatment group had an increase of 4.5 days in gestational age 
(p=0.048) and significantly lower incidence of preterm birth (5%; n=3) compared to infants born 
to mothers in the control group (18%; n=10; χ2=4.97, p=0.026). No significant differences were 
seen between treatment groups or DHA intake groups in infant growth measurements at birth or 
at 2 months of age, although 2 month breastmilk DHA proportion of fatty acids was negatively 
correlated with 2 month weight (r= -0.22, p=0.048). 
An intake of 600 mg of DHA per day or greater during the third trimester of gestation 
throughout the first three months of breastfeeding was associated with improved infant 
neurocognitive development. Genetic variants of the FADS1 FADS2 gene cluster influence 
erythrocyte and breastmilk fatty acids, and increased DHA intake does not effectively increase 
DHA proportions in minor allele carriers. Additionally, DHA supplementation increased 
gestational length and decreased preterm birth risk, however, did not affect infant birth weights. 
DHA supplementation during pregnancy and lactation could be beneficial for improving the 
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Docosahexaenoic acid (DHA; 22:6) is an omega-3 (n-3) long chain polyunsaturated fatty 
acid (LCPUFA) essential for central nervous system and retinal development that accumulates 
rapidly during the last trimester of gestation through the first 2 years of life.1,2 DHA is 
transferred to the fetus via the placenta and after birth through breastfeeding.3 Early 
neurocognitive development depends upon an adequate supply of DHA, and, thus, is influenced 
directly by the nutritional status of the mother during pregnancy and lactation.4-6 Evidence 
suggests the conversion of DHA from n-3 precursors in humans is extremely limited, therefore, it 
is optimal to receive preformed DHA directly from the diet, either from fish and seafood or 
supplementation.7,8  
Observational and randomized controlled trials (RCT) have reported maternal diets high 
in DHA during pregnancy are positively associated with improvements in health outcomes of 
human infants, including increased gestational age, decreased preterm birth, improved infant 
growth and enhanced neurocognitive development.9-13 However, results of recent studies are 
mixed due to varying amounts of DHA, supplementing for different lengths of time and possible 
genetic variation influences on the DHA content of breastmilk.14-19 Several RCT that failed to 
find a significant effect of DHA treatment often have found a significant association between 
DHA status and infant neurocognitive development.20-23 Additionally, non-significant RCT 
rarely account for all sources of DHA in the maternal diet outside of the study supplement. 
 2 
Accounting for DHA intake from food allows for a more accurate daily DHA intake to be 
estimated in RCT, which could dramatically affect results determining an association between 
DHA intake and improved infant growth and neurocognitive development. 
Several recent studies have demonstrated single nucleotide polymorphisms (SNPs) in the 
fatty acid desaturase (FADS)1 and FADS2 gene cluster are associated with altered proportions of 
DHA in erythrocyte, plasma phospholipids and breastmilk. The Δ5- and Δ6-desaturase enzymes 
essential to endogenous DHA synthesis are encoded by fatty acid desaturase (FADS)1 and 
FADS2, respectively, which are arranged in a head-to-head orientation on chromosome 11q, 
with a third desaturase gene, FADS3, which function is currently unknown.24 DHA proportions 
in erythrocyte, plasma and breastmilk fatty acids were lower in women homozygous for the 
minor alleles of 2 SNPs studied, FADS2 rs174575 and FADS1 rs174561, compared to women 
homozygous for the major allele.18 Additionally, several recent studies have determined an 
association between SNPs within the FADS1 FADS2 gene cluster and child cognitive abilities, 
with major allele carriers showing significant advantages over minor allele carriers.25-27 
The purpose of this study was to examine the effects of DHA intake during pregnancy 
and lactation on infant growth and neurocognitive development during the first year of life and 
the possible effects of SNPs within the FADS1 FADS2 gene cluster. The Omega Smart Baby 
Project was a double-blinded, randomized, placebo controlled clinical trial in which 115 
pregnant women were randomized to receive 300 mg of DHA or identical placebo for the last 





 The following hypotheses were addressed in this study: 
1. Increased maternal DHA intake during pregnancy and lactation will result in higher 
scores on the Bayley Scales of Infant Development III (BSID-III), indicating enhanced 
neurocognitive development. 
2. Increased maternal DHA intake during pregnancy will result in longer gestational 
lengths, decrease in preterm birth incidence and increased infant birth weights. 
3. As maternal DHA intake increases, breastmilk DHA will also increase. 
4. Minor allele carriers of SNPs within the FADS1 FADS2 gene cluster will have decreased 
breastmilk DHA compared to major allele carriers. 
5. Major allele carriers of SNPs within the FADS1 FADS2 gene cluster will have infants 








Long chain polyunsaturated fatty acids (LCPUFA) are essential constituents of all human 
cells. LCPUFA are incorporated into cell membranes, cholesterol esters, triglycerides and 
numerous other molecules providing both structural and functional roles throughout the body.28 
The majority of all LCPUFA in the human body are classified as either omega-3 (n-3) or omega-
6 (n-6), based upon the location of the first unsaturated bond from the methyl end of the fatty 
acid. The 18 carbon LCPUFA of the n-6 series, linoleic acid (LA; 18:2), and the n-3 series, α-
linolenic acid (ALA; 18:3), cannot be synthesized by the human body and are, therefore, 
essential to humans and must be obtained through diet.28  
The n-6 fatty acid LA is found in grains and vegetable oils and is the precursor of the 20 
carbon n-6 fatty acid arachidonic acid (AA; 20:4).29 Humans synthesize AA through a process of 
enzymatic elongation and desaturation, as shown in Figure 2.1, and also can obtain it preformed 
in the diet through red meat and meat products.30 The n-3 fatty acid ALA is found in plant oils 
and seeds and is an important precursor to LCPUFA, which include ecosapentaenoic acid (EPA; 
20:5) and docosahexaenoic acid (DHA; 22:6). Metabolic conversion of ALA to DHA is shown 
in Figure 2.1. Once ingested, ALA can be further metabolized by Δ6-desaturation, subsequent 
elongation and Δ5-desaturation to form EPA on the endoplasmic reticulum.28 EPA is then 
converted to docosapentaenoic acid (DPA; 22:5) via the addition of 2 carbons and subsequently, 
DPA undergoes further elongation and Δ6-desaturation. Upon transport to peroxisomes, ß-
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oxidation ensues to shorten the chain by two carbons yielding the end product of DHA.28 
Furthermore, enzymes within this metabolic pathway also require iron, zinc, vitamin B6 and 
vitamin E, therefore, it is possible that micronutrient intake may also play a role in the formation 
of LCPUFA.31 
While the synthesis of EPA and DHA from dietary ALA can occur in humans, in most 
individuals the conversion of DHA is estimated to be <0.1 to 1%.8,28 However, women of child-
bearing ages may convert ALA to DHA more effectively than men to compensate for the 
increased need of DHA during fetal development. Isotope labeled ALA was converted into DHA 
greater in women than in men, and DHA concentrations of subcutaneous adipose tissue were 
lower in men than in women.32,33 It is proposed that estrogen may increase the activity of 
enzymes within the DHA synthesis pathway, consistent with findings that DHA concentration in 
plasma phospholipids was higher in women taking oral contraceptives containing estrogen 
compared to women not on contraceptives.32,34 According to research conducted by the 
International Society for the Study of Fatty Acids and Lipids (ISSFAL) and European Influence 
of Dietary Fatty Acids on the Pathophysiology of Intrauterine Foetal Growth and Neonatal 
Development (PERILIP) group, ALA is not converted to DHA at levels that can be 
physiologically beneficial, especially during periods of increased need.35-38  
The rate-limiting step in the conversion of ALA to DHA in humans appears to be the 
preliminary desaturation step of 18:3 via Δ6-desaturase, with the second Δ6-desaturase step from 
24:5 fatty acid to DHA precusor 24:6 also limiting the completion of the metabolism to 
DHA.24,39 Low Δ6-desaturase activity could be due to numerous common single nucleotide 
polymorphisms (SNPs) decreasing enzyme activity in humans, consequently preventing adequate 
DHA synthesis and increasing dietary need.40 Additionally, recent research has shown that high 
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LCPUFA diets may in fact increase LCPUFA degradation and possibly decrease enzymatic 
activity of desaturases involved in EPA and DHA synthesis.24 Increased dietary DHA intake 
alters gene expression within the n-6 and n-3 synthesis pathways, possibly providing feedback 
regulation of LCPUFA synthesis.41 Since the synthesis pathways for both n-6 and n-3 LCPUFA 
compete for the same desaturase enzymes at multiple steps, it is possible that altering enzyme 
activity through feedback mechanisms and precursor ratios may affect downstream fatty acid 
proportions, thus reinforcing the need for obtaining EPA and DHA preformed directly from the 
diet. 
Preformed DHA and EPA in the human diet are largely supplied by the consumption of 
fish, especially fatty fish, and seafoods.28 While precursor n-3 fatty acid ALA is found in 
vegetable sources, DHA and EPA are not present in common vegetable fats and oils, including 
nuts, seeds and grains. Poultry, if consumed in large quantities can provide a significant source 
of DHA and EPA, depending upon DHA content of the chicken feed.42 Additionally, many 
manufacturers are currently supplementing common functional foods with n-3 fatty acids. Dairy, 
poultry, eggs, cereals and even peanut butters are now commonly enriched with n-3s and DHA 
specifically, which can provide lower but significant dietary sources.28 Yet, many of the current 
products marketed do not contain enough n-3 to provide any necessary benefit or do not properly 
protect the LCPUFA from oxidative damage. In the last 5-10 years, fish oil and DHA 
supplements have become one of the most common forms of dietary DHA sources.28 This is 
especially true for pregnant and lactating women, where DHA supplements may provide a safer 
means for obtaining DHA compared to consuming fish and seafood possibly contaminated with 
mercury. In 2001, the U.S. Food and Drug Administration (FDA) released a well publicized 
advisory recommending pregnant women avoid consuming long-lived predatory fish that contain 
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the highest levels of methyl mercury, and to limit ingestion of all other fish each week, to 
minimize mercury exposure that could cause developmental delays in the fetus.43 After the 
federal recommendations were disseminated, fish consumption by U.S. pregnant women 
decreased, but as awareness of possible health benefits DHA and fish oil can incur upon the 
developing fetus increase, obtaining DHA through purified supplements may also increase.44  
Anthropologic data indicates the evolution of modern man coincides with an increase in 
marine foods high in n-3 fatty acids in the diet and the presence of DHA in neuronal tissues.45,46 
However, the current diet of mankind has shifted away from seafood and toward a diet high in 
saturated fats and n-6 fatty acids, mostly due to the domestication of livestock and the 
agricultural and industrial revolutions.46 Numerous studies show increasing dietary ALA intakes 
will not increase DHA in blood lipids, indicating the diet directly induces compositional changes 
within cell membranes and suggests the need for obtaining preformed DHA directly from the 
diet.3,28,35,37 In 2002, the Institute of Medicine (IOM) concluded that insufficient data was 
available to set an official recommended daily amount or adequate intake (AI) for DHA or EPA, 
yet, years later many of the IOMs concerns have been resolved through recent research.47 The 
majority of recent dietary recommendations are for combined EPA+DHA without specific 
advice for each individual fatty acid, yet research clearly provides evidence that individual daily 
recommended intakes (DRI) are necessary for both EPA and DHA.47,48    
Currently, North American intakes of EPA and DHA are approximately 100-150 mg per 
day, low according to recent research.47 Researchers estimate the average American should 
consume greater than 250 mg of EPA+DHA per day upwards to 1 g per day, with increased 
amounts during pregnancy.47,48 The PERILIP group recommends pregnant and lactating women 
receive at least 200 mg per day of preformed DHA directly from the diet, through 
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supplementation or consuming one to two portions of fatty fish high in n-3 LCPUFA per week.38 
The 2010 Dietary Guidelines for Americans recommend a maternal dietary intake of 
approximately 250 mg of DHA per day from at least two servings of seafood per week during 
pregnancy and lactation to see associated improvements in infant health outcomes.49 Yet, DHA 
intake in the United States is estimated to be only 50 mg per day during pregnancy and lactation, 
lower than the 70 mg per day average of women of child-bearing age, due in part to government 
advisories warning about methyl mercury content of some fish.44,50  
Mechanisms of action 
DHA is abundant in the phospholipid bilayer of all cells and a major structural 
component of the brain, cerebral cortex, retina and skin.51 Lipids constitute 50-60% of the dry 
weight of the human brain and DHA is the most abundant n-3 fatty acid, comprising 10-20% of 
total brain fatty acids.52,53 The human brain is unable to synthesize DHA or EPA from precursor 
n-3 fatty acids, therefore, it must obtain them from elsewhere in the body.54 To maintain 
LCPUFA levels, the brain depends on the transfer of LCPUFA from plasma, which is directly 
affected by LCPUFA from the diet, mobilization of fat stores or synthesis in the liver.4 However, 
previously it was not clear how DHA could pass the blood brain barrier (BBB), since the 
majority of DHA in the blood is incorporated into phospholipids, triglycerides and cholesterol 
esters within plasma proteins, which are too large of complexes to cross the BBB.54,55 Recently, 
Ouellet et al. using the in situ brain perfusion technique demonstrated radiolabeled DHA and 
EPA in free form rapidly transported through the BBB in mice, comparable to highly diffusible 
drugs.56 Oulellet et al. also determined that bound to proteins, such as albumin, reduced, but did 
not completely prevent, the passage of DHA through the BBB and long-term high DHA dietary 
intake (~0.9 g per kg per day) reduced the uptake of DHA into the mouse brain.56 Although the 
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mechanisms are not completely understood, once in the brain, DHA has effects on changes in 
membrane fluidity, including regulating the activity of membrane, neuronal development and 
plasticity, receptor mediated signaling, the production of anti-inflammatory lipid mediators and 
act as direct ligands to transcription factors of genes involved in inflammation, oxidative stress, 
neurogenesis, differentiation and fatty acid metabolism.57-59 
Cellular membranes are complex in structure and LCPUFA have an important role in 
modulating the fluidity of the lipid bilayer. Plasma membranes contain specialized 
microdomains, called lipid rafts, that are comprised of tightly packed combinations of 
cholesterol, glycosphingolipids and glycolipids containing saturated fatty acyl residues that 
directly influence membrane fluidity and membrane protein trafficking.60,61 The incorporation of 
DHA in the membrane bilayer creates a more fluid, permeable membrane and displaces saturated 
fatty acids, thus disrupting lipid raft formation and maintaining optimal neural membrane 
fluidity.61 Additionally, improved fluidity of increased DHA within the membrane positively 
impacts the speed of signal transduction and neurotransmission, possibly leading to increased 
cognitive function.62 Increased dietary intake of DHA can directly alter membrane composition 
and distribution, whereas increased ALA consumption alone does not alter membrane 
phospholipids.63 DHA is rapidly incorporated into phospholipids, however the distribution 
between phospholipid classes is not equal, with preferential incorporation into 
phosphatidylethanolamine (PE) first, which is incorporated into white matter of the brain, neural 
tissue and the spinal cord, and to a lesser extent phosphatidylcholine (PC) or phosphatidylserine 
(PS), which is found in brain gray matter and rod photoreceptors of the retina.60 Improving 
membrane fluidity throughout the brain from the presence of increased DHA could result in 
improved neuronal development as well as enhanced cognitive function. 
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LCPUFA are insoluble in the cellular environment, therefore, fatty acid binding proteins 
(FABP) are necessary to transport LCPUFA into the cell and to appropriate intracellular 
compartments for use.64 FABP are a family of small cytosolic proteins coded by multiple genes. 
Multiple types of FABP have been identified, including brain FABP (B-FABP), which is present 
in radial glial cells and in the astrocytes, specialized glial cells that exert many essential and 
complex functions throughout the brain, of developing and adult brains.65 B-FABP is believed to 
be important in early neurogenesis, the process in which neurons are created including the 
development of axons and dendrites, and neuronal migration and expression in the developing 
brain parallels early neuronal differentiation.65 Research in mice indicates mutations impairing 
B-FABP results in a reduction of DHA with a corresponding increase in AA in astrocytes.66 The 
decrease in brain DHA is directly associated with increased anxiety and fear memory, as well as 
spatial learning and memory impairments later in life.66-68 Impairing DHA delivery into brain 
cells via B-FABP mutations suggest DHA plays an important role in early neuronal 
development, including influencing cognitive as well as behavioral functions of the brain. 
Additionally, recent research has linked polymorphisms within genes encoding for FABP with 
impaired activation of desaturase enzymes involved in LCPUFA synthesis, possibly further 
influencing the effects of LCPUFA throughout the body.69 Fatty acid transport proteins (FATP) 
and placental membrane FABP (FABPpm), located exclusively in the microvillous membranes 
of placental syncytiotrophoblasts, are responsible for the transfer of LCPUFA and other free fatty 
acids from the maternal blood stream to the growing fetus.70,71 Through the use of radiolabeled 
fatty acids, Campbell et al. demonstrated FABPpm preferentially binds maternal AA and DHA, 
compared to other fatty acids, for transport to the fetus.72 This emphasizes the importance for the 
fetus to receive preformed AA and DHA from maternal supplies.  
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LCPUFA, especially DHA, are known to effect gene expression throughout the central 
nervous system, influencing neurogenesis, synaptogenesis and neurochemistry.41,57 LCPUFA are 
ligands for the nuclear receptor peroxisome proliferator activated receptors (PPAR).73,74 
Although it is rarely found in the adult brain, PPARγ is expressed abundantly in the developing 
brain and appears to be important in regulating stem cell proliferation in early brain 
development.75 An increase in DHA within the brain subsequently increases the transcription of 
PPARγ.75 In addition to PPAR, DHA and AA are ligands for brain retinoid X receptor (RXR).74 
Once bound by ligand, PPAR heterodimerizes with RXR forming a complex that is then able to 
bind specific regions of DNA, regulating gene transcription controlling numerous cellular 
activities.76 DHA directly affects the activity of RXR, which, along with retinoic acid receptor 
(RAR), have important roles in neurogenesis, neuronal differentiation and neurotransmission 
specifically within the hippocampus.74,77 Several recent animal studies have linked DHA 
specifically to dopamine and serotonin production as well as to influencing their respective 
receptors and secondary messengers to facilitate neurotransmission.78-80 Human infants deficient 
in LCPUFA have decreased dopaminergic responses compared to infants with normal LCPUFA 
levels.81  
In addition to neuronal development, receptor-ligand interactions between DHA and 
PPAR interfere with the activation of nuclear transcription factor kappa-light-chain-enhancer of 
activated B cells (NFκB) proinflammatory signaling pathway, influencing the suppression of 
apoptotic pathways and proinflammatory cytokines, chemokines and enzymes, such as 
cyclooxygenase 2 (COX-2) and inducible nitric oxide synthase (iNOS).57,82-85 LCPUFA, 
including DHA, inhibit dimerization and activation of Toll-like receptors (TLR), proteins that 
induce inflammatory pathways, such as NFκB, and mediate the expression of cytokines within 
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the developing brain.86 Additionally, NFκB can be activated by proinflammatory cytokines such 
as interleukin (IL) 1 and tumor necrosis factor α (TNFα).87 Recent research determined DHA 
directly inhibited TNFα mediated signaling pathways and also interacts with G-coupled protein 
receptor (GPR) 120, inducing anti-inflammatory pathways responsible for further inhibition of 
both TLR and TNFα pro-inflammatory pathways.88,89 In addition, LCPUFA regulate the 
inflammatory processes of COX-2 converting AA to prostaglandins (PG) and subsequent pro-
inflammatory eicosanoids.90 Lee et al. recently reported EPA and DHA significantly reduced 
COX-2 expression, thus reducing PGE2 and IL-6.91 COX-2 expression, IL-6, TNFα and PGE2 
production have been associated with cognitive impairment and have been implicated in possibly 
causing preterm birth by degrading the uterine lining and stimulating uterine contractions.92-94 
The protection DHA may provide by inhibiting NFκB pro-inflammatory signaling pathway and 
COX-2 mediated inflammation could have vast impacts on neural development, maturation and 
possibly even gestational length. 
While DHA is important for neurocognitive development and cognitive function, it is 
also important to note that it is essential the fetus receive AA for proper development. AA is n-6 
fatty acid converted from LA using the same Δ6-desaturase enzyme used in the conversion of 
ALA to DHA, and competition exists between the n-6 and n-3 metabolic pathways.1 AA 
concentrations are subject to nutritional control, and there could be a risk in reducing AA levels 
in the fetus from increased DHA and n-3 fatty acids intake, disrupting the proper n-6:n-3 ratio 
for fetal development.95,96 Like DHA, AA is highly concentrated in the brain and retina of 
infants, with the majority of accumulation occurring in the last trimester through the first year of 
life.1 Additionally, much like DHA, AA plays a critical role in membrane structure and fluidity, 
and can activate PPARγ to promote neurogenesis.97 AA is also converted into prostaglandins, 
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eicosanoids and numerous signaling molecules utilized throughout the body and contribute to the 
development of innate immunity.91 AA is essential for fetal growth and proper brain 
development and high maternal status of AA in plasma phospholipids is positively associated 
with fetal growth, infant birth weight and postnatal growth.98-100 Additionally, lower levels of 
AA in cord blood and infant plasma phospholipids are associated with reduced performance on 
intelligence quotient (IQ) tests, motor development tests and behavioral measures.101-104 These 
findings indicate that AA is an important fatty acid and should possibly be considered when 
studying fatty acids and neurocognitive development.  
DHA during pregnancy 
Several studies have investigated maternal DHA levels in plasma phospholipids, total 
plasma lipids and erythrocytes during pregnancy.4,105 In healthy pregnant women not taking any 
supplements, an initial increase in DHA occurs until the 18th week of gestation.4 Otto et al. 
supplemented women with 570 mg DHA per day starting at the 16th-20th week of gestation and 
showed a significant increase in maternal DHA levels at weekly blood draws in both plasma and 
erythrocyte phospholipids after 4 weeks when compared to the control group.6 As DHA 
increases in the fetus during the third trimester, maternal DHA supplies are depleted, as indicated 
by a decrease in the percent total fatty acids of DHA on maternal RBC.106 Currently, during the 
last trimester it is estimated the fetus acquires 67-75 mg per day of DHA in utero, accounting for 
80% of brain DHA accumulating between week 26 and 40 of gestation.67,107,108 DHA 
accumulates rapidly in the infant brain between the 28th week of gestation and two years of age, 
during which the neurological system grows rapidly.2   
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Pregnancy is a period of increased metabolic demands and maternal nutrition plays a 
critical role in fetal growth and development.109 During gestation, the fetus has limited to no 
metabolic capability to convert ALA to DHA, therefore the fetus is entirely dependent on 
maternal sources of DHA.110 The placenta uptakes DHA circulating in the maternal bloodstream, 
which is influenced by maternal DHA synthesis, DHA from the diet and enhanced mobilization 
of DHA from maternal adipose stores.4 Whether the placenta is involved in DHA synthesis or if 
the selective transport of DHA to the fetus relies completely on maternal DHA stores is currently 
unknown. The amount of DHA synthesized or released from adipose tissue is unclear, but a 
strong link between maternal circulating DHA and dietary DHA intake during pregnancy 
suggests that diet may be the main source of DHA for the fetus.4,14,67,111,112  
Gestational length and preterm birth 
Preterm birth, defined as a birth of less than 37 weeks gestational age, is a major public 
health concern and is estimated to account for 3 million infant deaths worldwide every year.113 
Children born preterm are at an increased risk for a wide range of health problems, including 
neurodevelopmental and attention difficulties, memory and learning problems, visual deficits and 
pulmonary problems. Several studies determined increased intake of seafood and DHA during 
pregnancy promote decreased risk for preterm birth, increased gestational length, and increased 
infant birth weight.114-117  
Researchers in the 1980s first observed women living in the Faroe Islands, where high 
fish consumption is normal, had longer gestational lengths and delivered infants with higher birth 
weights (~200 g) at term when compared to infants born to women in Denmark.118 In a 
prospective cohort study by Olsen et al., increased fish and seafood intake during pregnancy 
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reduced the incidence of preterm birth and decreased the risk of having a low birth weight baby 
in 8729 women surveyed. Olsen et al. found an increase of 4 days in gestational length, only a 
1.9% incidence of preterm delivery (compared to 7.1% in the group never consuming fish) and a 
decreased risk for having a low birth weight baby [odds ratio (OR)=3.57; 95% confidence 
interval (CI) 1.14-11.14] in women who consumed fish during pregnancy compared to those 
never eating fish.115 However, in an earlier observational study, Olsen et al. showed positive 
association between the levels of LCPUFA in erythrocytes and a 5.7 day increase in gestational 
length in pregnant Danish women, yet no association was found in Faroese women (0.7 day 
increase in gestational length), who have a higher daily intake of fish and seafood compared to 
Danish women.119 It is possible that the effect of LCPUFA on gestational length may meet a 
saturation point, where no further effect of increased n-3 fatty acids can be detected.115,120 
Numerous randomized controlled trials (RCT) have attempted to validate the effect DHA 
supplementation, usually in the form of fish oil or purified DHA, has on increasing gestational 
length. The use of DHA supplementation in RCT has grown in recent years and with 
supplements ranging from 100 mg to 5 g of EPA+DHA per day.121,122 In a RCT, Olsen et al. 
reported a reduction in the odds of delivering earlier than 40 weeks in pregnant women 
supplemented with 100 mg EPA+DHA per day for an average of 20 weeks.123 In a U.S. trial, 350 
women were randomized to consume DHA enriched eggs (133 mg DHA) or normal eggs daily 
after the 24th week. Upon adjusting the data for confounders, Smuts et al. discovered a 
significant 6 day increase in gestational length in the women consuming the DHA enriched eggs 
compared to the normal egg group (276.5 vs 270.5 days; p=0.009).124 In the Fish Oil Trials in 
Pregnancy (FOTIP) study in Europe, 232 women at high risk for preterm birth supplemented 
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with 900 mg DHA per day versus olive oil control starting at the 20th week of gestation saw a 
reduction in preterm deliveries from 33% to 21% (OR=0.54, 95% CI 0.30-0.98; p=0.05).125  
Additionally, to determine the effect of DHA on gestational length, Olsen et al. 
randomized 533 women to receive fish oil, olive oil or no oil from 30 weeks gestation until 
delivery and found women on the fish oil supplementation had approximately 4 day increase in 
gestation compared to the control groups (283.3 vs 279.4 days; p<0.006).126 An Australian study 
of 2399 pregnant women randomized to receive a supplement containing 800 mg DHA per day 
or a vegetable oil control supplement found that fewer preterm births occurred in the DHA group 
compared to control (1.09% vs 2.25%; p=0.03) and the DHA group also saw a reduction in the 
risk of having a low birth weight baby (3.41% vs 5.27% control; p=0.03).127 Although Helland et 
al. did not find significant differences between supplemented and control groups in gestational 
length or birth weight in 341 subjects (n=148 cod liver oil 1.18g DHA, 0.8g EPA versus corn oil 
control n=137), when comparing the quartile with the highest concentration of DHA in umbilical 
plasma phospholipids with the lowest quartile, the upper quartile had a gestational length 
increase of 7.1 days (282.5 days vs 275.4 days).15   
Several meta-analyses have also examined the effect of DHA supplementation during 
pregnancy and gestational length and infant birth weight. A positive correlation between fish 
intake during pregnancy and an increase in gestational length was reported in Secher’s review of 
well-conducted observational studies, RCT, and meta-analyses.128 In the meta-analysis of RCT, 
Szajewska et al. reported only a modest 1.6 day increase in gestation in women supplemented 
with marine oils containing DHA (1278 infants from 6 trials).129 In their systematic review and 
meta-analysis, Salvig and Lamont reported results indicating a 4.5 day longer gestation and 71 g 
higher birth weight of infants in women who received LCPUFA (1187 women, 3 trials) as well 
 17 
as a reduction of preterm births (<37 weeks), which was previously undetermined by other 
reviews.130 
In Makrides’ 2006 Cochrane review, which covered 6 trials involving 2783 pregnant 
women, an increase of 2.6 days in gestation (95% CI 1.03-4.07 days; 3 trials, 1621 women) 
occurred in women supplemented with marine oil compared to placebo or no treatment. 116  
Additionally, marine oil supplemented mothers were 31% less likely deliver preterm (<34 
weeks) and delivered slightly heavier infants (47 g difference, 95% CI 1-93 g; 3 trials, 2440 
women) and the relative risk for preterm birth before 34 weeks gestation was lower (RR 0.69, 
95% CI 0.49-0.99; 2 trials, 860 women).116 Most recently, Imhoff-Kunsch et al. 2012 systematic 
review, which included 15 RCT examining the effect of LCPUFA in pregnancy, determined an 
outcome similar to Makrides’ with women receiving LCPUFA having a 26% lower risk of early 
preterm delivery (<34 weeks) (RR=0.74; 95% CI 0.58-0.94), as well as a decreased chance of 
delivering a low birth weight baby (RR=0.92; 95% CI 0.83-1.02).131 
However, several well-designed trials and observational studies have found no beneficial 
effects of fish oil supplementation on gestational length.132-136 After supplementing 233 pregnant 
women with 1.62 g EPA and 1.08 g DHA per day, Onwude et al. determined no difference in 
gestational length, birth weight or hypertension/preeclampsia in an intention-to-treat analysis 
between placebo and treatment groups.133 In a RCT of a subgroup of 3098 pregnant women in 
the Danish National Birth Cohort with low fish intake and no fish oil or DHA supplementation, 
Knudsen et al. reported no difference in gestational length between five treatment groups 
randomized to receive 0.1 g, 0.3 g, 0.7 g, 1.4 g or 2.8 g EPA+DHA per day during pregnancy 
and the control group.132 An observational study of 2109 pregnant women from a U.S. birth 
cohort enrolled in Project Viva from 1999 to 2002 found no association between marine n-3 
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PUFA and seafood intake during pregnancy and gestational length or preterm birth risk.137 
Similarly, in a population based sample of 965 pregnant Danish women, no association was 
detected between n-3 fatty acid intake and gestational length or birth weight.138  
Although conflicting results do exist, accumulating evidence from both RCT and meta-
analyses indicate DHA positively affects gestational length and possibly subsequent infant birth 
weights, while reducing the risks for both preterm birth and low birth weight infants. While 
several studies indicated no benefit of DHA supplementation during pregnancy, it is important to 
note that dietary DHA was often not controlled or accounted for in participants, some sample 
sizes were low, and DHA concentrations were low or not analyzed by tertiles or quartiles of total 
daily DHA intake.   
Infant neurocognitive development  
It is well established that DHA is important in fetal neurological development.58,81,139 
DHA is preferentially transported to the fetus during the last trimester of gestation, which 
coincides with fetal retinal and brain development, specifically with a growth spurt in gray 
matter.5,67,98 Neurogenesis is at its maximum during the last trimester of gestation through two 
years of age. Several studies have shown a variety of visual, cognitive and behavioral 
impairments when infants are deficient in DHA during this critical development period.140 
Recent animal studies have suggested DHA exposure in utero influence neural differentiation, 
synaptogenesis and neurotransmitter target finding, and also indicate that once the window for 
development is past, deficits are not always reversible later.5,53,79  
Numerous animal studies have provided direct evidence for the importance of DHA in 
the development of the brain. Maternal diets deficient in n-3 fatty acids have resulted in 
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decreased neurogenesis and altered morphology of structures within the rat brain. Coti Bertrand 
et al. determined brains of embryonic pups of mothers eating a diet deficient in n-3 fatty acids 
had altered brain morphology and a 55-65% reduction in brain DHA content, with a 
compensatory increase in brain AA.141 Cao et al. showed inhibited neurite growth and 
synaptogenesis in the hippocampi of embryos of female rats fed n-3 deficient diets. By contrast, 
brains of embryos from dams receiving adequate DHA in their diets exhibited increased neurite 
growth and synapsin formation, providing further evidence DHA may play a direct role in 
improving cognitive function within the hippocampus.142 Studies in nonhuman primates show 
feeding diets with a high ratio of LA to ALA causes a significant decrease in the normally high 
brain DHA accumulation that occurs during development and results in less mature development 
of visual acuity as well as altered attention and behavior, suggesting slower brain maturation.143-
145 Levant et al. found rats fed a low ALA diet had a significant reduction of brain DHA, altered 
brain serotonergic system, increased hypothalamic pituitary axis response to stress, and altered 
dopaminergic function within the brain, indicating brain DHA depletion may be related to 
neurotransmitter programming and subsequent related behavioral changes that may not be 
reversible after the development stage is complete in early infancy.146-148 In a recent review, 
Davis-Bruno et al. concluded deficiencies of DHA during the critical time period of brain growth 
may result in neuronal development deficits that are not corrected by later increases in dietary 
DHA, suggesting a crucial time frame may exist for receiving adequate DHA for optimal brain 
development.149 
Observational longitudinal studies in humans support a relationship between DHA status 
during pregnancy and infant neurocognitive development. Cord blood DHA status was 
determined in Inuits from Artic Quebec, a population with typically high fatty fish intake, and 
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DHA levels were associated with improved cognitive, visual and motor development during the 
first year of life.12 Several large birth cohorts, including the Avon Longitudinal Study of Parents 
and Children (ALSPAC), Project VIVA and the Danish National Birth Cohort, have further 
supported the importance of DHA during pregnancy, determining positive associations between 
maternal fish intake during pregnancy and the cognitive abilities of the children.11,13,150 Through 
the ALSPAC cohort, Hibbeln et al. demonstrated women consuming greater than 340 g of fish 
per week had a decreased risk of their children performing poorly on standardized IQ tests when 
compared to mothers with low seafood intake during pregnancy.11 Using a prospective U.S. 
cohort of 341 mother-child pairs, Oken et al. reported maternal intake of greater than 2 servings 
of fish per week during pregnancy is positively associated with improved child cognitive test 
performance on the Peabody Picture Vocabulary Test (PPVT) and Wide Range Assessment of 
Visual Motor Abilities (WRAVMA) at 3 years of age, whereas maternal fish intake ≤2 
servings/week was not associated with a benefit.13 A recent prospective longitudinal 
observational study of 154 Inuit children, with regularly high dietary fish intake, reported higher 
umbilical cord blood DHA concentrations were associated with improved performances on 
memory assessments at school age (mean 11.3 years).151 While results from observational studies 
are important, it should be noted that such studies are limited and often cannot adjust for 
complex confounding variables that influence early cognitive development. 
RCT are necessary to establish a relationship between maternal DHA intake during 
pregnancy and lactation and infant neurological development. Numerous recent RCT have 
associated increased maternal DHA intake during pregnancy with improvements in cognitive 
development of the offspring, however, many results are mixed. In a RCT, Dunstan et al. 
supplemented pregnant women with high doses of DHA at 2.2 g per day beginning at 20 weeks 
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gestation through delivery and assessed child cognitive development using several cognitive 
assessment tests at 2.5 years of age and determined children born to the supplemented group had 
significantly higher scores on hand-eye coordination subtests compared to the control group 
(p=0.02), however, no other significant differences were apparent in other tests.9 Colombo et al. 
supplemented pregnant women with DHA eggs (135 mg DHA per egg) or normal eggs (35 mg 
DHA per egg) and assessed the effects of maternal DHA intake on look duration and attention 
span of 75 infants at 5 time points during the first 18 months of life.21 Children whose mothers 
had the highest DHA status at delivery showed the shortest look duration at 4 and 6 months and, 
although this advantage was absent at 8 months, at 12-18 months infants born to mothers with 
the highest DHA levels demonstrated more mature attention spans and were less easily distracted 
when compared to infants born to mothers with low DHA status.21 
In a double-blind, placebo-controlled RCT, Judge et al. supplemented pregnant women 
beginning at 24 weeks gestation through delivery with cereal bars containing 300 mg DHA 
consumed an average of 5 days per week or placebo bars. Judge et al. found infants born to 
mothers in the DHA supplemented group performed significantly better on problem-solving 
tasks in the Infant Planning Test at 9 months (p=0.017 total intention score; p=0.011 total 
intentional solutions) when compared to infants born to mothers of the placebo group, yet no 
differences were seen in any measure of the Fagan Test of Infant Intelligence (FTII).16 
Additionally, Judge et al. measured infant sleep/wake patterns on postnatal days 1 and 2 and, 
after controlling for ethnic variation, discovered significantly fewer quiet sleep (QS) arousals on 
day 1 (p=0.006) and day 2 (p=0.011) and less arousals in active sleep (AS) on day 1 (p=0.012) in 
the infants born to mothers in the DHA supplemented group compared to the placebo group.152 
Cheruku et al. also determined newborn sleep organization to be associated with maternal DHA 
 22 
status during pregnancy, showing infants born to mothers with plasma phospholipid DHA >3.0% 
total fatty acids had significantly lower ratio of AS to QS and less AS compared to infants of low 
DHA status mothers.153 Increased quiet sleep with less arousals in both quiet and active sleep in 
infants are characteristic of more mature neurological development, less negative emotionality 
and indicative of improved cognitive and developmental outcomes at 5 years of age.154 
Using the BSID-II to assess the impact of DHA supplementation in pregnant women and 
infant neurocognitive development in a developing country, Tofail et al. randomly assigned 
women to receive 4 g of fish oil supplement per day (1.2 g DHA and 1.8 g EPA) or soy oil 
control from 25 weeks gestation until delivery. BSID-II was performed on a total of 249 infants 
born within the trial at 10 months of age, and no significant differences were determined between 
treatment groups.155 However, it should be noted that the study took place in the developing 
country of Bangladesh, where 28% of mothers in the study suffered from maternal under-
nutrition, were likely to have low DHA stores and possibly lack additional essential nutrients, 
and where the BSID has not been validated or standardized. Additionally, the investigators 
explained while they achieved a sample size with >80% power, the study attrition of 38% from 
the original randomized sample could have significantly impacted study outcomes. Subjects lost 
could have benefited more from the study intervention because they were at significantly greater 
risk for neuro-developmental problems due to increased poverty, lower birth size, and increased 
complications during pregnancy and at birth when compared to subjects that remained in the 
study.155 
Another large RCT supplemented 315 pregnant women in Spain, Germany and Hungary 
with 1 sachet per day of a 15 g milk-based supplemented containing modified fish oil providing 
500 mg DHA and 150 mg EPA, 400 µg per day of 5-methyltetrahydrofolate, both or placebo 
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from 20 weeks gestation until delivery. Neurological development was examined focusing on the 
detection of minor degrees of neurological function using the Hempel minor neurological 
dysfunction (MND) at 4 years of age on 175 children born within the study and with the Touwen 
MND at 5.5 years of age on 157 children, both reaching sample sizes with a power of >80%.156 
Escolano-Margarit et al. reported no significant differences between any of the treatment groups 
within the study, indicating DHA supplementation during pregnancy may not benefit or harm the 
long-term neurologic development of children.156 However, it should be noted that higher DHA 
levels in fetal and maternal blood are correlated with each other and were also related to 
improved performance on the neurological assessments at 5.5 years of age.156,157 In a follow-up 
study of 154 children from this same birth cohort, Campoy et al. observed no significant 
differences in the Kaufman Assessment Battery for Children (K-ABC) at 6.5 years of age 
between study intervention groups.20 Yet, interestingly, children with a Mental Processing 
Composite (MPC) score greater than the 50th percentile were born to mothers with significantly 
higher percent of DHA concentrations in erythrocyte phospholipids (p<0.001), indicating 
prenatal DHA status may have subtle positive effects on the neurological development of the 
offspring.20 
Similarly, van Goor et al. investigated the effects of maternal DHA supplementation 
during both pregnancy and lactation on infant neurological development as well as whether 
additional AA supplementation could further modulate the effects of DHA. Women were 
supplemented with 220 mg DHA (n=42), 220 mg of both DHA and AA (n=41) or control 
soyabean oil per day from 15.6 to 17.4 weeks gestation through 3 months postpartum and infant 
neurological development was tested at 2 weeks and 12 weeks after birth using a sensitive 
general movement quality assessment. Supplementation with DHA alone resulted in mildly 
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abnormal general movements in early infancy compared to the DHA+AA and control groups.158 
In a later follow-up evaluation of children born in the trial, no differences were found between 
any of the supplemented groups on the Hempel MND and BSID-II at 18 months of age, 
indicating maternal DHA or DHA+AA supplementation did not influence toddler neurocognitive 
development.159 However, it is interesting to note that van Goor et al. did find umbilical blood 
DHA concentrations were lower in children with simple MND and umbilical blood AA 
concentrations were higher in children with complex MND compared to children with normal 
neurological condition.159  
To assess the effects of DHA supplementation during both pregnancy and lactation, 
Helland et al. supplemented pregnant women in a RCT in Norway, beginning at 18 weeks 
gestation through 3 months postpartum with cod liver oil containing 1.18 g DHA per day or corn 
oil and initially found no improvements in cognitive development of children at 6 and 9 months 
of age when compared to control.15 However, a follow-up study of a subset of 34 infants from 
the study determined that children born to mothers on the cod liver oil had higher composite 
score on K-ABC at 4 years of age (p=0.049).10 Yet, in an additional follow up at 7 years of age, 
scores on the K-ABC did not differ between groups, indicating the positive effect from early 
DHA exposure may not remain through school age.160 In the double blind, multicenter, RCT 
DOMInO study, 2320 women were randomized to receive DHA rich fish oil providing 800 mg 
DHA and 100 mg EPA per day or vegetable oil control supplements beginning at approximately 
22 weeks gestation until delivery. Neurodevelopment was assessed on a total of 694 children 
born within the study using the BSID-III and Makrides et al. did not determine any significant 
differences in any neurocognitive development outcomes between treatment groups.127 Yet, the 
researchers did note that fewer children born to mothers in the DHA supplemented group had 
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delayed cognitive development (BSID scores <85) compared to the control group, indicating 
early DHA supplementation may have an effect on preventing cognitive delays.127  
Most of the evidence for the effect of DHA on infant cognitive development is provided 
by studies focusing on DHA supplementation during pregnancy, however some studies have 
examined possible infant benefits of DHA exposure after birth. Postnatal DHA supplementation 
is most often studied through the use of DHA enriched formulas or maternal DHA 
supplementation during lactation. Preterm infants are at the greatest risk for neurocognitive 
development impairments, possibly because they lack the opportunity to accumulate large 
amounts of DHA commonly occurring during the last trimester of gestation. Therefore, many 
compelling studies on the effects of DHA on infant neurocognitive development are performed 
in preterm infants. For instance, O’Connor et al. determined preterm infants fed formula 
supplemented with DHA in the form of fish oil (DHA 0.26% fatty acids of formula) had higher 
BSID-II scores and MacArthur Communicative Inventory scores at 12 months of age when 
compared to age-matched infants that were not supplemented with DHA.161  
In the DIAMOND study infants enrolled at 1-9 days of age were provided with infant 
formulas containing one of four levels of supplemented DHA (0% fatty acid DHA, 0.32% DHA, 
0.64% DHA or 0.96% DHA) until the infants were 12 months of age.  Cognitive function of the 
131 children was assessed by BSID-II at 18 months of age and Drover et al. determined 
significantly higher BSID Mental Development Index (MDI) scores for infants supplemented 
with any level of DHA (all three groups combined), compared to the no DHA formula group 
(104.1 vs 98,4; p=0.02).162 In another RCT in which infants were supplemented with DHA 
formula (35% fatty acid DHA) or control formulas, Birch et al. demonstrated a mean increase of 
7 points on the MDI of the BSID-II.163 A recent meta-analysis of prevention trials, showed a 3.44 
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point advantage (95% CI 0.57-6.31) on the BSID-II of preterm infants fed LCPUFA 
supplemented formulas compared to infants on control formula.17  
Unlike the controlled DHA concentrations found in infant formulas, the concentration of 
DHA in breastmilk varies widely worldwide and is strongly associated with maternal DHA 
intake.105 Breastmilk DHA levels and infant neurocognitive development have been shown to be 
positively associated in numerous recent studies.5,28,68,164 Using multiple regression analysis, 
Lassek and Gaulin looked at Programme for International Student Assessment (PISA) math 
scores in 2009 as an index of cognitive performance in children from 28 countries and country-
specific breastmilk DHA levels and found DHA was significantly associated with math scores 
(p=0.006), greater than any other control variables including per capita Gross Domestic Product 
and per pupil education expenditures.165 
Focusing on lactation and DHA supplementation, the DINO trial investigated the effects 
of postnatal DHA exposure in very preterm infants (<33 weeks gestation) and infant 
neurocognitive development.23 Mothers were supplemented with 3 g DHA per day, a high 
amount of DHA designed to match the degree of in utero accumulation of DHA, 3 g of placebo 
soy oil, or, if formula was required, a preterm formula containing a matching DHA composition 
or control formula.23 Makrides et al. determined no significant differences in infant BSID-II MDI 
scores at 18 months of age between treatment groups, although significant reductions were seen 
in the proportion of children with cognitive delays (BSID <85) in the DHA supplemented groups 
compared to controls.23 To look at varying DHA supplementation during lactation, Gibson et al. 
assigned breastfeeding women to 200 mg, 400 mg, 900 mg or 1300 mg DHA per day or placebo 
for the first 12 weeks postpartum and determined infant erythrocyte DHA status at 12 months 
was associated with higher BSID-II MDI scores at 1 years of age, however not at 2 years of 
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age.22 With continued DHA supplementation during the first 4 months of lactation, Jensen et al. 
reported children born to women supplemented with 200 mg per day of DHA had significant 
increases in the BSID-II Psychomotor Development Index (PDI) at 30 months of age compared 
to children of vegetable oil control supplemented mothers (p<0.01).164 Yet, there were no 
statistically significant differences between supplementation groups on all BSID testing at 12 
months or on the BSID MDI at 30 months. In a follow-up at 5 years of age, Jensen et al. found 
that children of DHA supplemented mothers performed better on the Sustained Attention 
Subscale of the Lieter International Performance Scale (p<0.008) than children of mothers 
supplemented with vegetable oil, however, no significant differences between groups were seen 
on other neuropsychological tests.166  
While formal meta-analyses could not be performed in 2 recent systematic reviews due to 
differing infant outcome measurements, both Larque et al. and Lo et al. concluded there is 
currently insufficient evidence that increased DHA status results in neurocognitive 
improvements and most studies failed to show sustained benefits.167,168 However, both reviews 
did note that children with low DHA status appeared to benefit the greatest with increased DHA 
during gestation and lactation and DHA did appear to show the most improvements in preventing 
mild to moderate cognitive delays. Many of the trials reviewed had methodologic problems, 
issues with study designs, cognitive tests and time frames, and a lack of consistent LCPUFA 
supplementation. In the 2013 systematic review and meta-analysis, Gould et al. determined 
similar limitations in performing meta-analysis with a lack of standard cognitive tests throughout 
the studies, and stated current evidence does not conclusively show a benefit of DHA on 
neurocognitive outcomes, but also does not disprove the possibility of a benefit.169 Yet, Gould et 
al. determined evidence from 2 of the 11 RCT reviewed showed cognitive scores of children 2-5 
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years old were increased with LCPUFA supplementation during pregnancy or pregnancy and 
lactation (p=0.01), though the risk for bias is high.169 Similarly, in reviewing evidence from 
recent RCT, Dziechciarz et al. and Luchtman and Song found a lack of clear and consistent 
benefit for n-3 fatty acid supplementation in pregnancy on infant cognitive development.170,171 
The researchers noted that while individual trials reported improvements in some cognitive tests, 
the improvements were not consistent across trials and did not persist over time.  
Two recent Cochrane reviews focused on the benefits of LCPUFA and DHA 
supplemented infant formulas and cognitive development. Schulzke et al. reviewed 17 trials of 
LCPUFA supplemented infant formulas and did not find any benefit of supplementation on 
neurocognitive development in infants born preterm, however, it should be noted in most cases 
the studies included in the review used a mixture of n-3 and n-6 fatty acids within the 
formulas.172 Simmer et al. included 15 studies using infant formulas supplemented with DHA 
alone or DHA plus AA and concluded that results from the most well-conducted RCT did not 
show beneficial effects of LCPUFA supplementation of infant formulas on neurodevelopment of 
the infants born at term.173 Makrides et al. recent review determined developmental benefits of 
LCPUFA supplementation in infant formulas are consistently observed in preterm infants, while 
supplementation in term infants remains inconclusive.17 The researchers emphasized the need for 
continued well-designed RCT focused on determining effective timing and dose of DHA 
supplementation. Similarly, a Cochrane systematic review of 6 RCT focusing on n-3 
supplementation during lactation found supplementation had no significant effect on infant 
neurocognitive development.174 Current evidence does not conclusively support or refute 
supplementation of n-3 fatty acids postnatally through infant formulas or breastmilk has a 
positive effect on infant neurocognitive development. 
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An emerging research topic is whether boys and girls have different DHA requirements 
and thus would respond and benefit differently to DHA supplementation. Previous studies have 
documented lower neurodevelopment scores for boys compared to girls in early childhood, 
especially in preterm infants.175 Using stepwise regression analysis, Lassek and Gaulin looked at 
4154 American children aged 6-16 in the U.S. Third National Health and Nutrition Examination 
Survey (NHANES III), and after controlling for a variety of confounders, discovered a positive 
relationship between n-3 fatty acid intake of 1 g or greater and cognitive test scores in both males 
(0.19 point increase) and females (0.38 point increase). However, in female children, the positive 
effects were twice as strong as in males (p=0.001), suggesting female children may benefit more 
cognitively from increased n-3 intakes.176 Utilizing the Danish National Birth Cohort, Lauritzen 
et al. investigated the effects of supplementing breastfeeding mothers below the median fish 
intake with 1.5 g of fish oil containing 900 mg DHA per day and infant cognitive 
development.177 No significant differences were found in infants born in the study at 4 months, 1 
year and 2 years of age between treatment groups on any cognitive development test, however, 
when analyzing based upon gender, a significant positive association between fish oil 
supplementation and problem solving on the Infant Planning Test at 9 months of age was found 
in girls, where no positive association was determined in boys. Additionally, it should be noted 
that word comprehension at one year of age was inversely associated with 4 month infant 
erythrocyte DHA concentration and at one year of age, passive vocabulary was lower in children 
born to the fish oil supplement group compared to the olive oil control (p<0.05), however no 
differences were found by 2 years of age.177  
Supplementing early preterm infants (<33 weeks gestation) with high dose DHA (~1% 
total fatty acids) formula from day 2-4 until term age, at 18 months resulted in no significant 
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differences in overall neurocognitive development as shown on the BSID MDI. However, when 
separated the data by gender, the MDI scores for girls with high DHA supplementation, through 
DHA supplemented mothers breastmilk or DHA enriched formula, were significantly higher than 
girls on control formula (p=0.03; adjusted mean difference 4.7; 95% CI 0.2-9.2), with no 
difference discovered among the boys.23 Additionally, higher DHA supplementation reduced the 
risk of mild [BSID developmental quotient (DQ) <85; p=0.01] and severe (BSID DQ<70; 
p=0.02) cognitive delay for girls at 18 months of age, while no effect was noted for boys.23 A 
review of two large-scale intervention trials of DHA supplementation of preterm infants found 
significant differences between boys and girls in response to DHA supplementation and 
neurocognitive development.178 These studies indicate that boys and girls respond differently to 
DHA supplementation and opens up a new avenue of research in the field of DHA and 
neurocognitive development. 
Breastmilk and DHA  
Important cognitive, visual, and motor development milestones are reached within the 
first two years of life and the lipids of breastmilk are of critical importance by providing not only 
a major energy source, but also LCPUFA that infants are unable to synthesize and are required 
for normal growth. The American Academy of Pediatrics recommends exclusively breastfeeding 
infants for the first 6 months, with continuation of breastfeeding for 1 year or longer.179 
Compared to infants who never breastfed, infants exclusively breastfed for 4-6 months showed 
significantly lower incidences of several illnesses, including respiratory tract illnesses, 
gastrointestinal illnesses and dermatological conditions.180,181 Additionally, breastfed infants 
perform better on visual and cognitive development tests compared to formula-fed infants.182-184 
Breastfed infants were found to have improved psychomotor development at 4 months and 
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higher IQ throughout childhood when compared to infants fed formula lacking LCPUFA185.  
Lucas et al. concluded that children breastfed as infants had significantly higher IQ scores at 7.5 
to 8 years of age than those not breastfed.186 A recent meta-analysis of controlled clinical trials 
concluded that after controlling for confounding factors, IQ in breastfed infants was higher than 
formula fed infants beginning as early as 6 months of age.187 This beneficial effect of 
breastfeeding was still present at 15 years of age, with the cognitive benefits increasing with 
increased breastfeeding duration. 
The major components of breastmilk are proteins, carbohydrates and lipids, with lipids 
representing the second largest fraction at 40 g/L.188 DHA in breastmilk ranges from 0.17% to 
1.0% of total fatty acids and research indicates lactating women supplemented with DHA see 
increasing levels of breastmilk DHA based upon supplement concentrations.189,190 DHA, like 
other fatty acids, is rapidly transferred into milk with no known selectivity between fatty acids. 
Breastmilk DHA can be drastically altered within 2-3 days based upon maternal intake of 
DHA.191,192 Studies using stable isotope tracers have provided evidence of DHA from the 
maternal diet transfers directly into breastmilk.193 Breastmilk DHA content has been shown to 
increase by 76% and infant plasma phospholipid DHA by 35% when the mother is exclusively 
breastfeeding and supplemented with 200 mg of DHA per day.164 However, supplementing with 
an ALA source, such as flax seed oil, with no preformed DHA, breastmilk DHA content does not 
increase.194 Infant formulas, while mimicking components of human breastmilk, often lack 
LCPUFA or contain fatty acid ratios not as beneficial to infant development as compared to 
breastmilk, and, consequently, may not be able to provide the same benefits to the infant as 
breastmilk.195 
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After birth, breastmilk or formula are the sole sources of n-3 and n-6 fatty acids to the 
infant, therefore, it is essential for development that the infant receive adequate amounts of these 
important LCPUFA. The concentrations of DHA in breastmilk are correlated with both visual 
acuity and neurocognitive development.164,190,196 Piglets fed formula containing corn oil and no 
DHA showed marked deficits in DHA accretion in the brain and retina.197 An autopsy study of 
human infants, Makrides et al. reported lower brain and erythrocyte DHA in infants who had 
been fed formula lacking DHA compared to breastfed infants (p<0.005). In addition, Makrides et 
al. also found brain cortex DHA increased in breastfed infants over time (r2=0.72, p<0.01), 
indicating the duration of breastfeeding affected DHA levels of the infant (r2=0.62, p<0.01).198 
Due to early birth and decreased DHA accretion in utero, preterm infants are born with lower 
DHA levels compared to term infants and are, therefore, at an even greater need for receiving 
DHA externally from breastmilk to develop at a normal, healthy pace.199 Preterm infants not 
breastfed and fed infant formula lacking in LCPUFA had lower DHA status, decreased growth 
and showed a reduction in mental development from 9 to 12 months of age.200 
The Danish National Birth Cohort, examined 25,446 children and found both fish intake 
during pregnancy and the duration of breastfeeding were independently associated with 
improved early child development. Children born to mothers with the greatest fish intake during 
pregnancy (OR=1.29; 95% CI 1.20-1.38), when compared to the lowest, and who breastfed for 
≥10 months (OR=1.28; 95% CI 1.18-1.38), compared to ≤1 month, had higher child 
development scores at 18 months of age.150 Unfortunately, in this study, fish intake during 
lactation was not assessed to determine a possible influence of increased breastmilk DHA on 
early child development. 
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Maternal genetics and breastmilk DHA 
The concentrations of fatty acids, including DHA, in breastmilk are highly dependent 
upon the mother’s diet, with breastmilk levels increasing proportional to maternal dietary 
increases.190 In addition to dietary supply, DHA in breastmilk can be endogenously derived from 
precursor fatty acids by elongation and desaturation, of which the rate-limiting enzymes in this 
cascade are believed to be the Δ6-desaturase enzyme.39 The Δ6 and Δ5-desaturase enzymes are 
encoded by FADS2 and FADS1 genes, respectively, which are arranged in a head-to-head 
orientation on chromosome 11q, with a third desaturase gene, FADS3, which function is 
currently unknown.  In recent years, several studies have shown that SNPs in the FADS1FADS2 
gene cluster are associated with altered DHA concentrations in erythrocytes, plasma and 
breastmilk.18,19   
Several recent studies demonstrate SNPs within the FADS1 FADS2 gene cluster 
significantly influence erythrocyte and plasma LCPUFA, especially DHA, concentrations.201-205 
In a genome wide association study of plasma LCPUFA concentrations, Tanaka et al. studied 
1,075 participants and found the strongest association between genetics and LCPUFA 
proportions of plasma fatty acids was in the FADS1 FADS2 gene. The SNP with the most 
significant association was rs174537, in which homozygous minor allele carriers had higher 
plasma concentrations of LA and ALA and lower concentrations of AA, EPA, docosapentaenoic 
acid (DPA) and DHA.205 Utilizing infants participating in the KOALA and LISA birth cohorts 
(n=879), Rzehak et al. found minor allele carriers of all five SNPs within the FADS1 FADS2 
gene cluster studied (including rs174575, rs174546, rs174556, rs174561 and rs3834458) showed 
higher levels of precursor fatty acids LA, dihomo-γ-linoleic acid (DGLA) and ALA with 
decreased levels of desaturase products, AA, EPA, DPA and DHA.204 Confirming these findings 
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in pregnant women, Koletzko et al. found pregnant women participating in the large ALSPAC 
birth cohort (n=4457) that were minor allele carriers of 12 FADS1 FADS2 SNPs studied had 
increases in desaturase substrates, such as LA, DGLA and ALA and, and decreased amounts of 
desaturase products, including AA and DHA.202 Studying the effects of FADS SNPs on infant 
DHA status, Harsløf et al. found infants homozygous for the minor allele of rs174575 and 
rs17448 had a decrease in erythrocyte DHA status, while minor allele carriers for rs1535 had 
increased DHA status, when compared to wild type carriers.206  
Xie and Innis provided evidence that SNPs in the FADS gene cluster are associated with 
breastmilk DHA concentrations.  The researchers recruited, assessed diets and determined the 
presence of 6 previously identified SNPs in the FADS1 FADS2 gene cluster in 54 pregnant 
women. Women homozygous for the minor allele of the rs174575 SNP in the FADS2 region had 
lower levels of AA (p=0.015), docosapentaenoic acid (22:5n-3; p=0.003), EPA (p=0.01) and 
DHA (p=0.044) in breastmilk, regardless of dietary intake, compared to women homozygous for 
the major allele.19 A subsequent study by Molto-Puigmarti et al. determined plasma and 
breastmilk DHA concentrations based on common (≥18% frequency) FADS1 FADS2 SNPs in 
309 Dutch women as part of the prospective KOALA Birth Cohort Study. DHA proportions in 
plasma (p<0.01) as well as breastmilk (p<0.05) were lower in women homozygous for the minor 
allele of all three SNPs studied, FADS1 rs174561, FADS2 rs174575 and intergenic rs3834458, 
than in women homozygous for the major alleles.18 This study found similar results to the study 
by Xie and Innis that, while breastmilk DHA levels did increase with increased dietary intake of 
DHA, the women homozygous for the minor alleles could not compensate for the lower 
incorporation of DHA into breastmilk by increasing fish and fish oil intake. 
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Studies have linked maternal genetic variations in the FADS1FADS2 gene cluster with 
child cognitive development.  Data from two population-based birth cohorts (n=740) was 
examined in Morales et al. 2011 study in which breastfed children of mothers with SNPs coding 
for lower FADS1 activity, higher FADS2 activity and higher DHA levels of breastmilk showed 
significant cognitive advantages at 14 months on the BSID-III.25 Caspi et al. determined SNPs 
within the FADS1FADS2 gene cluster interacted with breastfeeding to provide a significant IQ 
advantage, specifically major allele of rs174575 children showed a 6.4 IQ advantage at 7-13 
years of age over children not breastfed (p<0.001).26 Additionally, the study found that children 
who were minor allele carriers did not have any IQ advantage to being breastfed, suggesting the 
SNP somehow influences the positive benefits breastfeeding has on neurocognitive development. 
However, in a study of nearly 6000 children, Steer et al. determined no significant differences 
between breastfeeding and IQ based upon genetic variations, indicating the influence of 
genotype on IQ remains inconclusive.27 Genetic variations within the FADS1FADS2 gene 
cluster have also recently been shown to have an impact on adult cognition, cardiovascular 
disease, eczema and numerous other atopic diseases.201,207 
Body composition and DHA 
Currently, there is mounting evidence that increased LCPUFA, specifically DHA intake, 
can reduce body fat in both adults and children. Health during adulthood may have origins in 
both fetal and early infant life, a time in which the body may be programmed both positively and 
negatively.208 The relationship between breastfeeding and childhood obesity was investigated by 
Arenz et al. 2004 systematic review and meta-analysis in which the researchers determined after 
analyzing 9 studies with over 69,000 participants that breastfeeding significantly reduced the risk 
of obesity during childhood (OR=0.78; 95% CI 0.71-0.85).209 
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More specifically to LCPUFA, numerous animal studies have shown diets high in 
LCPUFA result in lower body fat accumulation and reduces obesity.210,211 In humans, DHA has 
been shown to reduce body fat by increasing oxidation and suppressing fat deposition.212 DHA 
supplementation in the maternal diet may influence the growth and deposition of adipose tissue 
both in childhood and adulthood.213 Donahue et al. determined higher maternal DHA+EPA 
intake during pregnancy and higher DHA plus EPA umbilical cord plasma phospholipids were 
associated with lower adiposity in children at 3 years of age, as measured by skinfold thickness 
[-0.31mm (95% CI -0.58,-0.04mm) for maternal diet and -0.91mm (95% CI -1.63,-0.20mm) for 
cord plasma] and odds of obesity (OR=0.68; 95% CI 0.50-0.92).213 
Pedersen et al. showed a significant association between breastmilk DHA and child body 
mass index (BMI) from 2 to 7 years of age in 222 mother-infant pairs in the Copenhagen 
Prospective Study on Asthma in Childhood birth cohort.214 In a double blind RCT in Germany, 
Bergmann et al. supplemented pregnant women beginning at 21 weeks gestation until the third 
month of lactation with a daily vitamin control or one containing 200 mg DHA and looked at the 
impact of DHA on postnatal growth.  After adjusting for confounders, Bergmann et al. 
discovered the DHA group had significantly decreased BMI (p=0.037) and weight (p=0.046) of 
the infants, which resulted in significantly lower BMI (-0.76 kg/m2; 95% CI -0.07, -1.46) and 
weight (-601g; 95% CI -171, -1030 g) of the children at 21 months of age when compared to the 
control group.215 However, it is important to note that at a 6 year follow-up of these children, 
there was no longer any statistically significant differences between any anthropometric 
measures between both groups.216 In a systematic review, Rodriguez et al. reported mixed results 
and concluded LCPUFA intake either maternally during pregnancy and lactation or from 
supplemented formulas does not adequately explain body composition differences in infants and 
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children.217 While current data does not suggest or refute beneficial effects early DHA 
supplementation may have on body composition later in life, it is an interesting avenue for future 
DHA research. 
Possible adverse effects 
In spite of a large amount of data on the beneficial effects of n-3 fatty acids, specifically 
DHA, on neurocognitive development and improvements in other infant outcomes, it should be 
noted that supplementation of n-3 fatty acids is not totally without risk. In their review of DHA 
supplementation during pregnancy and lactation in animal models, Davis-Bruno et al. concluded 
that balancing the supplementation ratio of DHA to AA is necessary for optimal retinal and 
neurocognitive development, however, prolonged excessive DHA supplementation may be 
detrimental by increasing oxidative stress and apoptosis, causing adverse effects on brain 
development, growth and even survival.149 The beneficial aspect of LCPUFA on cardiovascular 
disease through the antithrombotic actions in the inhibition of fatty acid oxidation and platelet 
aggregation could also cause adverse effects in high risk populations, such as women with 
complicated pregnancies or those at risk for stroke or bleeding.218 Furthermore, the anti-
inflammatory benefits of DHA could result in a potentially harmful suppression of an 
appropriate immune response in an immune-compromised individual.219 Additionally, in vitro 
studies have indicated chemical oxidation products formed from LCPUFA can produce 
mutagenic and carcinogenic responses.220,221 Potentially harmful oxidation products can occur 
within cells and also through improper storage of LCPUFA, such as exposure to UV light or high 
temperatures, and without naturally occurring protective antioxidants that accompany LCPUFA 
in foods with high endogenous LCPUFA, such as fish and seafood, LCPUFA supplementation 
could be a health concern.219,222 While there are no current reports in the literature of LCPUFA 
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supplementation and adverse birth outcomes, it is important to consider possible harmful 
outcomes when supplementing high-risk populations or when supplementing high doses, over 
long time periods. 
Discussion and conclusions 
Omega-3 fatty acids are important for human life, and DHA in particular must be 
obtained preformed from the diet, either from seafood or fish oil supplements. During pregnancy, 
DHA requirements increase as the fetus grows and more DHA is transferred from maternal 
supplies into the fetus for neural growth and development. Increased DHA status during 
pregnancy is associated with increased gestational age, decrease risk for preterm birth, and 
increase infant birth weight, all much to the improvement of infant health. While RCT are 
increasingly reporting varying results on the benefits of DHA supplementation early in 
development, both epidemiological and interventional studies provide evidence that DHA has an 
important role in healthy growth and neurocognitive development. Additionally, while human 
milk is important for providing growth and neurocognitive benefits alone, increasing the portion 
of DHA in the total fatty acids of milk provides even greater benefits to the child through 
improved cognitive and behavioral development, and even possibly reducing BMI and the risk of 
obesity later in life.  
While DHA has been shown to improve attention, information processing speed, and 
learning and memory, it is important to emphasize many studies have failed to provide 
conclusive results on the benefits of DHA during early development.144,158,164,182,223-227 The 
majority of trials to date often have relatively small sample sizes (n<100 per group) with high 
attrition rates (up to >80%), often far above the follow-up rate of ≥80% that is considered the 
 39 
minimum acceptable for minimizing attrition bias.228 Studies are often powered improperly to 
determine large differences rather than the modest effects that would be expected in DHA 
intervention trials. Additionally, supplementation varies greatly between studies, in amount, 
length of supplementation and time frame, usually either pregnancy or lactation. It is important 
to note that there is currently no standard supplementation guideline for which studies should be 
designed, with optimal supplementation time frames and dosages currently unknown for infant 
development.  
Contradictory findings amongst RCT could be due to several important factors that 
should be considered, including the source of supplemented DHA, too low of a supplemented 
dose to see any beneficial effect, and the DHA supplementation period was short or only during 
pregnancy or only during lactation. Additionally, most of the current intervention studies are 
conducted in populations with variable average DHA intakes from food and regularly fail to take 
into account dietary intakes of DHA aside from the treatment provided. Consumption of DHA 
directly from food sources can have a drastic effect on the overall DHA status of individuals and 
could possibly skew results to be non-significant, especially when comparing groups only by 
treatment and not DHA dosing effects.   
When focusing on neurocognitive development, inconsistency in study results could be 
due to the lack of globalized standard tests used to measure cognitive developments, especially 
in infants and young children. Standardized infant development tests, such as the BSID, use a 
variety of tasks to assess cognitive function and may provide a reliable estimate of later cognitive 
ability. The BSID is widely accepted and used throughout cognitive studies, and scores have 
been associated with IQ scores at 4 years of age in DHA supplementation published studies.229 
Studies that assess more specific aspects of cognitive functions, such as BSID subtests, means-
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end problem solving and attention tests, have reported more enhanced improvements in children 
supplemented with DHA.10,16,162,229  
However, current assessments of early cognitive function, such as the BSID or FTII, may 
not be sensitive enough to detect the specific effects DHA supplementation may have on certain 
aspects of cognitive development at certain time points. For instance, both Jensen et al. and 
Helland et al. reported no effects of maternal DHA supplementation on infant neurocognitive 
scores during the first year of life, yet found significant improvements once the children reached 
preschool ages.10,15,164,166 In addition to measurement means, the time at which to test children 
also remains highly debatable, with conflicting results at all ages, there appears to currently not 
be a defined proper cognitive testing age that is predictive of later IQ and long-term DHA 
supplementation effects. It is possible that the cognitive assessments currently used in RCT may 
not be ideal for the ages they are utilized or that the benefits of DHA supplementation early in 
development are not observable until cognitive function further develops and becomes more 
complex. Additionally, the use of the BSID as a reflection of infant cognitive development may 
no longer be appropriate. The BSID was originally designed as a measurement of infant 
cognitive development and to identify developmental delays, the test is not longer conclusively 
associated with school age IQ.230,231 Recently, more specific tests of attention and information 
processing have shown to possibly be betters measures of infant cognitive function and better 
predictors of later childhood IQ than the BSID and such measures should be considered when 
developing future research studies.232,233  
Much remains to be learned regarding the physiological effects of DHA on the 
developing child. It is clear by a growing body of evidence that increasing maternal DHA intake 
during pregnancy and lactation and prolonging breastfeeding may benefit child development. 
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Currently, low levels of dietary DHA consumption throughout westernized countries are of a 
primary concern and low DHA status in pregnant and lactating women may lead to suboptimal 
neurological development of the developing infant. While therapeutic recommendations exist for 
pregnant and lactating women based upon recent research, the recommendations are not 
standardized and the Institute of Medicine has currently not made any official dietary 
recommendations for Americans.47,49 In addition to promoting increased DHA intake during 
pregnancy, recommendations should be specified to continue increased DHA consumption 
during lactation, and breastfeeding should be promoted and supported to optimize a variety of 
child health outcomes.   
Future research should focus on optimizing supplementation recommendations, both 
dosing and duration, considering both short- and long-term effects of DHA on both preterm and 
term infants to improve infant development. Additionally, inter-individual differences, such as 
maternal and infant genetic variations in fatty acid desaturase activities and gender, and their 
impact on DHA developmental outcomes should be studied further. Future intervention studies 
should increase supplementation times to include both pregnancy and lactation, promote 
breastfeeding, control for dietary DHA intake in addition to supplementation, and should also be 
designed to examine not only visual and cognitive development, but also consider growth, body 
composition and possibly many other attention, behavioral and health disorders.   
In conclusion, increased DHA status of pregnant and lactating women through seafood or 
DHA supplement intake could positively impact numerous infant outcomes, including increased 
gestational age, decreased preterm birth risk, improved infant growth and enhanced 
neurocognitive development. However, with much variation in the research, the current evidence 
does not conclusively support or refute that increased DHA intake during pregnancy and/or 
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lactation positively benefits any infant development outcome and continued research is necessary 

































Figure 2.1. Diagram of omega-6 and omega-3 fatty acid metabolism. 
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 This chapter describes the methods used in this study.  
Subjects 
The Omega Smart Baby Project was a double-blinded, randomized, placebo controlled 
clinical trial. 115 women with singleton pregnancies were randomized to receive 300 mg of 
purified DHA or placebo between February 2010 and October 2011.  Women were recruited 
from Associates and Family Medicine and the Women’s Clinic of Colorado in the Fort Collins, 
Colorado area. A trained paraprofessional breastfeeding coach recruited women on or before 
their oral glucose screening appointment, between 24-28 weeks of gestation. Included women 
were 18-42 years of age with singleton pregnancies and were willing to breastfeed exclusively 
for the first 3 months of life. Exclusion criteria included maternal age <18 years, multiple 
fetuses, diabetes, HIV positive status, chronic illnesses or other conditions that could preclude 
breastfeeding and any known allergies to seafood or fish oils. The Institutional Review Board at 
Colorado State University approved all protocols and procedures (Appendix A). All women 
provided written informed consent prior to participation (Appendix B). 
Women were randomized to receive the study supplement of highly purified tuna fish oil 
containing 300 mg DHA and 67 mg EPA provided as HiDHA tuna oil (Nu-Mega Oil, Clover 
Corportation, Ltd; Appendix C) prepared as one hard capsule or Sunola, a high oleic acid 
sunflower oil placebo. The dose was selected based on previous pilot data with a power of 0.05% 
at the 80% confidence level. A block randomization procedure was used to assign women to 
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treatment. Women were provided with the study supplement at their oral glucose screen at 24-28 
weeks of gestation. Women were instructed to keep supplements in the provided container in a 
freezer to maintain quality and begin taking one capsule per day for the remainder of their 
pregnancy and until 3 months of breastfeeding were complete. Study supplements were provided 
in two opaque bottles with the study label attached, the first given at the entrance into the study 
and second at the first meeting between the breastfeeding coach and mother after giving birth.  
A food frequency questionnaire (FFQ) validated against erythrocyte DHA was used to 
estimate total DHA intake from food, prenatal vitamins and other sources (Appendix D). The 
FFQ included sources of DHA intake from fish and seafood, DHA enriched food products such 
as eggs or milk, and any fish oil or DHA supplements, including all prenatal vitamin 
information. Information was quantitated using the United States Department of Agriculture 
(USDA) National Nutrient Database for Standard Reference, Release 22. The FFQ was 
validated, with estimated DHA intake per week positively correlating with the percent total DHA 
in erythrocyte fatty acids (r=0.37, p=0.0002). Total weekly and daily DHA intake from the FFQ 
was calculated and verified with a 7-day diet record data (Appendix E). The 7-day diet record 
information was analyzed using Nutritionist Pro (Axxya Systems, Stafford, TX) software and 
total daily DHA intake from food was calculated. Participants received a printed copy of their 7-
day diet record analysis as a benefit to the study. Total dietary intake of the infants was gathered 
at 6 and 10 months of age in a 24-hour recall. Sociodemographic data, including age, race and 
marital status, were collected from each woman at the entrance into the study (Appendix F). 
Additionally, the date of the last menstrual period (LMP) and estimated due date were collected. 
Self-reported pre-pregnancy weight and height was used to determine maternal pre-pregnancy 
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body mass index (BMI). Infant birth information was gathered by the breastfeeding coaches at 
the first visit after delivery. 
Sample collection and fatty acid analyses 
A baseline blood sample was collected from women during their oral glucose screen 
between 24-28 weeks of gestation and stored briefly at 4oC until separated. Blood samples were 
collected in a Vacutainer containing EDTA and separated by centrifugation within 24 hours into 
erythrocyte, plasma and buffy coat fractions and stored at -80oC until further analysis. 
Breastmilk samples were obtained at 2 and 4 months postpartum and expressed using manual or 
electric breast pumps into sterile collection cups and transported on ice to the laboratory and 
immediately frozen and stored at -20oC. Lipids were extracted from maternal erythrocytes, 
plasma, and 2 and 4 month breastmilk samples using a modified Folch extraction 
(chloroform:methanol 2:1 v/v). Plasma phospholipids were further separated by thin layer 
chromatography and all lipid extracts were resuspended in 0.5 ml chromatographic grade 
hexanes. Fatty acid methyl esters (FAME) were prepared on all lipid extracts by direct 
transmethylation using 14% boron trifluoride in methanol (Sigma Chemical Co, St. Louis, MO).  
FAME were analyzed via gas chromatography on an Agilent 6890 chromatograph, using a 
ramped temperature program and flame ionization detection and a J&W DB225 column.  
Individual fatty acids were identified by comparison of retention times with known FAME 
standards (Nuchek Prep, Elysian, MN).   
Selection of SNPs and genotyping 
Two SNPs in the FADS1 FADS2 gene cluster were included for SNP analysis, FADS1 
rs174561 and FADS2 rs174575. The SNPs were chosen based upon previously reported 
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associations with differences in erythrocyte, plasma phospholipid and breastmilk DHA 
proportions, as well as associations with later child cognitive development. Additionally, the 
minor allele frequency for both SNPs was previously described as at least ≥ 18%, therefore, the 
expected number of subjects homozygous for the minor alleles in this study population would 
exceed 10.18,19,26,27 DNA was extracted from the buffy coat (white blood cells) collected from 
baseline maternal blood with the QIAamp DNA Blood Mini Kit (QIAGEN, Hilden, Germany). 
SNPs were genotyped with TaqMan SNP Genotyping assays (Applied Biosystems, Foster City, 
CA) with real-time polymerase chain reaction according to the manufacturer instructions using a 
StepOnePlus Real-Time PCR instrument (Applied Biosystems, Foster City, CA).  
Breastfeeding  
Exclusive breastfeeding was supported using a peer coaching model adapted from the in-
home breastfeeding support program, developed in North Carolina and tested in a WIC 
population. This model was adapted to a middle class, educated population and updated to meet 
current breastfeeding guidelines and policies.234,235 The program paired each pregnant woman 
with a well-trained paraprofessional breastfeeding coach, which provided support to the mother 
on an ongoing basis throughout lactation. The coach provided breastfeeding education prior to 
delivery, both in person and via phone or email, and began postnatal visits within days of 
delivery, with monthly contact throughout the study duration of 12 months. Coaches provided 
education, answered questions, assessed breastfeeding and provided recommendations and 
assistance to resolve any problems and helped the mothers reach their own personal 
breastfeeding goals beyond that of the study. In addition to the free breastfeeding support 
provided, as incentive to the study, each mother was provided with a complementary manual 
breast pump and had access to a medical grade electric pump if deemed necessary by the coach. 
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Exclusivity of breastfeeding was monitored and recorded by the coaches as reported by the 
mothers. Exclusive breastfeeding was classified as no food or formula other than breastmilk for 
the first 3 months of life.  Mothers were educated and encouraged to exclusively breastfeed 
through 6 months of life by their coaches and educated on proper progression of introducing and 
increasing infant appropriate foods according to the USDA Start Healthy Feeding Guidelines.236 
Infant cognitive testing 
The BSID-III Mental Development Index (MDI) subscales were administered on infants 
at 4 and 12 months of age by a trained technical assistant overseen by a licensed clinical 
psychologist in the Psychology Department at CSU. The BSID-III was selected as a 
measurement of neurocognitive development due to its ease of administration and for 
comparison to previous studies. The BSID-III MDI cognitive, language, social-emotional and 
general adaptive behavior scales were completed. The MDI has a mean score of 100 with 
standard deviation (SD) of 15 and includes items to measure performance in areas of knowledge, 
memory, problem solving, sensory perception, and early language. The BSID is widely accepted 
and used throughout cognitive studies, the test has excellent within age test-retest reliability and 
scores have been associated with intelligence quotient (IQ) scores at 4 years of age in DHA 
supplementation published studies.229 All BSID scores reported are composite scores and are, 
therefore, age corrected for each scale. To control for confounding effects of maternal IQ, 
mothers completed a maternal IQ test using the abbreviated Wechsler Adult Intelligence Scale 
(WAIS), including the block design and vocabulary subtests, which are highly correlated with 
full scale IQ (FSIQ; r2=0.84).237 To control for the confounding effect the degree of stimulation 
in the home environment may have on cognitive development, the mothers completed a self-
administered Home Screening Questionnaire (HSQ) at 9 months of age (Appendix G).238 Infant 
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characteristic questionnaire was completed by the mothers at 10 months of age to measure 
parental perception of infant temperament, focusing on difficult temperament (Appendix H).239 
Gestational length and infant anthropometric measurements 
Gestational length was calculated in days using the LMP method and infant date of birth. 
Infant anthropometric data was obtained from pediatric medical records. The mother reported 
infant birth weight, length and head circumference measurements to the breastfeeding coach at 
the first contact just after birth, and reported 2 month weights and heights after the 2 month well 
baby visit. Anthropometric data at birth and 2 months of age was normalized by expressing them 
as z scores based on term infants of the same age and sex by using parameters provided in the 
data files from the Centers for Disease Control and Prevention (CDC) growth charts released in 
2000 (www.cdc.gov/growthcharts). Pre-pregnancy maternal BMI was calculated based on self-
reported information on the study entrance form. 
Data analysis 
Participating women, all data collectors and investigators were blinded to supplement 
allocation until all study children were 12 months of age and had completed the cognitive testing.  
After all study data was collected, the study was unblinded only to study investigators for 
analysis, all other personnel collecting data will remain blinded because this cohort of children 
may be assessed for future development. Intent-to-treat (ITT) procedures were maintained 
throughout. Power was based on a previous pilot trial determining the effect DHA 
supplementation during pregnancy has on improved infant BSID scores at 4-6 months, 32 infants 
per supplementation group are necessary to reach a power of 0.05% at the 80% confidence level. 
Total daily DHA intake was calculated for each woman by adding estimated dietary DHA 
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intakes, maternal DHA supplementation (if applicable) and DHA study supplement. Data was 
analyzed based on treatment group, placebo versus DHA, as well as daily DHA intake groups 
broken into three groups: low = 0-299 mg per day DHA, medium = 300-599 mg per day DHA, 
high = ≥600 mg per day DHA. DHA cut-off points for the intake groups were determined on the 
basis of those falling below, at the median recommended intake and above the currently 
recommended intake.47,48 
Statistical analysis was completed using SPSS statistical software (SPSS, Chicago, IL) 
and GraphPad Prism V4.0 (GraphPad Software, San Diego, CA). Results are expressed as means 
± SD, unless otherwise specified. Deviations from Hardy-Weinberg proportions for the 
genotypes of each SNP were tested using chi-square tests.240 Two-tailed t test was used to 
analyze results based upon treatment and one-way analysis of variance (ANOVA) was used to 
compare means between all daily DHA intake groups. The data for each SNP was analyzed 
separately and categorized based upon genotype (homozygous for the major allele, MM; 
heterozygous, Mm; homozygous for the minor allele, mm) and/or daily DHA intake group (low, 
medium or high) or treatment group (placebo or DHA). Tukey’s post hoc tests were conducted 
on all statistically significant ANOVA results to determine if differences existed among group 
means. Correlations were computed using Pearson’s correlation coefficient. Statistical 
differences in fatty acid proportions and BSID-III scores were also tested with a two-way 
ANOVA and ANCOVA to determine possible interactions between SNP genotype and daily 
DHA intake level. Data was adjusted for potential confounders, when appropriate, including, 
maternal age at delivery, maternal BMI, maternal IQ, breastfeeding duration, gestational age and 






EFFECTS OF DOCOSAHEXAENOIC ACID INTAKE DURING PREGNANCY AND 
LACTATION ON INFANT GROWTH AND NEUROCOGNITIVE DEVELOPMENT: A 
RANDOMIZED CONTROLLED TRIAL1 
 
 
Background:  Maternal docosahexaenoic acid (DHA) intake during pregnancy and/or lactation 
has been positively associated with infant growth and cognitive development. However, the 
majority of studies to date have not examined the effect of supplementing mothers with DHA 
during both pregnancy and lactation and fail to account for total maternal DHA intake.  
Aims:  To determine the effect of increasing DHA intake during pregnancy and lactation on 
infant neurocognitive development in the first year of life.  
Study Design: A randomized, double-blinded, placebo-controlled design was used. 
Subjects: 115 pregnant women were randomized to receive purified tuna oil supplement 
containing 300 mg of DHA and 67 mg EPA per day or an identical placebo (Sunola Oil) for the 
last trimester of pregnancy through the first 3 months of lactation.  
Outcome Measures: Neurocognitive development was measured using the Bayley Scales of 
Infant Development III at 4 and 12 months of age.  
Results: Infants born to mothers with >600 mg DHA/day showed significantly higher scores on 
the 12 month cognitive scale of the BSID-III (p=0.018) compared to infants born to mothers with 
<300 mg DHA/day. Infants born to mothers in the DHA treatment group had an increase of 4.5 
                                                
1 In preparation for Early Human Development 
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days in gestational age (p=0.048) and significantly lower incidence of preterm birth (5%; n=3) 
compared to infants born to mothers in the control group (18%; n=10; χ2=4.97, p=0.026).  
Conclusions: An intake of ≥600 mg DHA/day during the third trimester of gestation throughout 
the first three months of breastfeeding was associated with enhanced neurocognitive 
development of the infants.  
Introduction 
Docosahexaenoic acid (DHA), a 22 carbon, six double bond omega-3 long chain 
polyunsaturated fatty acid (LCPUFA) is present in high concentrations in brain and neural tissue. 
Accumulation is greatest during the third trimester of gestation through the first 2 years of life.2 
During the last trimester, it is estimated the fetus acquires 67-75 mg per day of DHA, accounting 
for 80% of brain DHA accumulation between week 26 and 40 of gestation.67,107 Prior to birth, the 
fetus acquires DHA through placental transfer of DHA, which is influenced by DHA in the 
maternal diet, enhanced mobilization of DHA from maternal adipose stores, and maternal DHA 
synthesis.4 Synthesis of DHA from the essential dietary precursor n-3 alpha-linolenic acid (ALA) 
occurs in humans, but the conversion is estimated to be only <0.1-1%.7,8 Women of child-
bearing age may convert ALA to DHA more effectively due to the proposed influence of 
estrogen on DHA synthesis, yet the conversion may be insufficient to meet needs during periods 
of rapid growth and development.7 Low conversion rates suggest a requirement for preformed 
DHA obtained directly from the diet or supplements, during pregnancy and lactation. While no 
current daily U.S. recommended intake exists for DHA, the European Influence of Dietary Fatty 
Acids on the Pathophysiology of Intrauterine Foetal Growth and Neonatal Development 
(PERILIP) group recommends pregnant and lactating women receive at least 200 mg per day of 
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preformed DHA, through supplementation or consuming one to two portions of fatty fish high in 
n-3 LCPUFA per week.38 
Studies have demonstrated numerous benefits of maternal fish and seafood intake and/or 
DHA supplementation during pregnancy, including increased gestational age, decreased preterm 
birth incidence, and improved infant growth and cognitive development.9,11,13,115,118,124,137,138 The 
large Avon Longitudinal Study of Parents and Children demonstrated that women consuming 
greater than 340 g of fish per week gave birth to children with decreased risk for poor 
performance on age appropriate tests of cognitive development compared to mothers with low 
seafood intake during pregnancy.11 Randomized controlled trials (RCT) provide some evidence 
linking increased DHA intake during pregnancy with enhanced neurologic development and 
improved cognitive measurement scores, however, such trials report varying 
results.9,10,16,20,127,155,160 Furthermore, postnatal DHA supplementation studies have shown no 
conclusive effect of DHA intake on infant growth and neurocognitive development and, when 
significant, the most dramatic effects are seen in preterm infants.22,23,161-164 Postnatally, DHA is 
obtained from breastmilk or enriched infant formulas, and breastmilk DHA concentration is 
directly influenced by maternal intake.190,192  
Several systematic reviews and meta-analyses have reported that the benefits of DHA 
supplementation on neurocognitive development are currently inconclusive.167-170 Such studies 
remain mixed due to the large variation in DHA supplementation length and dose as well as 
varying cognitive tests. Yet, many studies that report inconclusive results between DHA 
treatment groups often have found a significant association between DHA status and infant 
neurocognitive development.20-23 Additionally, non-significant studies tend to analyze results by 
treatment groups and rarely account for DHA intake from food, which would allow for analysis 
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by daily dose of DHA that could dramatically affect results determining an association between 
DHA supplementation and improvements in infant growth and neurocognitive development. 
The present study was designed to examine the effects of DHA intake during pregnancy 
and lactation on infant neurocognitive development using the BSID-III at 4 and 12 months of 
age. Increasing maternal intakes of DHA during the important period of brain growth in the last 
trimester of gestation through the first few months of lactation was hypothesized to improve 
scores on the BSID-III at 4 and 12 months. Additionally, increasing maternal DHA status would 




The Omega Smart Baby Project was a double-blinded, randomized, placebo controlled 
clinical trial. 115 women with singleton pregnancies were randomized to treatment groups 
between February 2010 and October 2011. A trained paraprofessional breastfeeding coach 
recruited women from private practice gynecology and obstetric clinics in the Fort Collins, 
Colorado area on or before their oral glucose screening appointment, between 24-28 weeks of 
gestation. Included women were 18-42 years of age with singleton pregnancies and were willing 
to breastfeed exclusively for the first 3 months of life. Exclusion criteria included maternal age 
<18 years, multiple fetuses, diabetes, HIV positive status, chronic illnesses or other conditions 
that could preclude breastfeeding and any known allergies to seafood or fish oils. The 
Institutional Review Board at Colorado State University approved all protocols and procedures. 
All women provided written informed consent prior to participation. 
 55 
Women were randomized to receive the study supplement of highly purified tuna fish oil 
containing 300 mg DHA and 67 mg EPA provided as HiDHA tuna oil (Nu-Mega Oil, Clover 
Corportation, Ltd) prepared as one hard capsule or Sunola, a high oleic acid sunflower oil 
placebo. The dose was selected based on previous pilot data with a power of 0.05% at the 80% 
confidence level. A block randomization procedure was used to assign women to treatment. 
Study supplements were provided in two opaque bottles, the first given at the entrance into the 
study and second at the first meeting between the breastfeeding coach and mother after giving 
birth. Women were instructed to keep supplements in the provided container in a freezer to 
maintain quality and begin taking one capsule per day for the remainder of their pregnancy and 
until 3 months of breastfeeding were complete.  
A food frequency questionnaire (FFQ) validated against erythrocyte DHA was used to 
estimate total DHA intake from food, prenatal vitamins and other sources. The FFQ included 
sources of DHA intake from fish and seafood, DHA enriched food products such as eggs or milk, 
and any fish oil or DHA supplements. Information was quantitated using the United States 
Department of Agriculture (USDA) National Nutrient Database for Standard Reference, Release 
22. As shown in Figure 4.1, the FFQ was validated, with estimated DHA intake per week 
positively correlating with the percent total DHA in erythrocyte fatty acids (r=0.37, p=0.0002). 
Total weekly and daily DHA intake from the FFQ was calculated and verified with a 7-day diet 
record data. The 7-day diet record information was analyzed using Nutritionist Pro (Axxya 
Systems, Stafford, TX) software and total daily DHA intake from food was calculated. 
Sociodemographic data, the date of the last menstrual period (LMP) and estimated due date were 
collected from each woman at the entrance into the study. Self-reported pre-pregnancy weight 
and height was used to determine pre-pregnancy body mass index (BMI).  
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Sample collection and fatty acid analyses 
A baseline blood sample was collected from women during their oral glucose screen 
between 24-28 weeks of gestation and stored briefly at 4oC until separated. Blood samples were 
collected in a Vacutainer containing EDTA and separated by centrifugation within 24 hours into 
erythrocyte, plasma and buffy coat fractions and stored at -80oC until further analysis. 
Breastmilk samples were obtained at 2 and 4 months postpartum and expressed using manual or 
electric breast pumps into sterile collection cups and transported on ice to the laboratory and 
immediately frozen and stored at -20oC. Lipids were extracted from maternal erythrocytes, 
plasma, and 2 and 4 month breastmilk samples using a modified Folch extraction 
(chloroform:methanol 2:1 v/v). Plasma phospholipids were further separated by thin layer 
chromatography and all lipid extracts were resuspended in 0.5 ml chromatographic grade 
hexanes. Fatty acid methyl esters (FAME) were prepared on all lipid extracts by direct 
transmethylation using 14% boron trifluoride in methanol (Sigma Chemical Co, St. Louis, MO). 
FAME were analyzed via gas chromatography on an Agilent 6890 chromatograph, using a 
ramped temperature program and flame ionization detection and a J&W DB225 column. 
Individual fatty acids were identified by comparison of retention times with known FAME 
standards (Nuchek Prep, Elysian, MN).   
Breastfeeding  
Exclusive breastfeeding was supported using a peer coaching model adapted from the in-
home breastfeeding support program, developed in North Carolina and tested in a WIC 
population. This model was adapted to a middle class, educated population and updated to meet 
current breastfeeding guidelines and policies.234,235 The program paired each pregnant woman 
with a well-trained paraprofessional breastfeeding coach, which provided support to the mother 
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prior to delivery and on an ongoing basis throughout the study duration of 12 months. Coaches 
provided education, answered questions, assessed breastfeeding and provided recommendations 
and assistance to resolve any problems and helped the mothers reach their own personal 
breastfeeding goals beyond that of the study. In addition to the free breastfeeding support 
provided, as incentive to the study, each mother was provided with a complementary manual 
breast pump and had access to a medical grade electric pump if deemed necessary by the coach. 
Exclusivity of breastfeeding was monitored and recorded by the coaches as reported by the 
mothers. Exclusive breastfeeding was classified as no food or formula other than breastmilk for 
the first 3 months of life.  Mothers were educated and encouraged to exclusively breastfeed 
through 6 months of life by their coaches and educated on proper progression of introducing and 
increasing infant appropriate foods according to the USDA Start Healthy Feeding Guidelines.236 
Infant cognitive testing 
The BSID-III Mental Development Index (MDI) subscales were administered on infants 
at 4 and 12 months of age by a trained technical assistant overseen by a licensed clinical 
psychologist in the Psychology Department at CSU. The BSID-III was selected as a 
measurement of neurocognitive development due to its ease of administration and for 
comparison to previous studies. The BSID-III MDI cognitive, language, social-emotional and 
general adaptive behavior scales were completed. The MDI has a mean score of 100 with 
standard deviation (SD) of 15. The BSID is widely accepted and used throughout cognitive 
studies, the test has excellent within age test-retest reliability and scores have been associated 
with intelligence quotient (IQ) scores at 4 years of age in DHA supplementation published 
studies.229 All BSID scores reported are composite scores and are, therefore, age corrected for 
each scale. To control for confounding effects of maternal IQ, mothers completed a maternal IQ 
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test using the abbreviated Wechsler Adult Intelligence Scale (WAIS), including the block design 
and vocabulary subtests, which are highly correlated with full scale IQ (FSIQ; r2=0.84).237 To 
control for the confounding effect the degree of stimulation in the home environment may have 
on cognitive development, the mothers completed a self-administered Home Screening 
Questionnaire (HSQ) at 9 months of age.238 
Gestational length and infant anthropometric measurements 
Gestational length was calculated in days using the LMP method and infant date of birth. 
Infant anthropometric data was obtained from pediatric medical records. The mother reported 
infant birth weight, length and head circumference measurements to the breastfeeding coach at 
the first contact just after birth, and reported 2 month weights and heights after the 2 month well 
baby visit. Anthropometric data at birth and 2 months of age was normalized by expressing them 
as z scores based on term infants of the same age and sex by using parameters provided in the 
data files from the Centers for Disease Control and Prevention (CDC) growth charts released in 
2000 (www.cdc.gov/growthcharts).  
Data analysis 
Participating women, all data collectors and investigators were blinded to supplement 
allocation until all study children were 12 months of age and had completed the cognitive testing. 
After all study data was collected, the study was unblinded only to study investigators for 
analysis. Intent-to-treat (ITT) procedures were maintained throughout. Power was based on a 
previous pilot trial determining the effect DHA supplementation during pregnancy has on 
improved infant BSID scores at 4-6 months, 32 infants per supplementation group are necessary 
to reach a power of 0.05% at the 80% confidence level. Total daily DHA intake was calculated 
for each woman by adding estimated dietary DHA intakes, maternal DHA supplementation (if 
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applicable) and DHA study supplement. Data was analyzed based on treatment group, placebo 
versus DHA, as well as daily DHA intake groups broken into three groups: low = 0-299 mg per 
day DHA, medium = 300-599 mg per day DHA, high = ≥600 mg per day DHA. DHA cut-off 
points for the intake groups were determined on the basis of those falling below, at the median 
recommended intake and above the currently recommended intake.47,48  
Statistical analysis was completed using SPSS statistical software (SPSS, Chicago, IL) 
and GraphPad Prism V4.0 (GraphPad Software, San Diego, CA). Results are expressed as means 
± SD, unless otherwise specified. Two-tailed t test was used to analyze results based upon 
treatment and one-way ANOVA was used to compare means between all daily DHA intake 
groups. Tukey’s post hoc tests were conducted on all statistically significant ANOVA results to 
determine if differences existed among group means. Correlations were computed using 
Pearson’s correlation coefficient. Data was adjusted for potential confounders, when appropriate, 
including, maternal age at delivery, maternal BMI, maternal IQ, breastfeeding duration, 
gestational age and the effects of the home environment on cognitive development via the HSQ. 
Results 
Subject characteristics  
A total of 115 women enrolled in the Omega Smart Baby Project (Figure 4.2) and were 
included in the analysis. Of these, 55 were randomly assigned to the placebo and 60 to the DHA 
supplement. Study completion rates were 80% in the DHA treatment group but only 64% in the 
placebo group. End of study pill counts showed high rates of adherence to the study, with >90% 
of the women that completed the study consuming 99% of study supplements. The reasons for 
discontinuation in the study between the placebo and DHA treatment groups were similar and 
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most often due to cessation of breastfeeding before 2 months, loss of contact, or unwillingness to 
continue in the study. One infant died due to conditions not related to the study. Demographic 
data, including age, maternal weight, maternal BMI, maternal IQ or the proportion of DHA in 
erythrocyte and 2 month fatty acids did not differ between women that completed the study and 
those that did not.  
Complete demographic data for each group are provided in Table 4.1. There were no 
significant differences between the placebo and DHA group, or between any DHA intake group, 
in maternal age, race, marital status, pre-pregnancy maternal weight and height, and maternal IQ 
measurements. The mean maternal age at delivery was 31.5 ± 4.4 years of age, 93% were 
Caucasian and 93% were married. All enrolled pregnant women are accounted for, as shown in 
the consort diagram in Figure 4.2, with 90% completing the 4 month BSID cognitive testing, 
and 71% completing the 12 month cognitive testing. Additionally, 81% of enrolled women were 
still breastfeeding at 2 months, 78% were still breastfeeding at 4 months, and 57% had continued 
to breastfeed until study completion at 12 months. There was no significant difference in overall 
breastfeeding duration between treatment groups or DHA intake groups.  
DHA intake groups and fatty acid analysis 
Daily DHA intake ranged from 18 mg to 1.374 g per day of total DHA consumed, 
including the study DHA supplement. Mean DHA intake from food of all enrolled subjects was 
101 ± 99 mg per day, from additional supplementation was 209 ± 239 mg per day, and total 
DHA intake of all women was 468 ± 278 mg per day. Analysis of 7-day diet records determined 
no significant difference in macronutrient consumption, ALA, DHA, or fish intake at 2 months 
among the women. Total daily DHA intake at 2 months positively correlated with daily DHA 
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intake at baseline (r=0.58, p<0.0001), indicating daily DHA intake of women remained similar 
from baseline through 2 months. 
Differences in placebo versus DHA treatment groups are shown in Table 4.1. There was 
no significant difference in DHA consumption from food, but total DHA intake per day was 
significantly higher in the DHA group compared to the control group (p<0.0001), indicating the 
study supplement did effectively increase DHA intake in the participating women. The placebo 
group consumed higher daily DHA when compared to the mean of the DHA treatment group 
through additional supplementation (p=0.035). Maternal erythrocyte and plasma fatty acids 
percent total DHA at baseline was not significantly different between treatment groups. The 
mean percent total DHA in 2 month breastmilk fatty acids were significantly higher in the DHA 
treatment group compared to placebo control (p=0.017). After supplementation ended at 3 
months, breastmilk percent total DHA levels remained significantly different at 4 months 
(p=0.0007).   
Data were analyzed on the basis of total daily DHA intake (Table 4.1). Of the 115 
women, 27 women (23%) consumed less than 300 mg total DHA per day and were classified in 
the low DHA intake group, 54 women (47%) consumed between 300 and 599 mg DHA per day 
and were categorized in the medium DHA intake group, and 34 women (30%) consumed 600 mg 
or more of DHA per day and were categorized in the high DHA intake group. DHA intake from 
food and voluntary supplementation was significantly different (p<0.0001 and p<0.0001, 
respectively) between DHA intake groups, with estimated intakes significantly higher in the high 
DHA intake group compared to both the low and the medium intake groups (Tukey’s HSD 
p<0.001). Total daily DHA intake was significantly different based upon daily DHA intake 
group (p<0.0001). DHA intake was higher in the high DHA group compared to both the low and 
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medium DHA intake groups (Tukey’s HSD p<0.0001) and the medium group was also 
significantly higher than the low daily DHA intake group (Tukey’s HSD p<0.001).  
Analysis of maternal fatty acids by daily DHA intake group showed significant 
differences in the proportion of DHA in baseline erythrocyte fatty acids (p=0.0007), with 
significantly higher DHA in women within the high daily DHA intake group compared to the 
medium intake group (Tukey’s HSD p<0.001). Erythrocyte fatty acid DHA positively correlated 
with daily DHA intake (r=0.24, p=0.011; Figure 4.3a), indicating that increases in daily DHA 
intake correlated with increases in erythrocyte DHA proportion of fatty acids. 2 month 
breastmilk DHA was significantly different between daily DHA intake groups (p=0.003), with 
significantly higher proportions of DHA in the high intake group compared to the low DHA 
intake group (Tukey’s HSD p<0.01). Additionally, daily DHA intake positively correlated with 2 
month breastmilk DHA proportion of fatty acids (r=0.37, p=0.0002; Figure 4.3b). Increases in 
daily DHA intake correlated with increases in breastmilk DHA at 2 months of breastfeeding. At 
4 months, after cessation of the study supplementation, breastmilk percent total DHA levels were 
significantly different  (p<0.0001) due to DHA intake from food and voluntary supplementation.  
Neurocognitive development 
The results of the components of the 12 month BSID-III MDI are presented both by 
treatment type and DHA intake group in Table 4.2. No statistically significant differences were 
found on any BSID-III scale at 4 months of age, (data not shown). There were no statistically 
significant differences in the MDI scores at any time point, for any scale when analyzing by 
treatment group alone. Significant differences appear in the cognitive development of infants 
based upon maternal DHA intake group (p=0.018) at 12 months of age. Infants born to mothers 
consuming greater than 600 mg of DHA daily have higher scores on the 12 month cognitive 
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MDI test compared to both the low intake group and the medium intake group (Tukey’s HSD 
p<0.05). Furthermore, there was a positive correlation between 2 month breastmilk DHA and 12 
month scores on the cognitive MDI scale (r=0.27, p=0.031), as exhibited in Figure 4.4. No 
significant differences were seen between any groups on the 12 month social and general 
adaptation scales. Furthermore, maternal age, IQ, breastfeeding duration or HSQ did not 
correlate with any of the BSID-III scores. Results were not significant for any outcome analyzed 
based upon 4 month breastmilk samples, most likely since the sample was collected outside of 
study supplementation period. 
Neurocognitive results were also analyzed based upon gender. There were no statistically 
significant differences comparing male and female infants for any of the 4 or 12 month BSID-III 
tests. However, significant differences in the 12 month MDI cognitive score of the BSID-III 
emerged in female infants based upon maternal daily DHA intake (p=0.010). As shown in 
Figure 4.5a, female infants born to mothers in the high DHA intake group scored 12.3 points 
higher on the 12 month cognitive MDI scale (118.9 ± 10.4) compared to the female infants born 
in the low intake group (106.6 ± 12.9; Tukey’s HSD p<0.05) and scored 13 points higher 
compared to infants born in the medium daily DHA intake group (105.9 ± 12.7; Tukey’s HSD 
p<0.05). In contrast, no statistically significant differences were seen in male infants within DHA 
intake groups (p=0.529; Figure 4.5b). There were no statistically significant differences between 
daily DHA intake groups for either gender on the social or general adaptation testing at 12 
months, as well as on all 4 month BSID-III testing or when classifying by treatment group. 
Gestational length and premature birth  
Gestational length in the DHA treatment group was 4.5 days longer than the placebo 
group (p=0.048). No statistically significant differences in gestational length were seen among 
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daily DHA intake groups, although there was a trend of 6.1 day longer gestational length in the 
high daily DHA intake group compared to the low intake group (p=0.053). Total daily DHA 
intake positively correlated with gestational length (r=0.20, p=0.031), Figure 4.6. The incidence 
of preterm births in the study was 11%, with a significantly greater incidence in the placebo 
group with 18% (n=10) compared to 5% (n=3; p=0.021) in the DHA group (χ2=4.97, p=0.026). 
DHA intake during pregnancy was associated with a reduction in preterm births (OR= 4.2, 95% 
CI 1.10-16.26; RR=3.6, 95% CI 1.06-12.54). No statistically significant differences in the 
incidence of preterm birth were found between daily DHA intake groups. However, when 
combining the medium and high daily DHA intake groups compared to the low daily DHA 
intake group, the incidence of preterm births significantly decreased from 22% (n=6) in the low 
daily DHA group to 8% (n=7) in women consuming greater than 300 mg DHA per day (χ2=4.87, 
p=0.027). Women consuming 300 mg of DHA per day or greater had an associated reduction in 
the risk of preterm births compared to women less than 300 mg DHA per day (OR= 0.3, 95% CI 
0.09-0.92; RR=0.8, 95% CI 0.68-1.04). 
Infant anthropometric measurements 
Infant anthropometric data are shown in Table 4.3. No statistically significant differences 
were seen in any anthropometric measurements at birth or at 2 months of age when based upon 
treatment group or daily DHA intake group. 2 month weight was negatively correlated with 2 
month breastmilk DHA proportion of fatty acids (r= -0.22, p=0.048; Figure 4.7). Increases in 2 
month breastmilk DHA correlated with decreases in infant 2 month weight, indicating a possible 
relationship between infant DHA intake and growth in early infancy. No statistically significant 




The Omega Smart Baby Project significantly increased daily maternal DHA intake to 
effectively assess the relationship between maternal DHA intake during pregnancy and lactation 
and infant neurocognitive development. Pregnant women participating in the study had low 
baseline intakes of DHA, consuming roughly 90-100 mg of DHA per day during pregnancy and 
lactation from food sources. These intakes agree with findings from previous studies 
investigating DHA intake in pregnant women.16,152,241 DHA from food provided 22% of the total 
daily DHA intake, indicating food sources of DHA impact total daily DHA and should be 
accounted for in RCT. While 67% of women consumed voluntary DHA supplements daily, the 
addition of the study supplement significantly increased total daily DHA intake by 58% in the 
DHA treatment group compared to the placebo group, allowing a significant treatment affect to 
be detected. As demonstrated in this study, it is important for researchers to quantify daily DHA 
intake from food as well as from self-supplementation in order to properly determine 
comprehensive and accurate daily DHA intake levels.  
It is well established that DHA is important in fetal neurological development.58,81,139 
DHA is preferentially transported to the fetus during the last trimester of gestation, coinciding 
with fetal retinal and brain development, specifically with the growth spurt in gray matter and 
neurogenesis, which is maximal during the last trimester of gestation through two years of 
age.5,67,98 Results of numerous RCT showed no effects of DHA treatment during pregnancy, 
however, several RCT did show a significant correlation between maternal DHA status and 
infant neurocognitive development.9,10,16 The absence of consistent correlations between DHA 
treatment and infant neurocognitive development in RCT could be due to the lack of accurately 
accounting for maternal DHA intake from all sources. The current study estimated total daily 
 66 
DHA intake from food and supplements throughout pregnancy and the first 3 months of 
lactation, which allowed for the successful detection of a dosing effect of DHA intake on infant 
neurocognitive development. The current study showed an association between maternal daily 
DHA intake of 600 mg or greater and significantly improved scores on the cognitive MDI scale 
of the BSID-III at 12 months of age. Similarly, a recent RCT that also accounted for daily DHA 
intake found infants born to women supplemented with a functional food containing 300 mg 
DHA per day from the 24th week of gestation through delivery performed significantly better on 
problem-solving tasks at 9 months of age compared to infants born to mothers of the placebo 
group.16  
The timing and length of DHA supplementation are important factors in determining the 
effect DHA has on infant neurocognitive development. Many previous RCT stopped DHA 
supplementation after birth, a time of extensive brain growth for the infant. Numerous studies 
have shown breastfeeding improves cognitive development of infants, and increased DHA 
content of breastmilk is believed to be one of the major factors.164,182,183,187,242 DHA is rapidly 
transferred into breastmilk with no known selectivity and is altered within 2-3 days based upon 
maternal intake of DHA.190-192 This study showed DHA supplementation successfully increased 
breastmilk DHA and 2 month breastmilk DHA positively correlated with infant scores on the 
cognitive scale of the BSID-III at 12 months. To date, only 2 recent RCT supplemented DHA 
prenatally and maintained allocation to treatment postnatally.15,20 The current study successfully 
supplemented women with DHA for over 7 months, during the last trimester of pregnancy 
through the first 3 months of breastfeeding. It is possible that the positive association between 
maternal DHA intake and infant cognitive development at 12 months of age observed in this 
study could be due to the prolonged DHA supplementation period during both pregnancy and 
lactation.  
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A topic of emerging interest is gender differences of DHA requirements, with boys and 
girls responding and benefiting differently to DHA supplementation. Through a stepwise 
regression analysis, the positive relationship between omega-3 fatty acid intake of 1 g or greater 
and cognitive test scores were found to be twice as strong in female American children in the 
Third National Health and Nutrition Examination Survey (NHANES III) compared to male 
children, suggesting female children may benefit more cognitively from increased omega-3 
intakes.176 In the current study, female infants born to mothers in the high daily DHA intake 
group scored significantly higher on the 12 month cognitive scale of the BSID-III MDI 
compared to female infants born to women in the low intake group. However, daily DHA intake 
did not significantly affect male cognitive test scores. Similarly, the DINO trial of early preterm 
infants did not find a significant effect of DHA treatment on infant neurocognitive development, 
yet, when focusing on gender differences, the study showed girls with higher DHA 
supplementation had significantly improved BSID MDI scores and a reduction in the risk of mild 
[developmental quotient (DQ) <85] and severe (DQ<70) cognitive delays at 18 months of age, 
with no observed affect in boys.23 The reasons for these gender differences are currently 
unknown and research is very limited, yet, this data could open up a new avenue of research in 
the field of DHA and neurocognitive development. 
Numerous RCT have attempted to validate the effect of DHA supplementation on 
increasing gestational length, while subsequently reducing the risk of preterm birth and the 
incidence of low birth weight infants.15,124-127Several systematic reviews and meta-analyses have 
determined a 1.6 to a 4.5 day increase in gestational length in women supplemented with 
DHA.116,130,131 Additionally, many of the same reviews also determined increased DHA intake 
during pregnancy was associated with a reduction in preterm birth incidence up to 31% and 
increased infant birth weights as much as 71 g.116,130,131 The current study showed that 
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supplementing with 300 mg of DHA per day during pregnancy significantly increased 
gestational length and decreased the incidence of preterm birth, but did not have any affect on 
infant birth weight. The increase in gestational length shown in this study does not explain the 
improvements in cognitive test scores found in infants born to high daily DHA intake women 
because gestational age was controlled for in the analyses and each scale of the BSID is age 
corrected. 
The mixed results of RCT investigating effect of DHA supplementation and 
neurocognitive development are possibly due to several inconsistencies, including differing 
supplementation time periods, length of supplementation, varying amounts of DHA 
supplemented doses, and/or a failure to maintain assignment to treatment group postnatally. In 
recent RCT, the majority of DHA supplementation occurs in either pregnancy or lactation, but 
often not during both periods of extensive brain development and increased DHA need. 
Experimental groups were supplemented with a wide range of DHA, from as little as 200 mg up 
to 2.2 g of DHA per day, and the length of supplementation ranged from as little as 10 weeks to 
over 6 months. The current study chose to supplement women during the last trimester of 
gestation through the first 3 months of breastfeeding with a 300 mg daily dose of DHA based 
upon previous successful RCT and supplementation recommendations.38,243 Many RCT did not 
also account for total DHA intake, such as DHA intake from voluntary supplementation or food, 
assuming baseline DHA intake would be low. Failing to account for DHA sources outside of the 
study supplement may explain the lack of treatment effects demonstrated in recent studies. Many 
studies without a significant treatment effect have shown a significant association between DHA 
status and infant development.20-23,156,157 While no treatment effects were determined, by 
accounting for DHA intake from all sources in the maternal diet, the current study showed high 
DHA intake was associated with improved neurocognitive development. 
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Inconclusive RCT and meta-analyses could also be due to the large variation in the type 
of cognitive tests used and the age at which the tests are administered. The current study used the 
BSID because the test is widely accepted and commonly used throughout cognitive studies, and 
when administered in late infancy, has been shown to correlate with IQ scores at 4 years of 
age.229 The age when cognitive testing is performed may play a large role in successfully 
determining a positive association between DHA supplementation and infant neurocognitive 
development. The current study did not find any significant associations between maternal DHA 
intake and infant cognitive test scores at 4 months of age, but did see positive associations at 12 
months of age on the BSID-III. Similarly, several recent studies have failed to find an effect of 
DHA supplementation on infant cognitive development when the tests were administered <12 
months of age.21 Furthermore, it is possible that current cognitive assessments used early in 
infancy may not be sensitive enough to detect the specific effects DHA supplementation may 
have on certain aspects of cognitive development. A previous RCT showed 4 month BSID scores 
did not significantly relate to later cognitive performance, but the 12 month scores related 
significantly to preschool verbal and performance IQs as well as gross motor scores.244 
A possible limitation to this study was a completion rate of 80% in the DHA treatment 
group compared to only a 64% completion rate in the placebo control group. Reasons for the 
differences between treatment group study completion rates are unknown. However, study 
numbers at completion for each group were greater than the 32 infants determined necessary to 
detect a significant difference between groups. Additionally, due to the frequent contact between 
women and their breastfeeding coaches, study adherence of women that completed the study 
were excellent with over 90% of women taking all of the supplied study supplements. While 
compliance in this study was measured by end of study pill counts and not by a physiologic 
measurement, baseline maternal DHA in erythrocyte fatty acids did positively correlate with 
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daily DHA intake reported on the baseline FFQ (r=0.24, p=0.011) and DHA content of 2 month 
breastmilk samples also positively correlated with estimated DHA intake on the 2 month FFQ 
(r=0.21, p=0.045).  
Many prenatal supplements with DHA were recently introduced to the market within the 
last 5-10 years and women choosing to take a DHA supplement were not excluded from the 
study. Awareness of possible benefits DHA and fish oil can incur upon the developing fetus has 
increased over the last decade as more research studies provide positive associations and more 
obstetricians and dietitians promote DHA supplementation during pregnancy and lactation. In the 
current study, a large number of women were prescribed prenatal vitamins with DHA or were 
voluntarily supplementing with DHA or fish oil in addition to the study supplement during the 
study period. By accounting for this additional supplementation, the present study was able to 
more accurately estimate total daily maternal DHA intake and determine significant positive 
associations between maternal DHA intake and infant neurocognitive development beyond that 
of study treatment groups. 
In conclusion, supplementing pregnant and lactating women with DHA could safely 
enhance the neurocognitive development of the infants. The current study provides information 
on optimal DHA intake and timing of supplementation, and may also help to impact future 
national standards and recommendations for DHA supplementation during pregnancy and 
lactation. While numerous studies remain inconclusive, more research is necessary to determine 
whether DHA supplementation during pregnancy, lactation or continued intake through both 














Figure 4.1. Food frequency questionnaire (FFQ) validation. Weekly 
estimated maternal docosahexaenoic acid (DHA) intake is positively 
correlated with the proportion of DHA in maternal erythrocyte fatty 














Figure 4.2. Consolidated flow diagram of study data and sample collection. DHA, docosahexaenoic acid; FFQ, 
food frequency questionnaire; BSID, Bayley Scales of Infant Development III.
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a WAIS, Wechsler Adult Intelligence Scale; DHA, docosahexaenoic acid.   
b Mean ± SD (all such values).   
c Mean differences between placebo and DHA supplemented groups were tested with two-tailed t test.  





Figure 4.3. Daily maternal docosahexaenoic acid (DHA) intake. Graph a shows the correlation between daily 
DHA intake and the proportion of DHA in maternal erythrocyte fatty acids. Graph b shows the correlation between 








Neurocognitive development measured by the Mental Development Index (MDI) of the Bayley Scale of 
Infant Development (BSID) III of infants born to mothers classified based upon study treatment or daily 
DHA intake at 12 months of age.a  
a DHA, docosahexaenoic acid.   
b Mean ± SD (all such values).   
c Mean differences between placebo and DHA supplemented groups were tested with two-tailed t test.  
d Mean differences between daily DHA intake groups were assessed by ANOVA. 
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Figure 4.5. Infant motor development index (MDI) scores on the cognitive scale of the Bayley Scales of Infant 
Development III (BSID-III) at 12 months of age classified by gender and maternal daily docosahexaenoic acid 
(DHA) intake group. Graph a shows only female infant scores on the cognitive scale by daily DHA intake group and 
graph b shows only male infants scores.  * Significantly different from low daily DHA intake group (graph a), 
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Figure 4.4. Correlation between the proportion of 
docosahexaenoic acid (DHA) in 2 month breast milk fatty 
acids and infant motor development index (MDI) scores on 
the cognitive scale of the Bayley Scales of Infant 

















Infant characteristics and anthropometric measurements.a 
a DHA, docosahexaenoic acid.   
b Mean ± SD (all such values).   
c Mean differences between placebo and DHA supplemented groups were tested with two-tailed t test.  
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Figure 4.6. Correlation between maternal daily 


















2 Month Breast Milk
DHA - % Fatty Acid
Figure 4.7. Correlation between 2 month infant 
weight and the proportion of docosahexaenoic acid 







MATERNAL DOCOSAHEXAENOIC ACID INTAKE DURING PREGNANCY AND 
LACTATION AND GENETIC VARIANTS OF THE FADS1 FADS2 GENE CLUSTER ARE 
ASSOCIATED WITH ALTERED FATTY ACIDS IN ERYTHROCYTES AND 
BREASTMILK AND INTERACT WITH INFANT NEUROCOGNITIVE DEVELOPMENT2 
 
 
Effects of single nucleotide polymorphisms (SNPs) within the fatty acid desaturase 
(FADS)1 FADS2 gene cluster were previously associated with altered omega-3 (n-3) fatty acid 
composition, particularly docosahexaenoic acid (DHA), of erythrocyte, plasma phospholipids 
and breastmilk. The aim of this study was to determine if FADS SNPs influence fatty acid 
composition in mothers obtaining varying amounts of DHA daily and the subsequent affects on 
infant neurocognitive development. Women were randomly assigned to receive 300 mg DHA 
per day or Sunola capsules the 24-28th week of gestation through three months of lactation in a 
double-blinded placebo controlled clinical trial. Total daily DHA intake was estimated from all 
dietary sources. Fatty acids in erythrocytes and plasma phospholipids were determined in 
maternal baseline blood and in breastmilk from 2 month samples. Two SNP in the FADS1 
FADS2 gene cluster, rs174575 and rs174561, were analyzed from maternal DNA. Infant 
neurocognitive development was assessed with the Bayley Scales of Infant Development-III 
(BSID-III) at 4 and 12 months of age. High DHA intake ≥600 mg per day increased erythrocytes 
and breastmilk DHA in women homozygous for the major alleles of both SNPs, but did not 
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significantly increase DHA in women heterozygous or homozygous for the minor allele for SNP 
rs174575. Genotype had no direct effect on BSID-III scores, however, ANCOVA for 12 month 
cognitive MDI scale showed a statistically significant interaction between SNP rs174575 
genotype and daily DHA intake group. Genetic variants influence erythrocyte and breastmilk 
fatty acids, possibly affecting DHA transfer and infant neurocognitive development. 
Introduction 
Docosahexaenoic acid [DHA; 22:6(n-3)] and arachidonic acid [AA; 20:4(n-6)] are the 
most abundant long chain polyunsaturated fatty acids (LCPUFA) in the brain.2,3,98 DHA is 
important in fetal neurological development and accumulates within the brain during the third 
trimester of gestation through the first 2 years of life, coinciding with a growth spurt in gray 
matter and neurogenesis.2,5,67,98,107 Randomized controlled trials (RCT) provide some evidence 
linking increased DHA intake during pregnancy and lactation with enhanced neurocognitive 
development, however, such trials increasingly report varying and inconclusive 
results.9,10,16,21,127,155,156,160,162,164,166,168-170  
Prenatally, the fetus acquires DHA through placental transfer and, after birth, the infant 
receives DHA from breastmilk or enriched infant formulas.4,196 DHA is transferred to the fetus or 
breastmilk from the maternal bloodstream and is influenced by DHA in the maternal diet, 
enhanced mobilization of DHA from maternal adipose stores, and maternal DHA synthesis.4 
Synthesis of DHA from essential dietary precursor alpha-linolenic acid (ALA) occurs in humans, 
yet, the conversion is estimated at only <0.1-1%.7,8 Low rates of endogenous DHA synthesis 
suggest the need to obtain DHA preformed directly from the diet or supplements, especially 
during times of increased need, such as pregnancy and lactation. The European Influence of 
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Dietary Fatty Acids on the Pathophysiology of Intrauterine Foetal Growth and Neonatal 
Development (PERILIP) group recommends pregnant and lactating women receive at least 200 
mg per day of preformed DHA, through supplementation or consuming one to two portions of 
fatty fish high in n-3 LCPUFA per week, for healthy child development.38  
DHA, like other fatty acids, is rapidly transferred into breastmilk with no known 
selectivity between fatty acids, ranges from 0.17-1% total fatty acids and can be drastically 
altered within 2-3 days based upon maternal intake of DHA.190-192 In addition to dietary supply, 
DHA in breastmilk can be endogenously derived from precursor fatty acids by elongation and 
desaturation, in which the rate-limiting step in humans appears to be the Δ6-desaturase enzyme.39 
Decreased enzyme activity could be due to numerous common single nucleotide polymorphisms 
(SNPs).40 The Δ5- and Δ6-desaturase enzymes are encoded by fatty acid desaturase (FADS)1 and 
FADS2, respectively, are arranged in a head-to-head orientation on chromosome 11q.24 Several 
studies have demonstrated women homozygous for the minor alleles of SNPs in the FADS1 
FADS2 gene cluster, specifically FADS2 rs174575 and FADS1 rs174561, have lower 
erythrocyte, plasma and breastmilk DHA compared to women homozygous for the major allele, 
but results are mixed.18,19,202,206,245 Additionally, data from population-based birth cohorts found 
breastfed children of mothers with SNPs coding for lower FADS1 activity, higher FADS2 
activity and higher DHA breastmilk levels, as well as breast-fed children with the major allele of 
rs174575, showed significant cognitive advantages over minor allele carriers.25-27  
The present study was designed to examine the effects of SNPs within the FADS1 
FADS2 gene cluster in mothers supplemented and consuming varying amounts of DHA during 
pregnancy and lactation on fatty acid composition, particularly DHA, in erythrocyte, plasma 
phospholipids and breastmilk. Erythrocyte, plasma phospholipids and breastmilk DHA was 
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hypothesized to decrease in women homozygous for the minor alleles of SNPs in the FADS1 
FADS2 gene and could not be increased by increasing daily DHA intake. The final aim was to 
investigate a suspected correlation between maternal genotype and daily DHA intake interaction 
and the neurocognitive development in infants exclusively breastfed for the first 3 months of life. 
Methods 
The Omega Smart Baby Project was a double-blinded, randomized, placebo controlled 
clinical trial in which 115 women with singleton pregnancies were randomized to receive 300 
mg purified DHA or identical placebo between February of 2010 and October of 2011. Subjects 
were recruited on or before their oral glucose screening appointment, between 24-28 weeks of 
gestation, at private obstetric and gynecology and family practice clinics in Fort Collins, 
Colorado. Included subjects were 18-42 years of age with singleton pregnancies and were willing 
to breastfeed exclusively for the first three months of life.  Study exclusion criteria included 
maternal age less than 18 years, multiple fetuses, diabetes, HIV positive status, chronic illnesses 
or other conditions that could preclude breastfeeding and any known allergies to fish, seafood or 
fish oils. The Institutional Review Board at Colorado State University (CSU) approved all 
protocols and procedures. All subjects provided written informed consent prior to participation in 
the study. 
Women were randomized to receive the study supplement of highly purified tuna fish oil 
containing 300 mg DHA and 67 mg eicosapentaenoic acid (EPA) (HiDHA Nu-Mega Oil, Clover 
Corportation, Ltd) prepared as one hard capsule or Sunola, a high oleic acid sunflower oil 
placebo. The dose was selected based on a previous pilot data with a power of 0.05% at the 80% 
confidence level. A block randomization procedure was used to assign subjects to treatment. 
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Women were provided with the study supplement at their oral glucose screen at 24-28 weeks of 
gestation. Women were instructed to keep supplements in the provided container in a freezer to 
maintain quality and begin taking one capsule per day for the remainder of their pregnancy and 
until 3 months of breastfeeding were complete. Study supplements were provided in two opaque 
bottles, the first given at the entrance into the study and second at the first meeting between the 
breastfeeding coach and mother after giving birth.  
A food frequency questionnaire (FFQ) validated against erythrocyte was used to estimate 
total DHA intake from food, prenatal vitamins and other sources. The FFQ was validated prior to 
study initiation and estimated DHA intake per week positively correlated with the proportion of 
DHA in erythrocyte fatty acids (r=0.37, p=0.0002). The FFQ included sources of DHA intake 
from fish and seafood, DHA enriched food products such as eggs or milk, and any fish oil or 
DHA supplements, including all prenatal vitamin information. Information was quantitated using 
the United States Department of Agriculture (USDA) National Nutrient Database for Standard 
Reference, Release 22. Total weekly and daily DHA intake from the FFQ was calculated and 
verified with a 7-day diet record data. The 7-day diet record information was analyzed using 
Nutritionist Pro (Axxya Systems, Stafford, TX) software and total daily DHA intake from food 
was calculated. Sociodemographic data, including age, race and marital status, were collected 
from each participant at the entrance into the study.  
Sample collection and fatty acid analyses 
A baseline blood sample was collected from women in a Vacutainer containing EDTA 
during their oral glucose screen between 24-28 weeks of gestation and stored at 4oC until 
separated. Whole blood samples were separated by centrifugation within 24 hours into 
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erythrocyte, plasma and buffy coat fractions and stored at -80oC until further analysis. 
Breastmilk samples were obtained from each participant at 2 and 4 months postpartum and 
expressed using manual or electric breast pumps into sterile collection cups and transported on 
ice to the laboratory and immediately frozen and stored at -20oC. Lipids were extracted from 
maternal erythrocytes, plasma, and 2 and 4 month breastmilk samples using a modified Folch 
extraction (chloroform:methanol 2:1 v/v). Plasma phospholipids were further separated by thin 
layer chromatography and all lipid extracts were resuspended in 0.5 ml chromatographic grade 
hexanes. Fatty acid methyl esters (FAME) were prepared on all lipid extracts by direct 
transmethylation using 14% boron trifluoride in methanol (Sigma Chemical Co, St. Louis, MO). 
FAME were analyzed via gas chromatography on an Agilent 6890 chromatograph, using a 
ramped temperature program and flame ionization detection and a J&W DB225 column.  
Individual fatty acids were identified by comparison of retention times with known FAME 
standards (Nuchek Prep, Elysian, MN). 
Selection of SNPs and genotyping 
Two SNPs in the FADS1 FADS2 gene cluster were included for SNP analysis, FADS1 
rs174561 and FADS2 rs174575. The SNPs were chosen based upon previously reported 
associations with differences in erythrocyte, plasma phospholipid and breastmilk DHA 
proportions, as well as associations with later child neurocognitive development. Additionally, 
the minor allele frequency for both SNPs was previously described as at least ≥ 18%, therefore, 
the expected number of subjects homozygous for the minor alleles in this study population would 
exceed 10.18,19,26,27 DNA was extracted from the buffy coat collected from baseline maternal 
blood with the QIAamp DNA Blood Mini Kit (QIAGEN, Hilden, Germany). SNPs were 
genotyped with TaqMan SNP Genotyping assays (Applied Biosystems, Foster City, CA) with 
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real-time polymerase chain reaction (PCR) according to the manufacturer instructions using a 
StepOnePlus Real-Time PCR instrument (Applied Biosystems, Foster City, CA).  
Breastfeeding  
Exclusive breastfeeding was supported using a peer coaching model adapted from the in-
home breastfeeding support program, developed in North Carolina and tested in a WIC 
population. This model was adapted to a middle class, educated population and updated to meet 
current breastfeeding guidelines and policies.234,235 In addition to the free breastfeeding support 
provided, as incentive to the study, each participant was provided with a complementary manual 
breast pump and had access to a medical grade electric pump if deemed necessary by the coach. 
Exclusivity of breastfeeding was monitored and recorded by the coaches as reported by 
participants. Exclusive breastfeeding was classified as no food or formula other than breastmilk 
for the first 3 months of life. Participants were educated and encouraged to exclusively 
breastfeed through 6 months of life by their coaches and educated on proper progression of 
introducing and increasing infant appropriate foods according to the USDA Start Healthy 
Feeding Guidelines.236 
Infant cognitive testing  
The Bayley Scales of Infant Development III (BSID_III) Mental Development Index 
(MDI) subscales were administered on study participant infants at 4 and 12 months of age by a 
trained technical assistant overseen by a licensed clinical psychologist in the Psychology 
Department at CSU. The BSID-III was selected as a measurement of neurocognitive 
development due to its ease of administration and for comparison to previous studies. For the 
purpose of this study, only the BSID-III MDI cognitive, language, social-emotional and general 
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adaptive behavior subtests were completed. The BSID is widely accepted and used throughout 
cognitive studies, the test has excellent within age test-retest reliability and scores have been 
associated with intelligence quotient (IQ) scores at 4 years of age in DHA supplementation 
published studies.229 All BSID scores reported are composite scores and are, therefore, age 
corrected for each subtest. To control for confounding effects of maternal IQ, mothers completed 
a maternal IQ test using the abbreviated Wechsler Adult Intelligence Scale (WAIS), including 
the block design and vocabulary subtests, which are highly correlated with full scale IQ (FSIQ; 
r2=0.84).237 To control for the confounding effect the degree of stimulation in the home 
environment may have on cognitive development, the mothers completed a self-administered 
Home Screening Questionnaire (HSQ) at 9 months of age.238 
Data analysis 
Participants, all data collectors and investigators were blinded to supplement allocation 
until all study children were 12 months of age and had completed the cognitive testing. Intent-to-
treat (ITT) procedures were maintained throughout. Power was based on a previous pilot trial 
determining the effect DHA supplementation during pregnancy has on improved infant BSID 
scores at 4-6 months, 32 infants per supplementation group are necessary to reach a power of 
0.05% at the 80% confidence level. Total daily DHA intake was calculated for each woman by 
adding estimated dietary DHA intakes, maternal DHA supplementation (if applicable) and DHA 
study supplement. Data was analyzed based on treatment group, placebo versus DHA, as well as 
daily DHA intake groups broken into three groups: low = 0-299 mg per day DHA, medium = 
300-599 mg per day DHA, high = ≥600 mg per day DHA. DHA cut-off points for the intake 
groups were determined on the basis of those falling below, at the median recommended intake 
and above the currently recommended intake.47,48  
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Statistical analysis was completed using SPSS statistical software (SPSS, Chicago, IL) 
and GraphPad Prism V4.0 (GraphPad Software, San Diego, CA). Deviations from Hardy-
Weinberg proportions for the genotypes of each SNP were tested using chi-square tests.240 
Results are expressed as means ± standard deviation (SD), unless otherwise specified. The data 
for each SNP was analyzed separately and categorized based upon genotype (homozygous for 
the major allele, MM; heterozygous, Mm; homozygous for the minor allele, mm) and/or daily 
DHA intake group (low, medium or high) or treatment group (placebo or DHA). One-way 
analysis of variance (ANOVA) was used to compare mean fatty acid proportions between all 
categorized data, in which an additive model was assumed so that an increase or decrease in fatty 
acid proportions was tested for each increment of one minor allele (ie, homozygous for the major 
allele: coded 1; heterozygous: coded 2; homozygous for the minor allele: coded 3). Tukey’s post 
hoc tests were conducted on all statistically significant ANOVA results to determine if 
differences existed among group means. Statistical differences in fatty acid proportions and 
BSID-III scores were also tested with a two-way ANOVA and ANCOVA to determine possible 
interactions between SNP genotype and daily DHA intake level. Correlations between the 
proportions of a fatty acid in erythrocyte as well as plasma phospholipids and breastmilk samples 
were computed using Pearson’s correlation coefficient. Data was adjusted for potential 
confounders, when appropriate, including, maternal age at delivery, maternal IQ, breastfeeding 






Subject characteristics  
55 women were randomly assigned to the placebo and 60 to the DHA supplement. All 
enrolled women are accounted for, with 71% completing the 12 month cognitive testing. The 
study had completion rates of 64% in the placebo group and 80% in the DHA group. End of 
study pill counts showed high rates adherence to the study, with >90% of the women that 
completed the study consuming all study supplements. The reasons for discontinuation in the 
study between the placebo and DHA treatment groups were similar and most often due to 
cessation of breastfeeding before 2 months, loss of contact, or unwillingness to continue in the 
study. One infant died due to conditions not related to the study. Demographic data, including 
age, maternal weight, maternal BMI, maternal IQ or the proportion of DHA in erythrocyte, 
plasma phospholipids and 2 month fatty acids did not differ between participants that completed 
the study and those that did not. 
Complete demographic data for each group are provided in Table 5.1. There were no 
significant differences between the placebo and DHA group, or between any DHA intake group, 
in maternal age, ethnicity, marital status, pre-pregnancy maternal weight and height, and 
maternal IQ. The mean maternal age at delivery was 31.5 ± 4.4 years of age, 93% were 
Caucasian and 93% were married. There was no significant difference in overall breastfeeding 
duration between treatment groups or DHA intake groups. 
Daily DHA intake groups 
Daily DHA intake ranged from 18 mg to 1.374 g per day of total DHA consumed, 
including the study DHA supplement. Mean DHA intake from food of all enrolled subjects was 
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101 ± 99 mg per day, from additional supplementation was 209 ± 239 mg per day, and total 
DHA intake of all women was 468 ± 278 mg per day. Analysis of 7-day diet records determined 
no significant difference between subject macronutrient consumption, ALA, DHA, or fish intake 
at 2 months and 4 months. Daily total DHA intake at 2 months positively correlated with daily 
DHA intake at baseline (r=0.58, p<0.0001), indicating that daily DHA intake of subjects 
remained similar from baseline through 2 months. 
Differences in placebo versus DHA treatment groups and total daily DHA intake groups 
are shown in Table 5.1. Total daily DHA intake per day was significantly higher in the DHA 
treatment group compared to the control group, and in the high DHA intake group compared to 
the low intake group (Tukey’s HSD p<0.0001). Estimated daily DHA intake from food was not 
significantly different between treatment groups, but was significantly higher in the high DHA 
group compared to the low and medium intake groups (Tukey’s HSD p<0.01). Additional DHA 
supplementation was significantly different between treatment groups and daily DHA intake 
groups. 
DHA intake groups and fatty acid analysis  
The means and standard deviations for the fatty acid composition of erythrocyte, plasma 
phospholipids and 2 month breastmilk samples are shown in Table 5.2, classified by daily DHA 
intake group. Results analyzed by treatment groups were not statistically significant for 
erythrocyte and plasma phospholipids and are not shown, (see Appendix I). Additionally, 4 
month breastmilk samples were not analyzed by daily DHA intake groups since these samples 
were collected outside of the study supplementation period, therefore, results are not shown. 
One-way ANOVA revealed no statistically significant differences of any maternal plasma 
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phospholipid fatty acids analyzed by DHA intake group. In contrast, the analysis of maternal 
erythrocyte fatty acids between daily DHA intake groups showed significant differences in the 
percent fatty acids of DHA, with significantly higher DHA in subjects within the high daily 
DHA intake group compared to the medium intake group (Tukey’s HSD p<0.001). Additionally, 
differences were seen between daily DHA intake groups in erythrocyte palmitic acid (16:0), oleic 
acid (18:1n-9) and dihomo-γ-linoleic acid (DGLA; 20:3n-6), with decreased palmitic acid and 
DGLA and increased oleic acid in the high daily DHA intake group compared to the low intake 
group (Tukey’s HSD p<0.05). Erythrocyte DHA positively correlated with daily DHA intake 
(r=0.24, p=0.011), indicating that increases in daily DHA intake correlated with increases in 
erythrocyte DHA.  
Daily DHA intake significantly influenced 2 month breastmilk fatty acid composition, as 
shown in Table 5.2. High daily DHA intake resulted in significantly increased palmitic acid and 
stearic acid (18:0) and lower n-6 fatty acids linoleic acid (LA, 18:2) and AA in 2 month 
breastmilk samples compared to the low intake group (Tukey’s HSD p<0.05). For the n-3 family 
of fatty acids in 2 month breastmilk samples, subjects in the high daily DHA intake group had 
significantly lower ALA and significantly higher DHA compared to the low intake group 
(Tukey’s HSD p<0.05). Additionally, daily DHA intake positively correlated with 2 month 
breastmilk DHA proportion of fatty acids (r=0.37, p=0.0002). Increases in daily DHA intake 
correlated with increases in the proportion of DHA in 2 month breastmilk fatty acids. 
Additionally, when analyzing by treatment group, the DHA group had significantly higher DHA 
[t(90)=2.44, p=0.017] and lower oleic acid [t(90)=3.16, p=0.002] compared to the placebo 
control group in 2 month breastmilk. All other fatty acids were not statistically different between 
treatment groups and results are not shown (see Appendix J).  
 90 
Several positive correlations of 2 month breastmilk fatty acids and erythrocyte and 
plasma fatty acids were observed. As shown in Table 5.2, maternal baseline erythrocyte oleic 
acid, EPA and DHA positively correlated with 2 month breastmilk samples (2-tailed, p<0.05). 
Increases in erythrocyte oleic acid, EPA and DHA (Figure 5.1) correlated with increases in these 
fatty acids in 2 month breastmilk. Additionally, plasma phospholipid palmitic acid, oleic acid, 
LA, ALA and AA positively correlated with 2 month breastmilk samples (2-tailed, p<0.05). 
Increases in plasma palmitic acid, oleic acid, LA, ALA, and AA correlate with increases of these 
fatty acids in 2 month breastmilk. 
SNP associations with fatty acids 
SNPs rs174575 and rs174561 in the FADS1 FADS2 gene cluster were genotyped with a 
success rate of 100% from all 115 mothers within the study. The consort diagram in Figure 5.2 
shows the breakdown of subjects at baseline and 2 months postpartum by genotype. The 
genotypic distribution for both SNP did not deviate from Hardy-Weinberg equilibrium (p>0.05; 
Table 5.3). Minor allele frequencies analyzed for SNP rs174575 was 23% and SNP rs174561 
was 24% of the study population. Of the 7 women homozygous for the minor allele of SNP 
rs174575, 5 were also homozygous for the minor allele of SNP rs174561 as well. Of the 
remaining 2 women homozygous for the minor allele of SNP rs174575, both were heterozygous 
for the SNP rs174561. 8 women were homozygous for the minor allele of SNP rs174561, 5 of 
which were homozygous for the minor allele, 1 was heterozygous and 2 were homozygous for 
the major allele of SNP rs174575. Out of the 7 women homozygous for the minor allele of SNP 
rs174575 and out of the 8 women homozygous for the minor allele of SNP rs174561, only 5 
from each genotype completed the study.  
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Results based upon genotype alone appear to affect fatty acid composition. Table 5.4 and 
Table 5.5 show analysis of the association of the 2 SNPs, rs174575 and rs174561, with the fatty 
acid composition of maternal erythrocytes and plasma phospholipids, respectively, based upon 
genotype only. Erythrocytes and plasma phospholipids were similar and showed statistically 
significant differences between genotype in AA percent total of fatty acids for both SNP 
rs174575 and rs174561, with lower AA present in subjects homozygous for the minor alleles 
when compared to the major alleles (Tukey’s HSD, p<0.05). Additionally, erythrocytes had a 
statistically significant difference in the n-6 fatty acid DGLA for both SNP rs174575 and 
rs174561, with higher DGLA in women heterozygous compared to women homozygous for the 
major allele (Tukey’s HSD, p<0.01 for both SNPs).  
When comparing the fatty acid composition of 2 month breastmilk samples based on 
genotype, as shown in Table 5.6, AA percent total of fatty acids did not vary based upon 
genotype as erythrocyte and plasma AA did, however, DHA differed among women classified 
by the rs174575 allele, with significantly lower DHA in heterozygous subjects (Tukey’s HSD, 
p<0.01) compared to subjects homozygous for the major allele. Conversely, there was no 
significant difference seen in 2 month breastmilk DHA in relation to SNP rs175461 genotype. In 
4 month breastmilk samples, shown in Table 5.7, there were no significant differences in the 
DHA percent total of fatty acids for either SNP, but it must be noted that this sample set was 
outside of the study supplementation period. It is a possibility that without the study supplement, 
the greater variability between subjects may have affected the possibility of achieving a 
statistically significant outcome. For SNP rs174561, 4 month breastmilk AA was significantly 
different between genotypes, with lower proportions in heterozygous and minor allele carrier 
subjects compared to subjects homozygous for the major allele (Tukey’s HSD, p<0.05).   
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Genotype and daily DHA intake  
Fatty acid composition was also analyzed by genotype based upon treatment and daily 
DHA intake groups. The analysis of erythrocyte, plasma and 2 month breastmilk samples, as 
shown in Table 5.8, Table 5.9, and Table 5.10, respectively, provides evidence of the effect 
SNP may play in regards to total daily DHA intake. It should be noted that the results for 
subjects homozygous for the minor allele (mm) for all sample types could not be analyzed via 
ANOVA due to an n=1 in one of the groups, therefore, only mean ± SD are presented for mm 
subjects in Table 5.8, Table 5.9 and Table 5.10. Results analyzed based upon treatment, placebo 
versus DHA, were generally not statistically significant (unless mentioned) and therefore, data is 
not shown (see Appendix J). Genotypic analysis of 4 month samples based upon DHA intake 
group were not appropriate to be performed, since the 4 month sample was outside of the DHA 
study supplementation period, therefore, the same daily DHA intake classification would not 
apply.  
Statistically significant differences were seen in the percent total of fatty acids of 
erythrocytes based upon daily DHA intake for homozygous major allele carriers for both SNP 
rs174575 and rs174561, shown in Table 5.8. Women homozygous for the major allele of SNP 
rs174575 had decreased erythrocyte palmitic acid in the high daily DHA intake group compared 
to the medium intake group (Tukey’s HSD, p<0.05) and increased oleic acid in the high daily 
DHA intake group compared to the low intake group (Tukey’s HSD, p<0.01). Additionally, 
erythrocyte DHA significantly increased in the high daily DHA intake group compared to the 
low intake group in women homozygous for the major allele of rs174575 (Tukey’s HSD, 
p<0.05). However, no significant differences in erythrocyte DHA were noticed between DHA 
intake groups in women heterozygous or minor allele carriers [t(4)=0.63, p=0.561] of SNP 
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rs174575, (when a t test was performed between the medium and high daily DHA intake groups 
since an ANOVA could not be performed due to an n=1 in the low intake group).  
For SNP rs174561, erythrocyte oleic acid and DHA significantly increased in the high 
DHA intake group compared to the medium intake group in women homozygous for the minor 
allele (Tukey’s HSD, p<0.05). In SNP rs174561 heterozygotes, only oleic acid was significantly 
different for SNP rs174561, with increased erythrocyte oleic acid in the high DHA intake group 
compared to the medium intake group (Tukey’s HSD, p<0.05).  Analysis based on treatment 
group showed significant differences only in erythrocyte fatty acids in women homozygous for 
the minor allele, with increased stearic acid for SNP rs174575 [t(5)=3.53, p=0.017] and DGLA 
for SNP rs174561 [t(6)=2.87, p=0.028] in the DHA treatment group compared to the placebo 
control, and no significant differences between DHA proportions were seen (see Appendix J).  
Plasma phospholipid fatty acid composition showed statistically significant differences 
with both SNPs studied based upon daily DHA intake, (Table 5.9). Women homozygous for the 
major allele for SNP rs174575 had increased plasma oleic acid and decreased plasma DGLA in 
the high daily DHA intake group compared to the low intake group (Tukey’s HSD, p<0.05). 
Additionally, subjects heterozygous for SNP rs174575 had significantly increased plasma EPA 
in the high DHA intake group compared to the low (Tukey’s HSD, p<0.05). For SNP rs174561, 
only DGLA was significantly different in plasma fatty acids of homozygous major allele carriers, 
with decreased DGLA in the high daily DHA intake group compared to the low intake group 
(Tukey’s HSD, p<0.05). There were no statistically significant differences in the proportion of 
DHA in plasma fatty acids based on daily DHA intake group for any genotype, although this 
result would be expected based upon non-genotype classified results shown in Table 5.2. 
Additionally, when analyzing based on treatment group, only women heterozygous for both SNP 
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rs174575 and rs174561 in the DHA treatment group had significantly lower plasma DGLA 
[t(34)=2.19, p=0.036; t(39)=2.14, p=0.039; respectively], with no significant differences in 
plasma DHA proportions (see Appendix I).  
Analysis of 2 month breastmilk samples demonstrated that genetic variation within the 
FADS1 FADS2 gene cluster affects the fatty acid composition of breastmilk, and subsequently, 
influences fatty acids the infant receives. Similarly to the results classified by daily DHA intake 
alone shown in Table 5.2, as daily DHA intake increases, the breastmilk DHA also increases in 
subjects homozygous for the major alleles. As shown in Figure 5.3a, the percent total of fatty 
acids of DHA in 2 month breastmilk in women homozygous for the major allele of SNP 
rs174575 significantly increased in the high daily DHA intake group compared to the low intake 
group (Tukey’s HSD p<0.05). However, the differences in 2 month breastmilk DHA in 
heterzygotes for SNP rs174575 were only trending between daily DHA intake group (Figure 
5.3b) and, since an ANOVA could not be performed due to an n=1 in the low intake group, a t 
test between the medium and high daily DHA intake groups showed no significant differences 
between groups in women homozygous for the minor allele [t(2)=0.70, p=0.554; Figure 5.3c]. 
Additionally, women homozygous for the major allele of SNP rs174575 had significantly 
decreasred breastmilk palmitoleic acid and significantly increased stearic acid in the high daily 
DHA intake group compared to the medium intake group (Tukey’s HSD p<0.05). 
Analysis of 2 month breastmilk samples for SNP rs174561 showed the percent total of 
fatty acids of DHA was significantly increased in subjects homozygous for the major allele and 
heterozygous in the high daily DHA intake group compared to the low intake group (Tukey’s 
HSD p<0.05), as shown in Figure 5.3d and 5.3e, respectively. While an ANOVA could not be 
performed due to low incidence of SNP rs174575 in the high intake group, a t test between the 
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low and medium daily DHA intake groups showed no statistically significant difference in 2 
month breastmilk DHA in homozygous minor allele carriers [t(2)=0.16, p=0.891; Figure 5.3f]. 
No other fatty acids had any significant differences based upon daily DHA intake group for both 
SNP rs174575 and rs174561. When analyzing by genotype and treatment group, 2 month 
breastmilk DHA was only significantly higher in the DHA treatment group for women 
homozygous for the major allele of SNP rs174575 compared to the placebo control group 
[t(53)=2.60, p=0.012]. The DHA treatment group also had significantly decreased 2 month 
breastmilk oleic acid in women heterozygous for SNP rs174575 [t(30)=2.28, p=0.030] and in 
women homozygous for the major allele of SNP rs174561 [t(53)=2.28, p=0.027] as well as 
decreased AA in women heterozygous for SNP rs174575 [t(30)=2.57, p=0.015] compared to the 
placebo control group (see Appendix J).  
Infant neurocognitive development 
Significant differences in the cognitive scale of the BSID-III MDI at 12 month were seen 
based upon maternal DHA intake, with infants born to mothers in the high DHA intake group 
scoring significantly higher than the low intake group (p=0.018; Tukey’s HSD p<0.05). No 
significant responses were seen between any group on the 12 month language, social and general 
adaptation scales as well as all of the 4 month BSID-III testing. Furthermore, maternal age, IQ, 
breastfeeding duration or HSQ did not correlate with any of the BSID-III scores. BSID-III scores 
analyzed based upon SNP genotype showed no statistically significant differences for both SNP 
rs174575 and rs174561, as shown in Table 5.11. An ANCOVA for BSID-III MDI scores and 
daily DHA intake group was performed controlling for genotype of both SNP studied to 
determine if any interaction existed between SNP and daily DHA intake group on infant 
neurocognitive development. The ANCOVA for 12 month cognitive MDI test showed a 
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statistically significant interaction between daily DHA intake group and SNP rs174575 genotype, 
F=3.40, p=0.023. There was not a significant interaction between daily DHA intake group and 
SNP rs174561 genotype for the 12 month cognitive MDI test, F=0.42, p=0.793. ANCOVA for 
all other BSID-III MDI scales did not show a statistically significant interaction between daily 
DHA intake group and SNP genotype for both SNP studied.  
Discussion 
The effect of SNPs within the FADS1 FADS2 gene cluster on fatty acid composition of 
erythrocytes and plasma phospholipids seen in this study agree with several previous 
studies.18,19,40,203,245 A study of European adults reported higher proportions of serum LA and 
ALA and lower proportions of AA and EPA in minor allele carriers of several SNPs within the 
FADS1 FADS2 gene cluster.245 In the current study, decreased erythrocyte and plasma 
phospholipid AA in women carriers of the minor allele for both SNPs studied was identified. 
Additionally, increased daily DHA intake increased erythrocyte DHA in women homozygous for 
the major allele for SNP rs174575 and rs174561, but increasing DHA intake did not effectively 
increase erythrocyte DHA in women heterozygous or homozygous for the minor allele. Unlike 
several prior studies, FADS SNP or daily DHA intake did not significantly affect plasma 
phospholipids fatty acid composition in this study for reasons unknown. SNPs within the FADS1 
FADS2 gene cluster may result in decreased transcription or activity of the Δ5- and Δ6-
desaturases, which could explain observed decreases in desaturase products, such as AA and 
DHA.  
Postnatally, the infant receives fatty acids essential for growth and development, 
including DHA, from breastmilk or enriched infant formulas. Previous studies using stable 
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isotope tracers have shown DHA from the maternal diet transfers directly into breastmilk and 
several studies have indicated FADS1 FADS2 genotype affects the proportion of DHA in 
breastmilk.18,19,193 Women homozygous for the minor allele of SNP rs174575 were found in 
recent studies to have significantly decreased breastmilk AA, EPA and DHA compared to 
women homozygous for the major allele.18,19 Although both Δ5- and Δ6-desaturases are present 
in the lactating mammary gland, decreased desaturase expression and/or activity due to SNPs 
within the FADS1 FADS2 gene cluster could explain observed decreases in desaturase 
products.246 While no changes in breastmilk AA or EPA were observed based on FADS 
genotype in this study, a significant reduction in breastmilk DHA was observed in women 
heterozygous for SNP rs174575 compared to women homozygous for the major allele. However, 
no significant difference in 2 month breastmilk DHA was seen in women homozygous for the 
minor allele of SNP rs174575 or based on SNP rs174561 genotype. It is possible that significant 
results in carriers of homozygous minor alleles were not seen due to the low number of women 
in this group and the high variability of DHA proportion of breastmilk fatty acids, as 
demonstrated in Figure 5.3c.  
Based the results of previous studies, it would be expected that increasing the intake of 
preformed DHA would help women homozygous for the minor alleles of SNPs within the 
FADS1 FADS2 gene cluster to compensate for lower desaturase expression and/or activity. 
While increased daily DHA intake resulted in significant increases in 2 month breastmilk DHA 
in this study (Table 5.2), women homozygous for the minor allele of SNP rs174575 and 
rs174561 did not significantly increase breastmilk DHA with increased daily DHA intake. In 
contrast, major allele carriers of both SNPs had a significant increase in breastmilk DHA in 
response to a high daily DHA intake ≥600 mg compared to low daily intake <300 mg. Similarly, 
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Moltó-Puigmartí et al. found proportions of DHA in breastmilk only increased with increased 
fish and fish-oil intake in the major allele carriers for SNP rs174575 and rs174561 and not in the 
minor allele carriers.18 If incorporation of preformed DHA into breastmilk is limited based upon 
maternal genetic variation within the FADS1 FADS2 gene cluster, it may not be useful for 
mothers that are minor allele carriers of SNP rs174575 or rs174561 to increase their DHA intake 
for the purposes of raising breastmilk DHA. Such results may also indicate children born to 
mothers who are minor allele carriers of FADS1 FADS2 SNPs and have low DHA intake may be 
at risk for insufficient DHA supply below amounts recommended for brain and neurocognitive 
development.  
It is possible that SNPs within the FADS1 FADS2 gene cluster may result in decreased 
endogenous fatty acid synthesis due to possible decreased Δ5- and Δ6-desaturase activity.  The 
genomic structure surrounding SNP rs174575 was determined to contain binding sites for sterol 
regulatory element transcription factors (SREBPs) in which LCPUFA are able to modify gene 
expression of FADS2, thus affecting subsequent Δ6-desaturase activity, which is believed to be 
the rate limiting step on the metabolic pathway to producing DHA endogenously.26,247 However, 
DHA synthesis does not entirely account for breastmilk DHA, as indicated by our finding and 
others that increasing daily DHA intake results in an increase in the proportion of DHA in 
breastmilk.18,164,193 It is speculated that since the current study did not see an increase in 
proportions of DHA in breastmilk for women heterozygous or homozygous for the minor alleles 
of SNP rs174575 and rs174561 in response to increased daily DHA intake, there may be a 
modification in the incorporation of DHA into breastmilk as a result of genetic variation. SNP 
within the FADS gene cluster could be associated with fatty acid transport proteins (FATP), 
affecting transport of DHA from maternal supplies or dietary intake into breastmilk.248 
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Additionally, FADS1 FADS2 gene cluster markers could be linked to fatty acid binding proteins 
(FABP), a family of carrier proteins involved in the transfer of fatty acids between membranes. 
A recent study determined a polymorphism within the FABP2 gene was associated with 
impaired activation of Δ6-desaturase and subsequently resulted in decreased plasma AA 
proportions of plasma fatty acids.69  
Higher plasma AA has been positively associated in previous studies with fetal growth 
and development, whereas low fetal levels have been associated with reduced performance 
IQ.103,104,192,249 AA serves as a precursor for eicosanoids, signaling molecules that are important 
in many aspects of growth and development, including immune and inflammatory responses, in 
addition to digestive and neurological development.28,250,251 Confirming prior studies in adults, 
several recent studies determined pregnant women that were minor allele carriers of common 
SNPs in the FADS1 FADS2 gene cluster had lower plasma phospholipids and breastmilk 
AA.18,19 This study showed a significant decrease in erythrocyte and plasma phospholipid AA in 
women that were minor allele carriers of both SNP rs174575 and rs174561. However, a 
significant reduction in breastmilk AA was not seen in relation to SNP in this study. The 
decrease in AA proportions could be due to SNP affects on decreased Δ6-desaturase 
transcription or activation. It is currently unknown whether decreases in maternal AA 
proportions of fatty acids are disadvantageous to the fetus and child due to subsequent reduced 
eicosanoid production leading to diminished neurocognitive development.  
It is well established that DHA is important in fetal neurological development.58,81,139 
DHA is preferentially transported to the fetus during the last trimester of gestation, which 
coincides with fetal retinal and brain development, specifically with a growth spurt in gray 
matter and neurogenesis.5,67,98 While results remain mixed, previous research has shown 
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increased DHA intake during pregnancy and lactation and higher DHA status results in improved 
neurocognitive development in young children and enhanced IQ in later 
childhood.10,16,17,20,22,127,155,160-165,168,169 Similarly, the current study showed an association 
between maternal daily DHA intake of ≥600 mg per day during pregnancy and lactation and 
significantly improved BSID-III MDI cognitive scale scores at 12 months of age. Additionally, 
this study found a significant interaction between FADS2 SNP rs174575 genotype and daily 
DHA intake on infant cognitive scale scores at 12 months of age. Several recent studies have 
discovered a possible association between FADS SNP and child IQ.25,245,252 A recent study of 
large birth cohorts showed children breastfed that were major allele carriers for SNP rs174575 
had a significant increase in IQ compared to carriers of the same allele that were not breastfed.26 
Additionally, the study found children who were minor allele carriers did not have any IQ 
advantage to being breastfed, suggesting the SNP somehow influences the positive benefits 
breastfeeding has on neurocognitive development. It is unlikely that the breastfeeding effects on 
cognitive tests and IQ are influenced directly by genetic variation, but rather the SNP may 
influence the availability of DHA to the child through breastmilk, subsequently affecting child 
cognitive development.  
A potential limitation to this study was the limited number of minor allele carriers for 
each of the SNP investigated and a study population that was relatively homogenous in relative 
genetic background (94% Caucasian). Unfortunately, this study had less than the anticipated 10 
homozygous minor allele carriers based upon previously described minor allele frequency of at 
least ≥18%.18 Furthermore, the study was limited by only studying two SNP that were chosen 
based upon the effects on breastmilk fatty acid composition. Additional SNP may yield more 
significant results that could help to provide a clearer picture to the effect genetic variation 
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within the FADS1 FADS2 gene cluster has on DHA and other fatty acid proportions. Future 
supplementation studies could increase SNP studied as well as increase study subjects through a 
more diverse population to determine if the effects of our current study apply. In addition to 
increased subjects, additional cognitive testing of the children at a later age would be beneficial 
to determine if maternal genotype, AA and DHA proportions of breastmilk have an impact on 
child IQ and academic performance.   
Numerous prenatal supplements with DHA were recently introduced to the market within 
the last 5-10 years and women choosing to take a DHA supplement were not excluded from the 
study. The increased awareness of possible benefits DHA and fish oil can incur upon the 
developing fetus has increased over the last decade as more research studies provide positive 
associations and more health care providers promote DHA supplementation during pregnancy 
and lactation. In the current study, all sources of DHA in the maternal diet were accounted for, 
allowing for a more accurate total daily DHA intake to be estimated. Therefore, positive 
associations between total DHA intake and maternal fatty acid composition were determined 
beyond that of study treatment groups or genotype alone. 
In conclusion, this study confirmed previously reported associations between maternal 
SNPs within the FADS1 FADS2 gene cluster and fatty acid composition of erythrocytes and 
breastmilk, while also estimating total daily DHA intake from all sources during pregnancy and 
lactation. These results suggest that genetic variation may influence maternal-to-infant transfer of 

















a WAIS, Wechsler Adult Intelligence Scale; DHA, docosahexaenoic acid.   
b Mean ± SD (all such values).   
c Mean differences between placebo and DHA supplemented groups were tested with two-tailed t test.  
d Mean differences between daily DHA intake groups were assessed by ANOVA.   





Table 5.2  
Fatty acid composition (percentage of total fatty acids identified) of maternal baseline erythrocyte, baseline plasma phospholipids and 2 month 
breastmilk samples classified according to daily DHA intake group (low=0-299mg, medium=300-599mg, high=>600mg per day) and Pearson's 






a The number of women with erythrocyte and plasma phospholipid data in the low DHA intake group, medium DHA intake group, and high DHA intake group 
were as follows: 27, 55, and 33, respectively. The number of women with 2 month breastmilk samples in the low, medium and high DHA intake group are as 
follows: 18, 30 and 44, respectively. ALA, α-linoleic; DGLA, dihomo-γ-linolenic acid; AA, arachidonic acid; EPA, eicosapentaenoic acid; DPA, 
docosapentaenoic acid; DHA, docosahexaenoic acid, 2 mo BM, 2 month breastmilk samples.  Differences of fatty acid proportions between intake groups were 
assessed using ANOVA. 
b Mean ± SD (all such values). 
c Significant difference (p<0.05). 
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Figure 5.1. Correlation between maternal erythrocyte docosahexaenoic 


























Erythrocyte DHA - % Total Fatty Acids
 105 
 
Figure 5.2. Consolidated flow diagram of study subjects by SNP genotype. DHA, docosahexaenoic acid; 
Daily DHA intake groups: Low=0-299 mg DHA per day, Medium = 300-599 mg DHA per day, High = >600 mg 
DHA per day. 
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Table 5.3 






a M/m, major and minor alleles; MAF, minor allele frequency; HWE, Hardy-Weinberg equilibrium. 
b Number of women carrying M or m, the major and minor alleles, and carrying M/M, M/m or m/m genotypes, 
respectively. 






















Fatty acid (percentage of total fatty acids identified) of maternal baseline erythrocyte 












a The numbers of women with erythrocyte data with MM, Mm and mm genotype for SNP 
rs174575 were as follows: 72, 36, and 7, respectively. The numbers of women with erythrocyte 
data with MM, Mm and mm genotype for SNP rs174561 were as follows: 66, 41, and 8, 
respectively. SNP, single nucleotide polymorphism; MM, homozygous for the major allele; 
Mm, heterozygous; mm, homozygous for the minor allele; ALA, α-linolenic; DGLA, dihomo-
γ-linolenic acid; AA, arachidonic acid; EPA, eicosapentaenoic acid; DPA, docosapentaenoic 
acid; DHA, docosahexaenoic acid. Differences of fatty acid proportions between genotype were 
assessed by using ANOVA. 
b Mean ± SD (all such values). 










Fatty acid (percentage of total fatty acids identified) of maternal baseline plasma 


















a The numbers of women with plasma data with MM, Mm and mm genotype for SNP rs174575 
were as follows: 72, 36, and 7, respectively. The numbers of women with plasma data with MM, 
Mm and mm genotype for SNP rs174561 were as follows: 66, 41, and 8, respectively. SNP, 
single nucleotide polymorphism; MM, homozygous for the major allele; Mm, heterozygous; 
mm, homozygous for the minor allele; ALA, α-linolenic; DGLA, dihomo-γ-linolenic acid; AA, 
arachidonic acid; EPA, eicosapentaenoic acid; DPA, docosapentaenoic acid; DHA, 
docosahexaenoic acid. Differences of fatty acid proportions between genotype were assessed by 
using ANOVA. 
b Mean ± SD (all such values). 









Fatty acid (percentage of total fatty acids identified) of maternal 2 month breastmilk 














a The numbers of women with 2 month breastmilk data with MM, Mm and mm genotype for 
SNP rs174575 were as follows: 55, 32, and 5, respectively. The numbers of women with 2 
month breastmilk data with MM, Mm and mm genotype for SNP rs174561 were as follows: 54, 
33, and 5, respectively. SNP, single nucleotide polymorphism; MM, homozygous for the major 
allele; Mm, heterozygous; mm, homozygous for the minor allele; ALA, α-linolenic; DGLA, 
dihomo-γ-linolenic acid; AA, arachidonic acid; EPA, eicosapentaenoic acid; DPA, 
docosapentaenoic acid; DHA, docosahexaenoic acid.  Differences of fatty acid proportions 
between genotype were assessed by using ANOVA. 
b Mean ± SD (all such values). 









Fatty acid (percentage of total fatty acids identified) of maternal 4 month breastmilk 














a The numbers of women with 4 month breastmilk data with MM, Mm and mm genotype for 
SNP rs174575 were as follows: 55, 30, and 5, respectively. The numbers of women with 4 month 
breastmilk data with MM, Mm and mm genotype for SNP rs174561 were as follows: 54, 29, and 
5, respectively. SNP, single nucleotide polymorphism; MM, homozygous for the major allele; 
Mm, heterozygous; mm, homozygous for the minor allele; ALA, α-linolenic; DGLA, dihomo-γ-
linolenic acid; AA, arachidonic acid; EPA, eicosapentaenoic acid; DPA, docosapentaenoic acid; 
DHA, docosahexaenoic acid. Differences of fatty acid proportions between genotype were 
assessed by using ANOVA. 
b Mean ± SD (all such values). 
c Significant difference (p<0.05). 
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Table 5.8 
Fatty acid composition (percentage of total fatty acids identified) of maternal baseline erythrocyte samples classified according to both genotype 
for SNP rs174575 and rs174561, as well as daily DHA intake group (low=0-299mg, medium=300-599mg, high=>600mg per day).a 
a The numbers of women with erythrocyte data in the low DHA intake group, medium DHA intake group, and high DHA intake group for SNP rs174575 were as 
follows: MM, 18, 35, and 19, respectively; Mm, 8, 15, and 13, respectively; mm, 1, 4, and 2, respectively. The numbers of women with erythrocyte data in the 
low DHA intake group, medium DHA intake group, and high DHA intake group for SNP rs174561 were as follows: MM, 17, 27, and 22, respectively; Mm, 8, 
22, and 11, respectively; mm, 2, 5, and 1, respectively. SNP, single nucleotide polymorphism; MM, homozygous for major alelle; Mm, heterozygous; mm, 
homozygous for minor allele. ALA, α-linolenic; DGLA, dihomo-γ-linolenic acid; AA, arachidonic acid; EPA, eicosapentaenoic acid; DPA, docosapentaenoic 
acid; DHA, docosahexaenoic acid. Differences of fatty acid proportions between daily DHA intake group for each genotype were assessed by using ANOVA. 
b Mean ± SD (all such values). 
c Significant difference (p<0.05). 
d Due to low number of subjects homozygous for the minor alleles, ANOVA could not be run due to only one subject in the low DHA intake group for SNP 





Fatty acid composition (percentage of total fatty acids identified) of maternal baseline plasma phospholipid samples classified according to both 
genotype for SNP rs174575 and rs174561, as well as daily DHA intake group (low=0-299mg, medium=300-599mg, high=>600mg per day).a 
a The numbers of women with plasma data in the low DHA intake group, medium DHA intake group, and high DHA intake group for SNP rs174575 were as 
follows: MM, 10, 25, and 14, respectively; Mm, 6, 13 and 10, respectively; mm, 1, 2, and 2, respectively. The numbers of women with plasma data in the low 
DHA intake group, medium DHA intake group, and high DHA intake group for SNP rs174561 were as follows: MM, 10, 22, and 16, respectively; Mm, 5, 16 and 
9, respectively; mm, 2, 2, and 1, respectively. SNP, single nucleotide polymorphism; MM, homozygous for major alelle; Mm, heterozygous; mm, homozygous 
for minor allele. ALA, α-linolenic; DGLA, dihomo-γ-linolenic acid; AA, arachidonic acid; EPA, eicosapentaenoic acid; DPA, docosapentaenoic acid; DHA, 
docosahexaenoic acid. Differences of fatty acid proportions between daily DHA intake group for each genotype were assessed by using ANOVA. 
b Mean ± SD (all such values). 
c Significant difference (p<0.05). 
d Due to low number of subjects homozygous for the minor alleles, ANOVA could not be run due to only one subject in the low DHA intake group for SNP 




Fatty acid composition (percentage of total fatty acids identified) of maternal 2 month breastmilk samples classified according to both genotype 
for SNP rs174575 and rs174561, as well as daily DHA intake group (low=0-299mg, medium=300-599mg, high=>600mg per day).a 
a The numbers of women with 2 month breastmilk data in the low DHA intake group, medium DHA intake group, and high DHA intake group for SNP rs174575 
were as follows: MM, 10, 25, and 14, respectively; Mm, 6, 13 and 10, respectively; mm, 1, 2, and 2, respectively. The numbers of women with 2 month 
breastmilk data in the low DHA intake group, medium DHA intake group, and high DHA intake group for SNP rs174561 were as follows: MM, 10, 22, and 16, 
respectively; Mm, 5, 16 and 9, respectively; mm, 2, 2, and 1, respectively. SNP, single nucleotide polymorphism; MM, homozygous for major alelle; Mm, 
heterozygous; mm, homozygous for minor allele. ALA, α-linolenic; DGLA, dihomo-γ-linolenic acid; AA, arachidonic acid; EPA, eicosapentaenoic acid; DPA, 
docosapentaenoic acid; DHA, docosahexaenoic acid. Differences of fatty acid proportions between daily DHA intake group for each genotype were assessed by 
using ANOVA. 
b Mean ± SD (all such values). 
c Significant difference (p<0.05). 
d Due to low number of subjects homozygous for the minor alleles, ANOVA could not be run due to only one subject in the low DHA intake group for SNP 
rs174575 and only one subject in the high DHA intake group for SNP rs174561. 
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Figure 5.3. Maternal 2 month breastmilk docosahexaenoic acid (DHA) classified by daily DHA intake group as well as by genotype for SNP rs174575 and 
rs174561: graph a, homozygous for the major allele SNP rs174575; graph b, heterozygous SNP rs174575; graph c, homozygous for the minor allele SNP 
rs174575; graph d, homozygous for the major allele SNP rs174561; graph e, heterozygous SNP rs174561; graph f, homozygous for the minor allele SNP 
rs174561. SNP, single nucleotide polymorphism; low intake group, 0-299 mg DHA per day; medium intake group, 300-599 mg DHA per day; high intake group, 


























































































Neurocognitive development measured by the Mental Development Index (MDI) of the 
Bayley Scale of Infant Development (BSID) III of infants classified according to maternal 




a The numbers of infants with BSID-III MDI testing for SNP rs174575 were as follows: MM 51, 
Mm 28, and mm 4. The numbers of infants with BSID-III MDI testing for SNP rs174561 were as 
follows: MM 49, Mm 30, and mm 4. SNP, single nucleotide polymorphism; MM, homozygous for 
major allele; Mm, heterozygous; mm, homozygous for minor allele. Differences of BSID-III MDI 
subtest scores between intake groups were assessed by using ANOVA. 























Docosahexaenoic acid nutrition is of interest in pregnancy nutrition because of recent 
evidence that increased intakes can improve pregnancy outcomes, increase infant growth, and 
enhance neurocognitive development of the offspring. DHA is present in high concentrations in 
the brain and neural tissues and accumulates during the third trimester of gestation through the 
first 2 years of life.2 Laboratory experiments and animal studies have shown that DHA 
influences inflammatory processes related to preterm birth, as well as neurogenesis, 
synaptogenesis and neurochemistry, enhancing cognitive processes throughout the 
brain.41,57,253,254 Randomized controlled trials (RCT) in humans have demonstrated numerous 
benefits of maternal DHA intake during pregnancy, such as increased gestational age, reduced 
risk of preterm birth, and improved infant growth and cognitive development.9,10,16,20,127,155 
However, results remain mixed and inconclusive. 
The Omega Smart Baby Project was a double-blinded, randomized, placebo controlled 
trial that was designed to determine the relationship between maternal DHA intake during 
pregnancy and lactation and infant neurocognitive development. The study supplement increased 
maternal DHA intake during the last trimester of pregnancy through the first 3 months of 
breastfeeding. Daily maternal DHA intake positively correlated with maternal erythrocyte and 
breastmilk DHA proportions, and 2 month breastmilk DHA positively correlated with infant 
cognitive test scores at 12 months of age. This study was different from other RCT in that it 
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supplemented DHA during both pregnancy and early lactation and accounted for all sources of 
DHA in the maternal diet, including food and self-supplementation. 
Prenatally, it is important for the fetus to receive adequate DHA for optimal growth and 
development. The fetus is supplied with DHA from the maternal circulation, which is directly 
influenced by maternal DHA synthesis and stores as well as maternal nutrition.4 Observational 
studies in several large birth cohorts have shown an association between increased fish and 
seafood intake during pregnancy and improved infant cognitive development.11-13,150 Although 
results vary, RCT have provided evidence of increased DHA intake during pregnancy with 
enhanced neurologic development and improved cognitive measurement scores.9,16,20,124,127,156 
However, the majority of these studies do not continue DHA supplementation after birth, 
reducing potential benefits DHA may have on brain development postnatally in early infancy.  
Like human adults, infants have a limited ability to synthesize DHA from n-3 fatty acid 
precursor alpha-linolenic acid (ALA), and, therefore, must obtain preformed DHA from 
breastmilk or enriched infant formulas for optimal development.7 RCT involving infant DHA 
supplementation postnatally have shown a positive association between increased DHA intake 
and enhanced neurocognitive development.22,23,161-164 Yet, results from postnatal RCT have not 
established an indisputable benefit to postnatal DHA supplementation, and many trials show the 
most beneficial results in preterm infants. Additionally, postnatal DHA supplementation trials 
often fail to supplement prenatally, excluding a time of immense brain DHA accumulation and 
growth.  
A limited number of RCT have supplemented with DHA and/or accounted for DHA 
intake during both pregnancy and lactation, with mixed results.10,15,20,159 Campoy et al. 
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supplemented women with 500 mg of DHA per day during pregnancy, and postnatally, 
encouraged breastfeeding or matched infant formula DHA based on study randomization for the 
first 6 months of life. Cognitive testing of the children at 6.5 years of age found no significant 
improvement in cognitive function based on maternal DHA intake.20 Helland et al. found infants 
born to women supplemented with 1.18 g DHA cod liver oil per day from 18 weeks of gestation 
through 3 months after delivery scored higher on the Mental Processing Composite of the 
Kaufman Assessment Battery for Children (K-ABC) at 4 years of age when compared to corn oil 
controls.10 Yet, no significant differences occurred between the two groups on the Fagan Test of 
Infant Intelligence (FTII) at 6 or 9 months of age or on the K-ABC at 7 years of age.14,15 In the 
current study, infants born to mothers consuming 600 mg of DHA per day or greater exhibited 
significantly improved scores on the cognitive scale of the Bayley Scales of Infant Development 
III (BSID-III) Mental Development Index (MDI) at 12 months of age. It is possible that the 
positive association between maternal DHA intake and improved infant cognitive test scores was 
due to the prolonged supplementation period during a critical time of brain development in the 
last trimester of pregnancy through the first 3 months of life.  
An emerging body of evidence points to differences in the response to DHA 
supplementation during development between the genders. Evidence is particularly compelling 
in preterm infants in which boys showed slower and poorer neurodevelopment compared to girls 
in early childhood. It is also suggested that due to potential estrogen effects, females may 
synthesize DHA more efficiently from precursor fatty acids than males.7 Several RCT have 
failed to determine a significant association between DHA supplementation and neurocognitive 
development, yet when analyzed based upon gender, found significant differences, with girls 
significantly benefiting developmentally from supplementation.23,70 In the DINO trial of early 
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preterm infants, no significant results were seen between treatment groups, however, a 
significant interaction between higher postnatal DHA supplementation and gender was found. 
Higher DHA significantly improved the cognitive development of girls and reduced the risk of 
both mild (developmental quotient (DQ) <85) and severe (DQ<70) cognitive delay at 18 months 
of age, while no effect of higher DHA was noted for boys.23 In the current study, a differing 
gender response to high DHA supplementation was seen on neurocognitive development. Female 
infants born to mothers consuming ≥600 mg of DHA per day scored significantly higher on the 
12 months cognitive BSID-III MDI subtest compared to female infants born to mothers with 
<300 mg of DHA intake per day, yet, no significant difference was seen between intake groups 
in male infants. Female infants appear to be more responsive to early DHA supplementation and 
further studies are necessary to validate these results and possibly define additional sub-groups 
of children that can benefit from DHA supplementation. No significant differences in 4 month 
BSID-III testing were found between any group, and no significant differences were seen 
between treatment groups on the 12 month BSID-III testing in this study. 
Several observational and prospective studies have positively associated increased fish 
and seafood intake with longer gestation durations, decreased preterm birth incidence and 
increased infant birth weights.114,115,118,120,135 RCT have attempted to validate the effect DHA 
supplementation has on increasing gestational length and decreasing preterm births with variable 
results.15,123-127,132,133,138 An Australian study of pregnant women found a daily supplementation 
of 800 mg of DHA per day was associated with a reduction in preterm births, an increase in 
gestational length and a significant reduction in the risk of having a low birth weight baby, 
compared to women supplemented with vegetable oil.127 The current study showed a significant 
increase of 4.5 days in gestational length in the DHA treatment group compared to the placebo 
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group.  Women consuming >300 mg DHA per day were >4 times more likely not to have a 
preterm birth (<37 weeks) with a significantly decreased incidence of preterm birth of 8% (n=7) 
compared to 22% (n=6) in women consuming <300 mg of DHA per day. However, no 
significant effects of DHA supplementation were associated with infant birth weights. The 
reasons and mechanisms behind the influence of DHA on gestational length and preterm birth 
are currently unknown. It is possible that DHA may affect and prevent several causes of preterm 
birth, such as inflammatory processes or vascular tone, or possible further unknown causes, 
subsequently increasing gestational length and infant birth weight. 
Unlike some previous studies linking increased DHA intake during pregnancy with 
increased infant birth weight, in the present study there was no significant increase in the birth 
weight of infants in any DHA intake or treatment group. The same was true for infant birth 
length and head circumference, with no significant differences between any of the study groups. 
Additionally, no statistically significant differences were determined between any of the 2 month 
measurements based upon treatment or daily DHA intake. However, it is interesting to note that 
increases in the proportion of DHA in 2 month breastmilk fatty acids correlated with decreases in 
infant 2 month weights, showing a negative association between DHA consumption and weight 
gain in early infancy. It is possible that as breastmilk DHA increases and the infant receives 
more DHA, adipose deposition could be affected, which may have an effect later in 
childhood.212,213 Pedersen et al. showed a significant inverse association between breastmilk 
DHA and child BMI from 2 to 7 years of age in the Copenhagen Prospective Study on Asthma in 
Childhood birth cohort.214 Additionally, Donahue et al. determined higher maternal DHA+EPA 
intake during pregnancy and higher DHA+EPA umbilical cord plasma phospholipids were 
associated with lower adiposity in children at 3 years of age.213 The negative correlation shown 
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here is worth following up in future studies involving this same cohort of infants to determine if 
DHA intake during pregnancy and lactation has any affect on childhood body composition. 
Breastfeeding has been associated with improved infant visual and neurocognitive 
development, improved behavior and decreased risk for infection. Enhanced neurocognitive 
development has been directly associated with the concentrations of DHA in breastmilk.164,190,196 
Due to limited endogenous synthesis of DHA, postnatally, the infant must receive preformed 
DHA from breastmilk or enriched infant formulas.7 Average concentrations of DHA in 
breastmilk range from 0.17% to 1.0% of total fatty acids and are directly effected by maternal 
DHA intake.189,190 Breastmilk DHA content has been shown to increase by 76% and infant 
plasma phospholipid DHA by 35% when the mother is exclusively breastfeeding and 
supplemented with 200 mg of DHA per day.164 In the current study, successfully increasing the 
dietary intake of DHA resulted in increased breastmilk DHA, showing a positive association 
between daily DHA intake and 2 month breastmilk DHA proportions.  
In addition to increased breastmilk DHA, this study showed high maternal daily DHA 
intake ≥600 mg resulted in significant decreases in 2 month breastmilk arachidonic acid (AA), as 
well as desaturase substrates linoleic acid (LA) and ALA, compared to women consuming <300 
mg DHA per day. AA is an omega-6 (n-6) fatty acid essential for growth and development and 
studies have shown significantly increasing DHA in the maternal diet could result in decreased 
AA proportions.95,96 The decrease in AA in breastmilk of women with high daily DHA intake 
could be due in part to decreased enzyme transcription and/or activity in the endogenous 
synthesis of LCPUFA. Increased dietary DHA has been shown to alter gene expression in n-6 
and n-3 synthesis pathways, possibly affecting the feedback regulation of the synthesis of 
LCPUFA.41 Since the synthesis pathways of both n-6 and n-3 fatty acids compete for the same 
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desaturase enzymes at multiple steps, it is possible that altering the enzyme activity through 
feedback mechanisms or precursor ratios may affect downstream fatty acid proportions unless 
supplemented from the diet. 
Although limited, breastmilk DHA can be endogenously synthesized from precursor fatty 
acids by elongation and desaturation, in which the rate-limiting step in humans appears to be the 
Δ6-desaturase enzyme.39 Both Δ5- and Δ6-desaturases necessary for LCPUFA synthesis are 
present in the lactating mammary gland, however, decreased desaturase expression and/or 
activity could be due to numerous common single nucleotide polymorphisms (SNP).40,246 The 
Δ5- and Δ6-desaturase enzymes involved in LCPUFA synthesis are encoded by fatty acid 
desaturase (FADS)1 and FADS2, respectively, which are arranged in a head-to-head orientation 
on chromosome 11q, with a third desaturase gene, FADS3, which function is currently 
unknown.24 Recent studies have demonstrated that SNP in the FADS1 FADS2 gene cluster 
contribute to variability of DHA in erythrocyte and plasma phospholipids, as well as breastmilk, 
indicating a possible link between SNP and DHA enrichment of breastmilk.18,19,245 DHA 
proportions in erythrocyte, plasma and breastmilk were lower in women homozygous for the 
minor alleles of 2 SNP recently studied, FADS2 rs174575 and FADS1 rs174561, compared to 
women homozygous for the major allele.18 This study showed a significant reduction in 2 month 
breastmilk DHA in women heterozygous for the rs174575 SNP, but not for those women 
homozygous for the minor allele, when compared to women homozygous for the major allele. 
Additionally, no significant differences in breastmilk fatty acids based on SNP were found 
regarding SNP rs174561. It is possible that significant results in carriers of homozygous minor 
alleles were not seen due to the low number of subjects and the high variability of breastmilk 
DHA proportions. 
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It would be expected that decreased breastmilk DHA in women carriers of SNP within 
the FADS1 FADS2 gene cluster could be compensated with increased dietary DHA intake, 
however, this appears to not be the case. In the current study, increased daily DHA intake did not 
significantly increase 2 month breastmilk DHA in women heterozygous or homozygous for the 
minor allele for SNP rs174575, yet, women homozygous for the major allele did see significantly 
increased breastmilk DHA with high daily DHA intake compared to low daily intake. Similarly, 
Moltó-Puigmartí et al. found proportions of DHA in breastmilk only increased with increased 
fish and fish-oil intake in the major allele carriers for SNP rs174575 and rs174561 and not in 
minor allele carriers.18 If synthesis and transfer of DHA into breastmilk is impaired by SNP 
within the FADS1 FADS2 gene cluster, it may not be beneficial to increase maternal DHA 
intake for the purposes of increasing DHA transfer to the infant, and thus, alternative DHA 
supplementation for the infant may need to be investigated.  
SNP within the FADS1 FADS2 gene cluster may affect a reduction in breastmilk DHA 
due to decreased Δ5- and Δ6-desaturase transcription and/or activity, while also possibly 
affecting transfer and incorporation of DHA into breastmilk from dietary and maternal sources. 
The reduction in DHA transferred into breastmilk in women carriers of FADS SNP could be due 
to alterations involving fatty acid transport proteins (FATP), fatty acid binding proteins (FABP) 
or modifications of the incorporation of DHA in phospholipid classes or 
chylomicrons.60,61,65,66,69,72,248,255 A polymorphism within the FABP2 gene was recently found to 
be associated with impaired Δ6-desaturase activation and resulted in decreased plasma AA. 
Although dietary increases in DHA did not result in increased breastmilk DHA in women with 
SNP within the FADS1 FADS2 gene cluster, it is not possible for the current study to infer the 
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mechanisms involved in the affect genetic variations may have on DHA transfer. Future, more 
detailed studies are necessary to determine how FADS SNP are associated with breastmilk DHA. 
Previous research has shown increased DHA intake during lactation, increased breastmilk 
DHA, and higher DHA status results in improved neurocognitive development in young children 
and enhanced IQ in later childhood, however results remain mixed.10,16,17,20,22,127,155,160-165,168,169 
Several recent studies have reported a possible association between FADS SNP and child 
IQ.25,245,252 A recent study of large birth cohorts reported children breastfed that were major 
allele carriers for SNP rs174575 had a significant increase in IQ compared to carriers of the same 
allele that were not breastfed.26 Additionally, the study found that children who were minor allele 
carriers did not have any IQ advantage to being breastfed, suggesting the SNP somehow 
influences the positive benefits breastfeeding has on neurocognitive development. It is believed 
to be unlikely that the breastfeeding effects on IQ are caused directly by genetic variation, but 
rather the SNP may influence the availability of DHA to the child through breastmilk. However, 
a study of nearly 6000 children found no significant differences between breastfeeding and IQ 
based upon genetic variations, indicating the influence of genotype on IQ remains inconclusive.27 
In the current study, a significant interaction was found between SNP rs174575 genotype and 
daily DHA intake on infant cognitive test scores. While SNP alone did not have any significant 
effect on infant scores on the BSID-III MDI cognitive subtest at 12 months of age, SNP appeared 
to interact with daily DHA intake by possibly affecting the availability of DHA to the infant 
through reduced breastmilk concentrations, subsequently impacting infant neurocognitive 
development.  
Many recent RCT and meta-analyses have reported inconclusive results regarding an 
association between DHA and neurocognitive development.20,127,155,160,168-170 Differences in RCT 
 125 
are possibly due to several differences in study designs. RCT supplement with a wide range of 
DHA, from 200 mg to 2.2 g of DHA per day, and the length and timing of supplementation 
varies largely in cognitive studies. Trials most often supplement during pregnancy only, not 
taking into account the importance of brain development and increased dietary DHA need in 
early infancy after birth. The most convincing RCT supplement DHA during the last trimester of 
pregnancy through the first few months of life and benefit preterm infants the greatest. For these 
reasons, the current study chose to supplement women during the last trimester of pregnancy 
through the first 3 months of lactation with a dose of DHA based on previous research studies 
and above the daily DHA intake recommended by the European Influence of Dietary Fatty Acids 
on the Pathophysiology of Intrauterine Foetal Growth and Neonatal Development (PERILIP) and 
other groups.38,243  
Inconclusive results from DHA RCT may also be due to the disparity between cognitive 
tests used and the age at which the tests are administered. Current assessments of early cognitive 
function, such as the BSID and Fagan Test of Infant Intelligence (FTII), may not be sensitive 
enough to detect the specific effects DHA supplementation may have on certain aspects of 
cognitive development at certain ages. Several recent RCT have found no effects of maternal 
DHA supplementation on infant neurocognitive development during the first few months of life, 
yet, found significant improvements in cognitive scores once the children reached 12 months of 
age into preschool ages.10,15,21,164,166 Standardized infant development tests, such as the BSID, 
use a variety of tasks to assess cognitive function and may provide a better estimate of later 
cognitive ability. The current study used the BSID because the test is widely accepted and 
commonly used throughout cognitive studies, and when administered in late infancy has been 
shown to correlate with IQ scores at 4 years of age.229 Additionally, the current study did not find 
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an association between daily maternal DHA intake and infant neurocognitive development early 
in infancy at 4 months of age, but found a significant association at 12 months of age on the 
BSID-III MDI cognitive subtest. However, more specific tests of attention and information 
processing have recently been shown to possibly be better measures of infant cognitive function 
and predictors of later childhood IQ than the BSID, all of which were determined after the 
current study was designed and completed, but are important to consider in future cognitive 
studies.232,233 
Additionally, the majority of RCT were performed in developed countries in presumably 
well-nourished women. Failure to determine a significant association between DHA and infant 
neurocognitive development in such trials could be explained by a sufficient baseline of DHA 
and not accounting for all sources of DHA in the maternal diet. By accounting for all sources of 
DHA, this study was able to estimate total daily DHA intake and determined a significant dosing 
effect of DHA on infant growth and cognitive development. In this study, DHA supplementation 
was not associated with infant neurocognitive development based on treatment, most likely due 
to a 56% higher DHA intake, through food and self-supplementation, in the placebo control 
group compared to the DHA treatment group. Several previous RCT have shown no significant 
results based upon DHA treatment, yet did show a significant association between DHA status 
and infant neurocognitive development.20-23,156,157 Recent systematic reviews and meta-analyses 
have noted children with low DHA status benefit the most from increased DHA during gestation 
and lactation.167,168 Additionally, genetics may also play a large role on DHA status and the 
benefits of DHA supplementation on infant neurocognitive development. SNP within the FADS1 
FADS2 gene cluster and other currently unknown genetic differences may dramatically affect 
DHA synthesis, transfer and utilization involved in neurocognitive development. 
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A possible limitation to this study is a completion rate of 80% in the DHA treatment 
group with only a 64% completion rate in the placebo control group. The reasons for the 
differences between completion rates are unknown, however, total numbers per treatment group 
were greater than the 32 infants determined necessary by a pilot study to detect a significant 
difference between groups. Despite the disparity in completion rates between groups, the 
adherence of women that completed the study was excellent, with greater than 90% of the 
women taking all of the supplied study supplements. Study compliance was measured by end of 
study pill counts and not by a physiologic measurement, which could present another possible 
study limitation. Yet, estimated baseline daily DHA intake positively correlated with baseline 
maternal erythrocyte DHA (r=0.24, p=0.011) and at 2 months, daily DHA intake estimated from 
the 2 month food frequency questionnaire (FFQ) positively correlated with breastmilk DHA 
(r=0.21, p=0.045). Postpartum and infant blood samples would have allowed for an objective 
mean of measuring study compliance and also provided information on infant DHA status.  
Another potential limitation to this study was the homogeneity of the study population 
which resulted in a limited number of minor allele carriers for each of the SNP investigated. 
Unfortunately, this study had less than the anticipated 10 homozygous minor allele carriers, 
based upon previously described minor allele frequency of ≥18% , and even fewer minor allele 
carriers that completed the study.18 Additionally, only two SNP were analyzed in the current 
study, thus further limiting potential genetic interaction with fatty acid composition and infant 
neurocognitive development. The SNP studied were chosen based upon previous research 
indicating possible SNP effects on breastmilk DHA, yet more SNP could have provided a clearer 
picture to effect SNP within the FADS1 FADS2 gene cluster have on DHA proportions. The 
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study also lacked infant genetic information, which could have shown further important 
influences of DHA on neurocognitive development.  
The study had several strengths in design and execution, most notably that all sources of 
DHA were accounted for in the maternal diets, including DHA from voluntary supplementation 
and food. The current study collected data from each subject regarding prenatal vitamins, DHA 
or fish oil supplements, as well as food sources of DHA through a FFQ administered at baseline 
and 2 months postpartum and a 7-day food record. No effects were determined between DHA 
treatment group and infant neurocognitive development, most likely due to the high level of self 
supplementation in the placebo control group. By accounting for all sources of DHA, this study 
was able to effectively determine a significant association between high daily maternal DHA 
intake and improved cognitive development scores on the BSID-III at 12 months of age. 
Additionally, DHA was supplemented in this study for a longer period of time than most RCT, 
through important times of extensive infant brain growth and development. The study utilized 
the BSID-III as a general measure of overall cognitive performance and administered the test at 
two time points in infant development. By testing at one year of age, it was possible to 
successfully determine a significant association between early maternal DHA intake and 
cognitive development. If BSID-III testing was only performed early in infancy, results would 
not have shown any positive association of maternal DHA intake and the specific function of 
DHA on cognitive development may have been missed.  Additionally, this study controlled for 
potential confounders, including gestational age, maternal IQ and the home environment, all of 
which could have dramatically impacted the effects DHA had on neurocognitive development. 
Future DHA supplementation studies should focus on supplementing DHA for a longer 
length of time during critical times of infant neurological growth and development in a large 
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study population. A larger and more heterogeneous population would allow for more minor 
allele SNP to be detected and possibly allow for the determination of the impact SNP may have 
on DHA treatment. The current study could analyze additional SNP from stored purified DNA to 
determine if other SNP within or outside of the FADS1 FADS2 gene cluster have a more 
significant effect on DHA proportions and neurocognitive development. Additionally, cord blood 
and infant blood would be of interest in future studies to provide infant DHA status 
measurements and infant genetic information. Mechanism of action studies would be beneficial, 
focusing on effects of DHA in neurological development, preterm births, infant anthropometric 
measurements. Studies focusing on mechanisms behind SNP interactions with DHA and 
neurological development are also of great interest to determine not only desaturase activity 
effects but also SNP effects on DHA transfer into breastmilk. 
It would be of great interest to perform IQ and cognitive testing on the children within 
this study at a later age to determine the effect maternal DHA supplementation may have on 
childhood cognitive ability. This would also provide information on whether or not the positive 
association seen in this study between maternal DHA supplementation and improved infant 
cognitive scores on the BSID-III at 12 months of age continues into preschool, school or even 
adolescent ages. Additionally, it would be of great interest to investigate any affect DHA may 
have on BMI, adipocity and childhood obesity. Future studies could investigate an association 
between increased maternal DHA intake and infant adipocity using infant Peapod or DEXA 
scans and follow the children into early adolescence. Furthermore, childhood adipocity, BMI and 
obesity could be analyzed in children from the current study through future research. 
In conclusion, supplementing pregnant and lactating women with DHA could safely 
enhance the neurocognitive development of infants as well as possibly increase gestational 
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length and reduce preterm birth risk. Additionally, SNP within the FADS1 FADS2 gene cluster 
significantly alter erythrocyte and breastmilk DHA, subsequently impacting the DHA received 
by the infant through breastmilk and possibly influence infant neurocognitive development. Total 
DHA intake and maternal genetics should be taken into account in future RCT to properly assess 
the effects DHA supplementation has on infant outcomes. The current study provides 
information on optimal DHA intake and may also help to impact future national standards and 
recommendations for DHA supplementation during pregnancy and lactation. While further 
research is necessary, DHA supplementation during pregnancy and lactation could improve the 
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Consent to Serve as a Subject in Human Research 
 
Title of Project:  Omega Smart Baby Project   
(Study of the relationship between infant growth and neurocognitive development and maternal 
intake of omega-3 DHA) 
 
Principal Investigator: Mary Harris, PhD, RD, BC-ADM  
Co-Investigators:  Susan Baker, EdD 
    Deana Davalos, PhD 
 
WHO IS DOING THE STUDY? Colorado State University is conducting the study.    The 
study is being funded by the USDA. 
 
WHAT IS THE PURPOSE OF THIS STUDY?   
The primary purpose of the study is to see if DHA taken during pregnancy and lactation 
improves your infant’s performance on standard tests of infant growth (weight and length 
measurements) and mental development using a state-of-the-art electrophysiological measure of 
brain activity.  You will be asked to fill out pencil and paper surveys of your infant’s 
temperament and home environment.  At various time points, we will ask you for a record of 
your infant’s dietary intake.   
 
WHY AM I BEING ASKED TO PARTICIPATE IN THIS RESEARCH?  You are being 
asked to participate in a study in which you will take an additional supplement of an essential 
nutrient (an omega-3 fatty acid called DHA, or docosahexaenoic acid) from week 26 of 
pregnancy through the first 3 months of lactation.  The supplement will be provided as an all 
natural, highly purified tuna oil capsule.  You will be asked to commit to exclusive breastfeeding 
to feed your baby during the three months of life (exclusive breastfeeding means nothing except 
breast milk).  If you need to use formula to supplement your breast milk, we ask that you use 
non-DHA containing formula.  During the study, you may be receiving the tuna oil or you may 
receive the control treatment (Sunola oil).  DHA and tuna oil have been used as a dietary 
supplement in many pregnancy trials and has been found to be safe for use by pregnant women. 
It is available on the market but the optimum dose is not yet determined, many women may need 
more than is currently present in the maternal vitamin supplement.  You will continue to take 
your prescribed maternal vitamin and mineral supplement with or without small amounts of 
DHA that you and your physician agree upon. 
 







WHAT WILL I BE ASKED TO DO?  If you agree to be in the study, you will be regularly 
given a supply of study capsules which may contain tuna oil or placebo (Sunola) oil.  We will 
ask you to take one capsule each day.  We will ask you to provide an extra tube of blood during 
your test today for n-3 DHA analysis (this will amount to 10 milliliters, equivalent to about 2 
teaspoonfuls).  We will ask you to complete a food frequency questionnaire about your dietary 
protein intake today. Upon delivery of your baby, we will give you a card upon which to have 
your doctor record your infant's vital statistics (birth weight, length and head circumference and 
gestational age) and at your first postnatal visit.  During your pregnancy throughout the time you 
breastfeed, we will provide a personal Breastfeeding Coach to assist you with any questions or 
concerns you might have while breastfeeding your baby.  We will contact you periodically to see 
how you are doing and to obtain information about your baby’s current diet.  Your Breastfeeding 
Coach will give you her cell phone number so that you may contact her whenever the need or a 
question arises.  When your baby is 4 and 12 months of age he/she will be tested for mental 
development using a measure of brain waves.  The tests will be completed at CSU at no charge 
to you.  These tests take about 45-90 minutes to administer.  Most mothers and babies find it to 
be a fun experience.  During these developmental tests we will ask you to fill out a questionnaire 
of your baby’s temperament, the baby’s environment (toys, siblings to play with etc), and a 
simple Maternal Health Measures survey. In addition, you will be asked to complete a brief 
cognitive measure assessing verbal and visual processing. These should not take more than 30 - 
45 minutes to fill out.  We will also ask you to give a small sample (10cc) of breast milk after 2 
and 4 months of lactation so that we may analyze breast milk DHA content and to keep a diet 
record at this time.  Milk samples will be obtained in about the middle of a feeding using your 
breast pump and your Breastfeeding Coach will be available to assist you with this collection if 
you wish. 
 
WHERE WILL THE STUDY TAKE PLACE?  Blood will be drawn at the Women's Clinic 
lab in Fort Collins.  Infant and toddler testing will take place at Colorado State University. 
 
HOW LONG WILL THE STUDY LAST?  The study will last from week 24-26 of pregnancy 
through the first year of your baby’s life.   
 
WHAT ARE THE POSSIBLE RISKS AND DISCOMFORTS?   It is not possible to identify 
all potential risks in a research procedure, but the researchers have taken  
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reasonable precautions to minimize any known and potential, but unknown, risks. There are no 
anticipated physical risks for participating in the brainwave measurement.  Your infant will be 
sitting on your lap for the tests but it is possible that he/she could possibly become upset by the 
testing.  We will stop the test immediately if such an event occurs.  The risks of blood drawing 
are: a possible hematoma (bruise) at the site where blood was drawn and the remote risk of 
infection.  There are no other known or anticipated risks associated with the study other than 
those addressed above. 
 
WILL I RECEIVE ANY COMPENSATION FOR TAKING PART IN THIS STUDY? You 
will receive a free high-quality manual breast pump and the assistance of a  
personal Breastfeeding Counselor for participating in the study.  You will receive a complete diet 
analysis during lactation.  Your infant will receive tests of cognitive 
development and we will send the results to your baby’s doctor if you wish us to. While there is 
no guarantee that your baby will receive any health benefits from participation in this study, your 
infant may perform better on the cognitive tests if you and your baby were in the DHA group.    
 
WHAT WILL IT COST ME TO PARTICIPATE? There will be no costs to you. 
 
DO I HAVE TO TAKE PART IN THE STUDY? / CAN MY TAKING PART IN THE 
STUDY END EARLY?  Your participation in this research is voluntary.  If you decide to 
participate in the study, you may withdraw your consent and stop participating at any time 
without penalty or loss of benefits to which you are otherwise entitled.  If you decide that you 
cannot breastfeed exclusively as defined in the study, you will still remain in the study for the 
purpose of infant testing if you wish to continue.   
 
WHO WILL SEE THE INFORMATION THAT I GIVE?    
We will keep private all research records that identify you, to the extent allowed by law. 
Your information will be combined with information from other people taking part in the study. 
When we write about the study to share it with other researchers, we will write about the 
combined information we have gathered. You will not be identified in these written materials. 
We may publish the results of this study; however, we will keep your 
name and other identifying information private. We will not ask for access to your medical 
records, we will only ask that you have your baby’s doctor record your baby’s gestational age, 
birth weight, height and head circumference information.   
 
WHAT HAPPENS IF I AM INJURED BECAUSE OF THE RESEARCH?  The Colorado 
Governmental Immunity Act determines and may limit Colorado State University's legal 
responsibility if an injury happens because of this study.  Claims against the University must be 
filed within 180 days of the injury. 
 
 







WHAT IF I HAVE QUESTIONS?       
Before you decide whether to accept this invitation to take part in the study, please ask any 
questions that might come to mind now.  Later, if you have questions about the study, you can 
contact the investigator, Dr. Mary Harris at 970-491-7462.  If you have medical questions about 
the study we encourage you to discuss them with your obstetrician.  If you have any questions 
about your rights as a volunteer in this research contact Janell Barker, Human Research 
Administrator at 970-491-1655.  We will give you a copy of this consent form to take with you. 
 
Your signature acknowledges that you have read the information stated and willingly sign this 
consent form.  Your signature also acknowledges that you have received, on the date signed, a 





Participant name (printed)  
    
_________________________________  _________________ 
Participant Signature     Date 
 
__________________________________  ___________________ 
Witness to signature (project staff)                        Date 
 
 








































































































Omega Smart Baby Project Food Journal  
 
1. Please write down everything you eat or drink for a 7-day period. 
 
2. The attached sheets will give you some directions on how to fill 
out a food journal so that we can provide you with an accurate 
analysis of your diet. 
 
3. You do not need to have a special form to record your 
information on, use the sheets attached or whatever is 
convenient for you.  
 
4. If the food you eat is a mixed dish, please provide the recipe and 
the yield (or the package label if purchased ready to eat). 
 





















Food Record – Day 1    Date:___________________ 
 
Day of the week MEAL was eaten (please circle):  Sun     Mon     Tues     Wed     
Thurs     Fri      Sat 
 
Directions:  Record all foods and beverages (except water) that you ate on the day circled 
above.  Write the time (column 1), food eaten (column 2), and how much you ate (column 
3). 




Time of Day 
 
 
List and describe  



















    
    
    
    
    
    
    
    





Food Record – Day 2   Date:___________________ 
 
Day of the week MEAL was eaten (please circle):  Sun     Mon     Tues     Wed     





Time of Day 
 
 
List and describe  
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Food Record – Day 3    Date:___________________ 
 
Day of the week MEAL was eaten (please circle):  Sun     Mon     Tues     Wed     





Time of Day 
 
 
List and describe  



















    
    
    
    
    
    
    
    
    




Food Record – Day 4   Date:___________________ 
 
Day of the week MEAL was eaten (please circle):  Sun     Mon     Tues     Wed     





Time of Day 
 
 
List and describe  



















    
    
    
    
    
    
    
    
    




Food Record – Day 5    Date:___________________ 
 
Day of the week MEAL was eaten (please circle):  Sun     Mon     Tues     Wed     




Time of Day 
 
 
List and describe  



















    
    
    
    
    
    
    
    
    





Food Record – Day 6   Date:___________________ 
 
Day of the week MEAL was eaten (please circle):  Sun     Mon     Tues     Wed     





Time of Day 
 
 
List and describe  
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Food Record – Day 7   Date:___________________ 
 
Day of the week MEAL was eaten (please circle):  Sun     Mon     Tues     Wed     




Time of Day 
 
 
List and describe  



















    
    
    
    
    
    
    
    
    




























































































































6 month                          Bates Lab 
                Dept. of Psychology 
                Indiana University 






Your baby’s name ___________________       Your name _________________________ 
 
Your baby’s birth date ________________     Address ___________________________ 
 
Your baby’s sex _____________________             __________________________________ 
 
Birth weight ________________________             Phone No. _________________________ 
 
Length at birth ______________________             Today’s date _______________________ 
 
Present weight (if known) _____________ 
 
 
Part II.  On the following questions please circle the number that is most typical of your baby.  
“About average” means how you think the typical baby would be scored. 
 
1. How easy or difficult is it for you to calm or soothe your baby when he/she is  upset? 
 
1               2               3               4               5               6               7 
 
 very easy    about average        difficult 
 
2. How easy or difficult is it for you to predict when your baby will go to sleep and wake 
up? 
 
1               2               3               4               5               6               7 
 




3. How easy or difficult is it for you to predict when your baby will become hungry? 
 
1               2               3               4               5               6               7 
 
            very easy    about average         difficult 
 
4. How easy or difficult is it for you to know what’s bothering your baby when he/she cries 
or fusses? 
 
1               2               3               4               5               6               7 
 
very easy    about average         difficult 
 
5. How many times per day, on the average, does your baby get fussy and irritable—for 
either short or long periods of time? 
 
1               2               3               4               5               6               7 
 
never        1-2 times   3-4 times   5-6 times  7-9 times 10-14 times  more than     
                               per day      per day       per day     per day    per day         15 
 
6. How much does your baby cry and fuss in general? 
 
1               2               3               4               5               6               7 
 
        very little; much   average amount; about as                a lot; much  
        less than the                much as the average baby                more than the 
        average baby          average baby 
 
7. How did your baby respond to his/her first bath? 
 
1               2               3               4               5               6               7 
 
very well--            neither liked nor          terribly-- 
 baby loved it             disliked it                   didn’t like it 
 
8. How did your baby respond to his/her first solid food? 
 
1               2               3               4               5               6               7 
           very favorably--           neither liked nor     very negatively— 
            like it    disliked it                did not like it at all 
            immediately 
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9. How does your baby typically respond to a new person? 
 
1               2               3               4               5               6               7 
          almost always                responds favorably about              almost always responds 
          responds favorably              half the time                         negatively at first 
 
10. How does your baby typically respond to being in a new place? 
 
1               2               3               4               5               6               7 
          almost always                  responds favorably about              almost always responds 
          responds favorably               half the time                             negatively at first 
  
11. How well does your baby adapt to things (such as in items 7-10) eventually? 
 
1               2               3               4               5               6                7 
 
            very well,       ends up liking it about         almost always 
            always likes it              half the time          dislikes it 
            eventually              in the end 
 
12. How easily does your infant get upset? 
 
1               2               3               4               5               6                7 
 
       very hard to upset--               about average            very easily upset by 
       even by things that               things that wouldn’t 
       upset most babies            bother other babies 
 
13. When your baby gets upset (e.g., before feeding, during diapering, etc.), how vigorously 
or loudly does he/she cry and fuss? 
 
1               2               3               4               5               6                7 
 
         very mild intensity         moderate intensity        very loud or 
             or loudness               or loudness         intense, really 
               cuts loose 
 
14. How does your baby react when you are dressing him/her? 
 
1               2               3               4               5               6                7 
 very well--                 about average—doesn’t       doesn’t like 
 likes it        mind it            it at all 
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15. How active is your baby in general? 
 
1               2               3               4               5               6                7 
 
           very calm       average        very active 
and quiet            and vigorous 
 
16. How much does your baby smile and make happy sounds? 
 
1               2               3               4               5               6                7 
 
 a great deal,         an average amount        very little, 
much more than            much less than 
 most infants             most infants 
 
17. What kind of mood is your baby generally in? 
 
1               2               3               4               5               6                7 
  
very happy             neither serious           serious 
and cheerful              nor cheerful 
 
18. How much does your baby enjoy playing little games with you? 
 
1               2               3               4               5               6                7 
 
a great deal,              about average           very little, 
 really loves it              doesn’t like 
                 it very much 
 
19. How much does your baby want to be held? 
 
1               2               3               4               5               6                7 
 
 wants to be free      sometimes wants to be held,       a great deal--   
most of the time    sometimes not        wants to be held 
                almost all the time 
 
20. How does your baby respond to disruptions and changes in everyday routine, such as 
when you go to church or a meeting, on trips, etc.? 
 
1               2               3               4               5               6                7 
 
 very favorably,    about average    very unfavorably, 
 doesn’t get upset            gets quite upset 
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21. How easy is it for you to predict when your baby will need a diaper change? 
 
1               2               3               4               5               6                7 
 
very easy    about average     very difficult 
 
22. How changeable is your baby’s mood? 
 
1               2               3               4               5               6                7 
 
        changes seldom, and            about average      changes often 
        changes slowly when         and rapidly 
         he/she does change 
 
23. How excited does your baby become when people play with or talk to him/her? 
 
1               2               3               4               5               6                7 
 
 very excited             about average         not at all 
 
24. Please rate the overall degree of difficulty your baby would present for the average 
mother. 
 
1               2               3               4               5               6                7 
 
super easy       ordinary, some problems                highly difficult 















































Fatty acid composition (percentage of total fatty acids identified) of maternal baseline erythrocyte, baseline plasma phospholipids and 2 month 
breastmilk samples classified according to treatment and Pearson's correlation coefficients between erythrocyte and breastmilk fatty acids as well 
as plasma phospholipids and breast milk fatty acids.a 
a  The numbers of women with plasma and RBC data in the low DHA intake group, medium DHA intake group, and high DHA intake group were as follows: 55 
and 60, respectively;  39 and 53, respectively, for women also with 2 month breast milk samples. ALA, α-linoleic; DGLA, dihomo-γ-linolenic acid; AA, 
arachidonic acid; EPA, eicosapentaenoic acid; DPA, docosapentaenoic acid; DHA, docosahexaenoic acid, 2 mo BM, 2 month breastmilk samples.  Differences 
between fatty acid proportions between intake groups were assessed using ANOVA. 
b Mean ± SD (all such values). 









Fatty acid composition (percentage of total fatty acids identified) of maternal baseline erythrocyte samples classified according to both genotype for SNP 


























a  The numbers of women with baseline erythrocyte data in the placebo treatment group and DHA treatment group for SNP rs174575 were as follows: MM, 36 
and 36, respectively; Mm, 15 and 21, respectively; mm, 3 and 4, respectively. The numbers of women with baseline erythrocyte data in the placebo treatment 
group and DHA treatment group for SNP rs174575 were as follows: MM, 30 and 36, respectively; Mm, 19 and 22, respectively; mm, 5 and 3, respectively. MM, 
homozygous for major alelle; Mm, heterozygous; mm, homozygous for minor allele. ALA, α-linoleic; DGLA, dihomo-γ-linolenic acid; AA, arachidonic acid; 
EPA, eicosapentaenoic acid; DPA, docosapentaenoic acid; DHA, docosahexaenoic acid.  Differences between fatty acid proportions between treatment groups 
were assessed by two-tailed t test. 
b Mean ± SD (all such values). 





Fatty acid composition (percentage of total fatty acids identified) of maternal baseline plasma phospholipid samples classified according to both genotype for 



























a  The numbers of women with baseline plasma data in the placebo treatment group and DHA treatment group for SNP rs174575 were as follows: MM, 36 and 
36, respectively; Mm, 15 and 21, respectively; mm, 3 and 4, respectively. The numbers of women with baseline plasma data in the placebo treatment group and 
DHA treatment group for SNP rs174575 were as follows: MM, 30 and 36, respectively; Mm, 19 and 22, respectively; mm, 5 and 3, respectively. MM, 
homozygous for major alelle; Mm, heterozygous; mm, homozygous for minor allele. ALA, α-linoleic; DGLA, dihomo-γ-linolenic acid; AA, arachidonic acid; 
EPA, eicosapentaenoic acid; DPA, docosapentaenoic acid; DHA, docosahexaenoic acid.  Differences between fatty acid proportions between treatment groups 
were assessed by two-tailed t test. 
b Mean ± SD (all such values). 




Fatty acid composition (percentage of total fatty acids identified) of maternal 2 month breastmilk samples classified according to both genotype for SNP 
rs174575 and rs174561, as well as treatment type.a 
a The numbers of women with 2 month breastmilk sample data in the placebo treatment group and DHA treatment group for SNP rs174575 were as follows: MM, 
23 and 32, respectively; Mm, 14 and 18, respectively; mm, 2 and 3, respectively. The numbers of women with 2 month breastmilk sample data in the placebo 
treatment group and DHA treatment group for SNP rs174575 were as follows: MM, 20 and 34, respectively; Mm, 15 and 18, respectively; mm, 4 and 1, 
respectively. MM, homozygous for major alelle; Mm, heterozygous; mm, homozygous for minor allele. ALA, α-linoleic; DGLA, dihomo-γ-linolenic acid; AA, 
arachidonic acid; EPA, eicosapentaenoic acid; DPA, docosapentaenoic acid; DHA, docosahexaenoic acid.  Differences between fatty acid proportions between 
treatment groups were assessed by two-tailed t test. 
b Mean ± SD (all such values). 
c Significant difference (p<0.05). 
